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Glucocorticoids are steroid hormones that have potent anti-inflammatory actions. 
Endogenous glucocorticoid action is modulated by 11β-hydroxysteroid 
dehydrogenase (11β-HSD) which catalyses the interconversion of active 
glucocorticoids (cortisol, corticosterone) and intrinsically inert forms (cortisone, 
11-dehydrocorticosterone). There are 2 isozymes; 11β-HSD type 1 regenerates active 
glucocorticoids in vivo whereas 11β-HSD type 2 inactivates glucocorticoids. 
Although 11β-HSD1 is highly expressed in the lung, its role there has been little 
explored. In this study, the expression and localization of 11β-HSD1 mRNA in lung 
was confirmed by in situ hybridization. Immunohistochemical staining of mouse 
lung localized 11β-HSD1 to the cytoplasm of fusiform cells in alveolar walls, in a 
multivesicular pattern characteristic of interstitial fibroblasts. A lung fibrosis model 
of inflammation was used to test the role and regulation of 11β-HSD1. The results 
suggest that levels of 11β-HSD1 mRNA and enzyme were not changed during 
bleomycin-induced lung inflammation. However, 11β-HSD1-deficient mice showed 
a more severe inflammatory response than congenic wild-type controls, with greater 
inflammatory cell infiltration into the lung, and increased levels of HO-1 and iNOS 
mRNA 14 days following bleomycin installation into lung. Picrosirius red staining of 
lung sections suggested more collagen deposition in 11β-HSD1-deficient mice than 
in wild-type controls during the course of the lung inflammatory response. Moreover, 
whereas naïve 11β-HSD1-deficient mice had significantly lower collagen content in 
lung (84% of WT levels, p<0.05). 28d after bleomycin there was no significant 
difference between genotypes (KO having 94% of WT levels, p=0.42) confirming 
more collagen production in 11β-HSD1-deficient mice following bleomycin. 
 
 iii
Fibroblasts are critical in the regulation of inflammatory responses and are essential 
in the model of bleomycin-induced lung injury. Lung fibroblasts may have a different 
transcriptional regulation of 11β-HSD1 compared to other tissues. In the majority of 
tissues, 11β-HSD1 can be transcribed from 2 promoters; the P1 promoter is the main 
promoter used in lung, with other tissues mainly using the P2 promoter. To address 
the relevance of the P1 promoter in lung and to identify the cell type using the P1 
promoter, mouse lungs were collagenase-digested to isolate primary fibroblast and 
epithelial cells. Isolated lung fibroblasts highly expressed 11β-HSD1, predominantly 
from the P1 promoter. During passage, primary lung fibroblasts switched promoter 
usage from P1 to P2. In fibroblast primary culture, treatment with TGF-β  for 72h 
markedly decreased 11β-HSD1 expression to 38% of untreated levels, an effect 
which was reversed by SB431542, a TGF-β  receptor antagonist. Whilst TGF-β 
reduced levels of mRNA initiating at the P2 promoter, initiation from the P1 
promoter was completely repressed. Treatment with TGF-β receptor antagonist 
increased levels of P1-initiated 11β-HSD1 mRNA by 6.6-fold compared to untreated 
cells. These data suggest that the switch in 11β-HSD1 promoter usage may be 
regulated by TGF-β during an inflammatory response. Furthermore, as the P1 and P2 
promoters are differentially regulated (e.g. by C/EBPβ, a cytokine-responsive 
transcription factor), the promoter switch may place 11β-HSD1 under a different 
transcriptional regulation during inflammation. Taken together, these results suggest 
that 11β-HSD1 deficiency worsens lung inflammation and results in greater lung 
fibrosis. Therefore, amplification of intracellular glucocorticoids levels, by 
11β-HSD1, may represent an important mechanism to limit the inflammatory 
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1.1.1 The discovery and application of glucocorticoids 
Glucocorticoids (GC) were first discovered in the 1940s and in the years that 
followed, synthetic glucocortcoids soon became one of the most effective medicines 
to treat inflammation (Hench, Slocumb et al. 1949). As well as their function in 
immunomodulation, endogenous GC, produced in the adrenal gland, also regulate 
stress, metabolism, homeostasis and behavior. Endogenous GC are necessary for 
survival at birth (Cole, Blendy et al. 1995) and are also essential in adults following 
certain inflammatory or infectious stimuli (Webster and Sternberg 2004). 
Adrenalectomized mice died following treatment with LPS, TNF-α or IL-1, but 
pretreatment with the synthetic GC, dexamethasone, rescued the mice (Bertini, 
Bianchi et al. 1988). 
 
1.1.2 GC synthesis 
All steroid hormones are derived from cholesterol, the basic structure of which is 
maintained throughout the steroid biosynthetic pathways. Cholesterol contains a 
cyclopentane ring and 3 cyclohexane rings (Figure 1.1). Each steroid is synthesized 
by sequential enzymatic action – predominantly by hydroxylases located in either the 
smooth endoplasmic reticulum or in mitochondria. GC are produced by the adrenal 
cortex but the adrenals do not store GC, which are synthesized and secreted by the 








Figure 1.1 Summary of corticosteroid bio-synthetic pathways.  
Cortisol and corticosterone are synthesized from cholesterol in the adrenal cortex. 
The above pathways are all present in human adrenal gland. Rodents lack 
17α-hydroxylase in the adrenal gland and so cannot produce cortisol. Hence, in 
rodents, only corticosterone is made whereas humans (and most other vertebrate 













































































1.1.3 Regulation of GC secretion  
The hypothalamic-pituitary-adrenal (HPA) axis regulates GC secretion. GCs are 
secreted with a circadian rhythm and also in response to stress. Upon appropriate 
stimulus (e.g. stress, such as pain, trauma or emotional stress), the cells of the 
paraventricular nucleus of the hypothalamus express corticotropin-releasing hormone 
(CRH) which is released into the hypophyseal blood. CRH then stimulates the 
anterior pituitary gland to release adrenocorticotropin hormone (ACTH) into the 
bloodstream. Then, ACTH stimulates the synthesis and secretion of GCs from the 
adrenal cortex into the circulation (Axelrod and Reisine 1984). After HPA axis 
activation, GCs suppress their own synthesis via a negative feedback loop in which 
circulating GC inhibits the production of CRH and ACTH (Figure 1.2). 
 
Most circulating glucocorticoids are bound to plasma proteins; mainly corticosteroid 
binding globulin (CBG). Approximately 90% plasma cortisol and 80% plasma 
corticosterone is found associated with CBG, with much of the remaining GCs 
normally associated with albumin (Dunn, Nisula et al. 1981). New evidence suggests 
CBG is more than just a GC carrier; it is actively involved in influencing the GC 
response to stress (Richard, Helbling et al. 2010). Because GCs are lipophilic, they 
can easily cross cell membranes, binding to intracellular glucocorticoid receptors 
which then change their conformation and translocate to the nucleus where they bind 



























Figure 1.2 The HPA axis regulates GC secretion and GC regulate gene expression 
in target cells 
The hypothalamus expresses CRH which stimulates the anterior pituitary gland to 
release ACTH into the blood stream to stimulate the synthesis and secretion of GCs 
from the adrenal cortex into the circulation. GCs suppress their own synthesis via a 
negative feedback loop to inhibit the production of CRH and ACTH (indicated by red 
colour). In target cells, before hormone binding, GR in the cytoplasm is complexed 
with HSP. After binding to GCs, GR dissociates from the complex, and translocates 
to the nucleus where it binds to DNA to regulate target gene transcription. 
Arrows indicate the positive effect whereas bars indicate inhibitory effects. CRH, 
corticotropin-releasing hormone; ACTH, adrenocorticotropin hormone; GC, 
glucocorticoid; GR, glucocorticoid receptor; HSP, heart shock protein; GRE, 




There are 2 types of glucocorticoid receptor; the type I (or mineralocorticoid) 
receptor (MR) and the main receptor, the type II (or glucocorticoid) receptor (GR). 
 
1.1.4 Glucocorticoid receptor (GR) and its mechanism of action 
25 years ago, the cloning of GR opened up a new aspect to the research of GC 
function (Hollenberg, Weinberger et al. 1985). GR was the 2nd member of the nuclear 
hormone receptor family to be cloned, a family which includes receptors for other 
steroid hormones (Beato 1989). GR is a DNA binding protein that regulates 
transcription initiation (Yamamoto 1985). Before hormone binding, GR in the 
cytoplasm is complexed with chaperone proteins, that include heat shock proteins 
(Hsp) 90, 70 and 23, and the immunophilins; FKBP51, FKBP52, Cyp44, DP5 
(reviewed in (Pratt, Galigniana et al. 2004)) (Figure 1.2).  
 
After binding to GCs, GR dissociates from the complex and undergoes a 
conformational change, which exposes a nuclear localization sequence (Picard and 
Yamamoto 1987). GR then translocates into the nucleus to form a complex with 
regulatory cofactors, influencing target gene transcription (reviewed in (Beato 1989; 
Grad and Picard 2007)).  
 
GR both activates and suppresses target gene transcription. Genes positively 
regulated by GCs contain glucocorticoid response elements (GRE) within the 
promoter region (reviewed in (Beato 1989; Reichardt and Schutz 1998)). GR binds to 
 
 7
these elements, normally as a dimer (Wrange, Eriksson et al. 1989; Reichardt and 
Schutz 1998), although other configurations may be possible (Adams, Meijer et al. 
2003; Meijsing, Pufall et al. 2009) and recruits coactivator proteins to remodel 
chromatin and facilitate transcription (reviewed in (Rhen and Cidlowski 2005; 
Liberman, Druker et al. 2007)). The mechanism(s) by which GR repress transcription 
are less clear, although it has been proposed that monomers of GR can bind to 
pro-inflammatory transcription factors such as AP-1 and nuclear factor-κB (NF-κB), 
preventing their binding to cognate DNA binding sites and thus preventing 
pro-inflammatory gene transcription (reviewed in (McKay and Cidlowski 1999; 
Liberman, Druker et al. 2007)). 
 
1.1.5 Physiological effects of GC 
GCs affect many physiological processes, some of which are reviewed below. GC 
have critical effects on inflammation and inflammatory processes. There are 
reviewed in Section 1.4 (below). It is important to distinguish between the normal 
physiological effects of GCs and effects produced by supra-physiological levels 
(Munck and Naray-Fejes-Toth 1992). High levels of GC or long term 
pharmacological GC treatment causes Cushing’s syndrome (Dorn, Burgess et al. 
1995). Patients with Cushing’s syndrome show deleterious symptoms, including 
hypertension, insulin resistance, increased cardiovascular disease risk and atypical 
depression (Dorn, Burgess et al. 1995; Souverein, Berard et al. 2004). GC deficiency, 
for example seen in Addison’s disease, cause weight loss, increased insulin 
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sensitivity, fatigue and hypotension (Chrousos 2004). 
 
1.1.5.1 GC effects on lipid and glucose homeostasis 
GCs play an important role in the regulation of daily energy flow (Munck, Guyre et 
al. 1984). GCs promote hepatic glucose output, increasing gluconeogenesis, 
mobilizing stored glycogen and decreasing glucose uptake into peripheral tissues (eg. 
muscle). They also promote lipolysis of stored triglycerides from adipose tissue 
(Gaillard, Wabitsch et al. 1991).  
 
1.1.5.2 GC effects on development  
GCs are essential for tissue maturation in preparation for birth (Fowden, Li et al. 
1998). In particular, GCs are essential for lung maturation in both humans and mice 
(reviewed in (Garbrecht, Klein et al. 2006)). GCs are used clinically in premature 
infants with respiratory distress syndrome (Liggins and Howie 1972). In human fetal 
lung, GCs increase lung cell proliferation, promote the differentiation of type 2 
alveolar epithelial cells and cause thinning of alveolar walls (reviewed in (Garbrecht, 
Klein et al. 2006)). Surfactant is produced and secreted by type 2 alveolar epithelial 
cells, and functions to reduce surface tension at the alveolar air-liquid interface, 
thereby preventing alveoli from collapsing at the end of expiration. Pulmonary 
surfactant contains four surfactant proteins (SPs): SP-A, SP-B, SP-C and SP-D 
(reviewed in (Mason 2006)). GCs promote the expression and mRNA stability of 
SP-B, SP-C, and SP-D (Liley, White et al. 1989; Dulkerian, Gonzales et al. 1996). In 
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rats, GCs stimulate fetal lung fibroblasts to secrete fibroblast-pneumonocyte factor, 
which increases surfactant synthesis by type 2 alveolar epithelial cells in vitro and 
accelerates lung maturation in vivo (Floros, Post et al. 1985; Torday and 
Kourembanas 1990). 
  
Results from GR-deficient mice are consistent with these GC functions in lung. GR 
knockout mice die within a few hours after birth because of respiratory failure and 
lung structural immaturity (Cole, Blendy et al. 1995; Nemati, Atmodjo et al. 2008). 
The lungs at birth are severely atelectatic, and development is impaired from day 
15.5 of pregnancy (Cole, Blendy et al. 1995). The differentiation of type I epithelial 
cells is decreased by about 50% and the mRNA levels of SP-A and SP-C are also 
reduced by approximately 50% in GR knockout mice at day 18.5 of pregnancy (Cole, 
Solomon et al. 2004). Mice with tissue specific GR KO in lung airway epithelial cell 
using a Cre-LoxP system with Cre controlled by the SP-C promoter show 50% 
decreased viability shortly after birth, and their lungs have an immature appearance 
with increased lung cellularity and increased pools of glycogen in the epithelium 
(Manwani, Gagnon et al. 2009). These mice also showed reduced epithelial cell 
differentiation and reduced mRNA expression of all 4 surfactant proteins (Manwani, 
Gagnon et al. 2009). Another line of transgenic mice which expresses GR 
exclusively in the distal airway epithelium (KO for GR, with a transgene expressing 
GR from the human SP-C promoter), show a more mature histological appearance 
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than GR KO mice, with a reduction in cellularity to normal values (Gagnon, Atmodjo 
et al. 2006). However, those mice also develop respiratory insufficiency at birth and 
there is no difference in viability compared to GR KO mice (Gagnon, Atmodjo et al. 
2006). Those results suggest GC signaling through a fully functional GR is important 
for the maturation of the lung and restoration of GR expression only in airway 
epithelial cells is not enough to rescue GR KO mice. Therefore, GC must target other 
lung cells in addition to epithelial cells to mature the fetal lung. 
 
1.2 Inflammation 
Before considering the effects of GC on inflammation, it is necessary first to briefly 
review the processes affected. Inflammation is initiated at the site of injury. Resident 
macrophages play a key role in initiating the inflammatory response by secreting 
proinflammatory cytokines, including IL-1, IL-6, TNF-α and chemokines such as 
monocyte chemotactic protein (MCP)-1 (Topley, Mackenzie et al. 1993; Borish and 
Steinke 2003). These pro-inflammatory mediators recruit leukocytes to the site of 
injury along the chemotactic gradient, resulting in the pain, redness and swelling of 
inflammation (Kolaczkowska, Shahzidi et al. 2002; Borish and Steinke 2003). 
Activated granulocytes are quickly attracted to the injured site, followed by 
monocyte emigration from blood vessels and maturation into macrophages (reviewed 
in (Serhan and Savill 2005)). Then phagocytes (neutrophils and macrophages) start 
to ingest microbial pathogens and cellular debris from necrotic cells as well as 
apoptotic cells (Greenberg and Grinstein 2002). Following recruitment, neutrophils 
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undergo constitutive apoptosis, which leads to macrophage ingestion of the intact 
apoptotic neutrophils to prevent release of further proinflammatory mediators 
(Haslett, Lee et al. 1991). Usually, acute inflammation resolves quickly. However, it 
can become persistent and lead to a chronic inflammatory state that can progress to 




Lung fibrosis is a common final pathway of many interstitial lung diseases and is 
characterized by accumulation of excess collagen and other extracellular matrix 
(ECM) components, resulting in the destruction of normal tissue architecture and 
function (reviewed in (Shukla, Meisler et al. 1999)). The normal alveolar basement 
membrane is lined with alveolar epithelial cells. After epithelial damage, 
neutrophils/monocytes are accumulating in the injured area (Selman and Pardo 2002). 
Then epithelial cells can undergo transition to a mesenchymal phenotype giving rise 
to fibroblasts and myofibroblasts (Willis and Borok 2007) and 
fibroblasts/myofibroblasts generate extracellular matrix (ECM), which serves as the 
foundation for re-establishment of tissue integrity and provides tissue support 
(Gomperts and Strieter 2007). During the repair phase, myofibroblasts undergo 
apoptosis and disappear, and ECM is degraded and epithelial cells migrate denuded 
area to reepithelialize (Selman and Pardo 2002). Matrix proteins in the lung 
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including collagen are continually synthesized and degraded (Laurent 1987). 
Imbalances in this process lead to either more fibrosis or loss of connective tissue 
(Mays, McAnulty et al. 1989).  
 
1.3.1 Fibroblasts 
Fibroblasts are the most abundant cell type in stromal tissue and participate in repair 
and regenerative processes in almost every tissue and organ (reviewed in (White, 
Lazar et al. 2003)). They are traditionally identified by their spindle shape 
morphology and their ability to adhere to plastic in vitro (Tarin and Croft 1969). A 
few proteins have been used to identify fibroblasts, such as CD 90, vimentin, 
fibroblast-specific protein, fibroblast activation protein and CD248 (Franke, Schmid 
et al. 1978; Rettig, Garin-Chesa et al. 1993; Strutz, Okada et al. 1995; MacFadyen, 
Haworth et al. 2005). However, to date, there is no single marker to identify 
fibroblasts. Fibroblasts are not just passive structural cells, which form a scaffold to 
support the surrounding tissue, but are actively involved in immune regulation by 
producing growth factors, chemokines and extracellular matrix (reviewed in (Kalluri 
and Zeisberg 2006)). Fibroblasts are able to regulate tissue-infiltrating leukocytes, 
governing their accumulation, survival and differentiation (reviewed in (Parsonage, 
Filer et al. 2005)). Following injury to the lung, fibroblasts migrate to the damaged 
area and are stimulated to secrete collagen and other ECM (Kuhn and McDonald 
1991). They also release various proteases that can degrade and remodel these matrix 
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proteins (Parsonage, Falciani et al. 2003). They contribute to the tissue-specificity of 
inflammatory reactions and play an active role in the persistence of chronic 
inflammatory reactions (Parsonage, Falciani et al. 2003). Dysregulation of this 
process can result in fibroblast foci, followed by abnormal remodeling of the ECM 
and subsequent destruction of the lung architecture (Basset, Ferrans et al. 1986; 
Kuhn, Boldt et al. 1989). 
 
1.3.2 Myofibroblasts 
Myofibroblasts are unique mesenchymal cells with properties inherent to both 
smooth muscle and fibroblasts. They are widely distributed in embryos, are essential 
for the formation of functional adult tissue, and are intimately involved in tissue 
homeostasis and wound healing (reviewed in (Walker, Guerrero et al. 2001)). 
Cytoskeletal protein expression and contractile properties distinguish them from 
fibroblasts (reviewed in (Walker, Guerrero et al. 2001)). Myofibroblasts are the 
primary source of type I collagen gene expression in active fibrotic sites in animal 
models (reviewed in (Phan 2002)). In pulmonary fibrosis, myofibroblasts were 
shown to be derived from peribronchial and perivascular adventitial fibroblasts 
(Zhang, Rekhter et al. 1994), however, it is still controversial, some authors think 
they have hematopoietic origin (Ogawa, LaRue et al. 2006). A common marker for 
myofibroblast differentiation is the expression of α-smooth muscle actin (α-SMA) 
(Gabbiani, Hirschel et al. 1972). Primary cultured lung fibroblasts can be induced to 
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differentiate into myofibroblasts by treatment with cytokines such as transforming 
growth factor TGF-β (Hu, Wu et al. 2003).  
 
1.3.3 TGF-β 
TGF-β is member of a family of growth and differentiation factors with multiple 
functions in a variety of different organ systems. TGF-β is notable for its capacity to 
modulate a variety of cellular behaviors, including cell proliferation, differentiation, 
and apoptosis (reviewed in (Bartram and Speer 2004)). Its receptors and effects are 
found in all cells at injured or repaired tissue. There are 3 forms of TGF-β expressed 
by mammalian cells, TGF-β1-3, all of which are potential stimulators of ECM 
production, promoting synthesis of fibronectin, tenascin and collagen by fibroblasts 
(Ignotz and Massague 1986; Fine and Goldstein 1987; Shukla, Meisler et al. 1999). 
Of the TGF-βs, TGF-β1 is the isoform predominantly expressed during the 
pathogenesis of experimental pulmonary fibrosis (Coker, Laurent et al. 1997). It can 
stimulate fibroblast differentiation to the myofibroblast phenotype and suppress 
myofibroblast apoptosis (Zhang and Phan 1999). TGF-β intracellular signaling is 
mediated by the family of Smad transcription factors. Binding of TGF-β to its 
receptor leads to phosphorylation of Smad2 and Smad3, which then form a 
heteromeric complex with Smad4 (reviewed in (Bartram and Speer 2004)). Then, the 
Smad complex translocates to the nucleus and activates target genes by binding to 




Both GCs and TGF-β control collagen synthesis, but in opposite directions. GCs can 
decrease collagen production through a depressant effect on the synthesis of soluble 
collagen and decreased prolyl hydroxylase activity which hydroxylates proline to 
hydroxyproline, a major component of collagen, in rat lung (Cutroneo and Counts 
1975). In a bleomycin model of lung fibrosis (see section 1.8.2), rats treated with 
bleomycin showed higher prolyl hydroxylase activity and hydroxyproline content 
compared to untreated control rats (Sterling, DiPetrillo et al. 1982). However, when 
rats were treated with both bleomycin and GC, they showed normal prolyl 
hydroxylase activity and hydroxyproline content, similar to control rats without any 
treatment (Sterling, DiPetrillo et al. 1982). Dexamethasone (dex), a synthetic GC, 
caused a decrease in TGF-β1 mRNA in rat lung fibroblasts in vitro; the treatment also 
resulted in decreased TGF-β activity (Shull, Meisler et al. 1995). There is a putative 
GRE in the promoter region of TGF-β1 (Parrelli, Meisler et al. 1998) but this has not 
been investigated further. The gene encoding Proα1(I) collagen has a 
TGF-β response element in the promoter region (Meisler, Chiu et al. 1999). When rat 
skin fibroblasts were treated with Dex, less TGF-β nuclear activator protein was 
bound to the TGF-β response element in the promoter region of proα1(I) collagen 
which led to a decrease in proα1(I) collagen gene promoter activity (Meisler, Shull et 
al. 1995). These data indicate that GC may regulate collagen synthesis both by 
decreasing TGF-β levels and thus activity and also by interfering with 




1.4 GC effects on inflammation 
Clinically, GCs have been widely used for their immunosuppressive and 
anti-inflammatory function since their discovery in the 1940s. Synthetic GCs are 
commonly used to treat a variety of inflammatory diseases, including asthma and 
rheumatoid arthritis. More recent evidence suggests GC are not exclusively 
anti-inflammatory, they modulate the immune response as well (Sapolsky, Romero et 
al. 2000). GC exhibit immunosuppressive functions at higher doses, but show 
immunomodulatory function at physiological levels (Yeager, Guyre et al. 2004). 
 
One of the most intriguing effects of GC on immune cells (Figure 1.3) is the ability 
to induce apoptosis in immature thymocytes. Adrenalectomized mice showed 
increased thymus size and GC decreased thymus size (Jaffe 1924). GC-induced T 
cell death is believed to be one of the mechanisms by which T cell selection occurs in 
the thymus (Cohen, Fschbach et al. 1970). Also, GC decrease circulating 
lymphocytes in blood (Keller, Weiss et al. 1981), by reducing the availability of 
chemoattractants and suppressing adhesion molecules (Schneider, Bruckmann et al. 
1997). GC inhibit immunoglobulin synthesis on T cells and B cells, thus altering T 
























Figure 1.3 A scheme showing development of immune cells from 
lineage-restricted progenitor populations 
Common lymphoid and myeloid progenitor cells develop from hematopoietic stem 
cells. Common lymphoid progenitor cells develop into natural killer cells, B-cells 
and T-cells. Common myeloid progenitor cells develop into dendritic cells, mast cells, 
basophils, eosinophils, neutrophils and monocytes. Adapted from (Iwasaki, Mizuno 
et al. 2006). GC reduce lymphocyte numbers in blood, promote T cell apoptosis and 
T cell polarization, inhibit DC cell maturation, influence monocyte/macrophage 
function and accelerate eosinophil apoptosis whilst delaying neutrophil apoptosis and 








GC also modulate myeloid immune cells (Figure 1.3). GC increase neutrophil 
numbers in blood (Nakagawa, Terashima et al. 1998), possibly due to a delay in 
apoptosis (Meagher, Cousin et al. 1996; Zhang, Moilanen et al. 2001) as well as 
increased release from bone marrow (McEwen, Biron et al. 1997). Dendritic cells 
(DC) are specialized in antigen capture, processing and presentation to T cells. 
Mature DC can efficiently induce the development of T effector cells, whereas 
immature DC are involved in antigen-specific T cell tolerance, which is critical for 
the prevention of autoimmunity (reviewed in (Mahnke, Schmitt et al. 2002)). GCs 
potently regulate DC maturation and activation, decreasing the expression of 
cytokine and antigen presentation molecules (Piemonti, Monti et al. 1999; Matyszak, 
Citterio et al. 2000) and inhibiting the migration of DC towards lymph nodes 
(Cumberbatch, Dearman et al. 1999). GC-treated DC maintain an immature state and 
produce preferentially the immunomodulatory cytokine IL-10, rather than the 
proinflammatory cytokines, IL-6 and IL-12 (Luther, Adamopoulou et al. 2009). 
Moreover, GC-treated DC induce hyporesponsive CD4+ T cells, which suppress 
autologous CD4+ T cell proliferation to prevent autoimmunity (Luther, Adamopoulou 
et al. 2009). Therefore GCs are important in regulating the maturation and condition 
of DC, which may relate to the clinical effects of GCs. 
 
Macrophages play an important role in resolving inflammation by recognition and 
phagocytosis of dying cells (reviewed in (Savill, Dransfield et al. 2002)). GCs induce 
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human monocytes to become highly phagocytic, highly motile anti-inflammatory 
macrophages (Giles, Ross et al. 2001; Heasman, Giles et al. 2003). GC-stimulated 
macrophages show down-regulation of adhesion-related proteins and reduced ability 
to adhere to plastic surfaces (Ehrchen, Steinmuller et al. 2007) consistent with 
increased migratory properties. GCs can also cause macrophages to ingest more 
apoptotic leucocytes (Liu, Cousin et al. 1999), a process that depends on the Mer 
tyrosine kinase-dependent apoptotic cell clearance pathway (McColl, Bournazos et al. 
2009). GCs suppress expression of a number of cytokines in macrophages, to alter 
immune responses (Reichardt, Tuckermann et al. 2001). Importantly, in mouse 
monocytes, GCs induced a phenotype with low adhesiveness, high migratory 
capacity and markers suggestive of a tumor-associated macrophage phenotype 
(Varga, Ehrchen et al. 2008). 
 
Traditionally, gene activation by GR was believed to occur exclusively through 
homodimers of GR binding to a consensus GR binding site, comprising two 6bp 
“half sites” arranged in an inverted repeat (palindrome) separated by a 3bp spacer 
(reviewed in (Beato 1989; Karin 1998)). The dimerization of the DNA binding 
domain of GR is dependent on a short 5 amino acid segment and the mutation of 
these residues strongly impaired binding of GR as a dimer to a palindromic GRE 
(Dahlman-Wright, Wright et al. 1991). Mice with a mutation in this region of GR 
(known as GRdim), unable to transactivate via GR binding to palindromic GREs but 
 
 20
still able to repress NF-κB and AP-1, maintain anti-inflammatory activity in vivo 
(Reichardt, Kaestner et al. 1998). This has supported the hypothesis that the 
anti-inflammatory actions of GR are mediated by dimerization-independent 
interactions with other transcription factors, especially NF-κB and AP-1, impairing 
their ability to activate pro-inflammatory gene expression.  
 
Dual specificity phosphatase (DUSP)-1, also known as MKP-1 (mitogen activated 
protein kinase [MAPK] phosphatase 1) is a crucial anti-inflammatory factor 
(Hammer, Mages et al. 2006). It dephosphorylates and inactivates members of the 
MAPK family which regulate inflammatory gene expression at both transcriptional 
and post-transcriptional levels (reviewed in (Dean, Sully et al. 2004)). Typically, the 
expression of DUSP1 is rapidly increased after GC stimulation (reviewed in (Clark 
2007)). The induction of DUSP1 by dex is unimpaired in GRdim mouse macrophages 
and GCs fail to suppress zymosan-induced inflammation in DUSP1-/- mice, whereas 
inflammation was suppressed in control mice (Abraham, Lawrence et al. 2006), 
implying that GR dimerization is unnecessary to activate DUSP1 expression and 
demonstrating that DUSP1 induction is an important mechanism in the 
anti-inflammatory effects of GC. More recently, GREs containing GR binding sites 
have been identified in both the human and mouse DUSP1 loci (Tchen, Martins et al. 
2010), supporting direct regulation of DUSP1 by GR in a dimerization-independent 
manner. How many of the anti-inflammatory effects of GC are attributable to DUSP1 
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induction remain unclear. 
 
Although GCs are universally considered to be anti-inflammatory, there is some 
evidence suggesting that GCs contribute to pro-inflammatory responses as well. If 
GCs are administered prior to Lipopolysaccharides (LPS) challenge, they potentiate 
both the peripheral and central pro-inflammatory response; however, if GCs are 
administered after LPS challenge, GCs suppress the pro-inflammatory response to 
LPS (Frank, Miguel et al. 2010). Experiments on macrophages show different 
concentrations of GC have different effects (Lim, Muller et al. 2007). Low levels of 
GCs enhance NO production as well as pro-inflammatory cytokine and chemokine 
production, whereas high GC concentrations repress macrophage function (Lim, 
Muller et al. 2007). It is also important to note that most experiments to test the 
effects of GC on cells are carried out with high doses of synthetic GC (e.g. dex), and 
lower doses or endogenous GC (which are metabolized more readily, bind less avidly 
to receptors and which activate both MR and GR (Rousseau, Baxter et al. 1972)) 
may have different effects. 
 
1.5 11β-HSD and pre-receptor GC metabolism 
Physiological GC action depends on the intracellular concentration of GC. In intact 
cells, 11β-HSDs regulate intracellular GC levels (reviewed in (Seckl 2004)). There 
are two 11β-HSD isozymes, 11β-HSD1 and 11β-HSD2, which both belong to the 
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short-chain dehydrogenase reductase (SDR) family (Baker 1994). They interconvert 
active GC (cortisol in humans and corticosterone in rodents) and inactive GC 
(cortisone in humans and 11-dehydrocorticosterone in rodents) using nicotinamide 
cofactors to transfer hydride (Figure 1.4) (reviewed in (Agarwal and Auchus 2005)). 
 
1.5.1 11β-HSD1 and 11β-HSD2; biochemistry 
11β-HSD1 cDNA was first purified and cloned from rat liver (Lakshmi and Monder 
1988; Agarwal, Monder et al. 1989) and it encodes an NADP(H)-dependent enzyme. 
Although bidirectional in homogenates (Lakshmi and Monder 1988) and some 
transfected cells (Agarwal, Monder et al. 1989; Bujalska, Shimojo et al. 1997; 
Odermatt, Arnold et al. 1999; Atanasov, Nashev et al. 2004), in intact cells and in 
vivo, 11β-HSD1 mainly shows reductase activity e.g. (Low, Chapman et al. 1994; 
Jamieson, Chapman et al. 1995; Kotelevtsev, Holmes et al. 1997; Jamieson, Walker 
et al. 2000). 11β-HSD1 is localized to the endoplasmic reticulum (ER) lumen with 
its N-terminus anchored to the ER membrane and the C-terminus inside the ER 
























Figure 1.4 The reaction catalyzed by 11β-hydroxysteroid dehydrogenase 
(11β-HSD)  
11β-HSD1 and 11β-HSD2 use nicotinamide cofactors to transfer hydride to 
interconvert active GC (cortisol in humans and corticosterone in rodents), able to 
bind to receptors, and inactive GC (cortisone in humans and 
11-dehydrocorticosterone in rodents), which show negligible binding to receptors. A 
circle indicates the hydroxyl/keto group at the 11 position of cortisol/cortisone, 
respectively. In intact cells, 11β-HSD1 is predominately a reductase, converting 
cortisone (or 11-dehydrocorticosterone) to cortisol (or corticosterone), whereas 






11β-HSD1 utilizes the cofactor NADP(H) within the lumen of the ER (Odermatt, 
Atanasov et al. 2006). Hexose-6-phosphate dehydrogenase (H6PDH) which is 
adjacent to 11β-HSD1 in the ER lumen (Atanasov, Nashev et al. 2004), generates 
NADPH by catalyzing the first two steps of the pentose-phosphate pathway (Mason, 
Stevens et al. 1999), thereby stimulating oxoreductase activity of 11β-HSD1 
(Atanasov, Nashev et al. 2004). H6PDH KO mice lose 11β-HSD1 reductase activity 
but gain dehydrogenase activity through changes in NADPH cofactor provision 
(Lavery, Walker et al. 2006). Although research on cortisone reductase deficiency 
(CRD) patients originally implicated a combination of mutations or gene variants in 
11β-HSD1 and H6PDH which interacted to cause CRD (manifest in a reduction in 
11β-HSD1 expression and impaired conversion of cortisone to cortisol) (Draper, 
Walker et al. 2003), more recent analysis has shown those patients only have H6PD 
gene mutations which suggests that CRD is caused by inactivating mutations in the 
H6PD gene and not in the 11β-HSD1 gene as originally thought (Lavery, Walker et 
al. 2008). 
 
11β-HSD2 is an NAD(H)–dependent enzyme that oxidizes active GCs to their 
inactive 11-keto forms (Albiston, Obeyesekere et al. 1994; Brown, Chapman et al. 
1996). It is also localized to the ER but with the opposite orientation to 11β-HSD1, 
facing the cytoplasm (Odermatt, Arnold et al. 1999). 11β-HSD2 dictates the 
specificity for the mineralocorticoid receptor (MR) by converting active GCs into 
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inert GCs, leaving aldosterone to occupy the MR (Edwards, Stewart et al. 1988; 
Funder, Pearce et al. 1988). Congenital deficiency of 11β-HSD2 results in the 
syndrome of apparent mineralocorticoid excess (AME); in these patients cortisol acts 
as a potent mineralocorticoid causing high blood pressure (Edwards, Walker et al. 
1993). Whilst 11β-HSD1 is widely expressed, 11β-HSD2 shows a more restricted 
distribution, being mainly expressed in mineralocorticoid-target tissues, such as 
kidney and colon (reviewed in (Stewart and Krozowski 1999)). However, it is 
becoming clear that it is expressed in other tissues as well, e.g. the vasculature and 
the placenta (Li, Smith et al. 1996; Christy, Hadoke et al. 2003). 
  
1.5.2 Tissue-specific distribution of 11β-HSD1 
11β-HSD1 shows a broad tissue distribution in humans and rodents, with 
predominant expression in liver, brain, lung, kidney and adipose tissue (Moisan, 
Seckl et al. 1990; Tannin, Agarwal et al. 1991; Whorwood, Franklyn et al. 1992; 
Ricketts, Verhaeg et al. 1998; Brereton, van Driel et al. 2001). 11β-HSD1 is not 
always, however, uniformly expressed in the whole organ. For example, in kidney 
11β-HSD1 is expressed in all renal tubular epithelia but is not detected in medullary 
interstitial cells (Yau, Van Haarst et al. 1991). During mouse development, 
11β-HSD1 mRNA expression is first observed at E15 in lung and liver, and rises 
strongly later (Speirs, Seckl et al. 2004). 11β-HSD1 is also highly expressed in rat 




1.5.3 The role of 11β-HSD1  
11β-HSD1 plays an important role in regulating GC activity. The in vivo role of 
11β-HSD1 has been elucidated largely by the generation of mice homozygous for a 
targeted disruption of the 11β-HSD1 gene (Kotelevtsev, Holmes et al. 1997). 
Experiments on 11β-HSD1-deficient mice confirm that 11β-HSD1 is the only 
11β-reductase in mice, as they are unable to convert 11-dehydrocorticosterone to 
corticosterone (Kotelevtsev, Holmes et al. 1997). 11β-HSD1-deficient mice show 
compensatory increased adrenal secretion of corticosterone as well as adrenal 
hypertrophy and they have elevated basal plasma corticosterone levels (Kotelevtsev, 
Holmes et al. 1997). They also showed reduced sensitivity to glucocorticoid negative 
feedback upon the HPA axis and elevated responses to acute restraint stress (Harris, 
Kotelevtsev et al. 2001). However, transgenic re-expression of 11β-HSD1 selectively 
in liver of 11β-HSD1-deficient mice restored the HPA-axis phenotype (Paterson, 
Holmes et al. 2007) demonstrating that hepatic GC metabolism influences the 
function of the HPA axis. After back-crossing to the C57BL/6J genetic back-ground 
(from the original mixed 129/MF1 background), 11β-HSD1-deficient mice showed 
normal blood glucocorticoid levels (Yau, McNair et al. 2007; Carter, Paterson et al. 
2009), but compensatory changes in GR expression in areas of the brain involved in 
GC negative feedback (Carter, Paterson et al. 2009). Therefore the different strains of 
mice have different mechanisms of regulating HPA activity and the genetic 
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background of mice influences the HPA phenotype of 11β-HSD1-deficient mice. 
Compared to wild-type mice, 11β-HSD1-deficient mice showed an enhanced 
angiogenesis in vitro and in vivo within sponges, wounds, and infarcted myocardium 
(Small, Hadoke et al. 2005). 11β-HSD1-deficient mice are also resistant to 
diet-induced metabolic disease, and have increased hepatic and adipocytic insulin 
sensitivity (Morton, Holmes et al. 2001; Morton, Paterson et al. 2004). They are also 
resistant to cognitive decline in old age (Yau, Noble et al. 2001; Yau, McNair et al. 
2007). Mice deficient in 11β-HSD1 also reportedly lack bone marrow adipocytes 
(Justesen, Mosekilde et al. 2004) although this has not been confirmed in recent 
experiments (Agnes Coutinho, personal communication). 
 
Based on the protective effects of 11β-HSD1-deficiency in metabolic disease and 
age-related cognitive decline (reviewed in (Seckl 2004)), 11β-HSD1 enzyme 
inhibition has been investigated as a treatment for type II diabetes, insulin resistance, 
cardiovascular disease and cognitive dysfunction (reviewed in (Seckl 2004)). 
Treatment with the non-selective 11β-HSD1 inhibitor, carbenoxolone, improved 
verbal fluency in healthy men and verbal memory in type 2 diabetes patients 
(Sandeep, Yau et al. 2004). In a murine model of atherosclerosis, inhibition of 
11β-HSD1 slowed plaque progression in apolipoprotein E-deficient Apoe-/- mice, and 
the mice showed less accumulation of total cholesterol in aorta, as well as lower 
serum cholesterol (Hermanowski-Vosatka, Balkovec et al. 2005). Now clinical trials 
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have been reported by several pharmaceutical companies (Boyle and Kowalski 2009). 
Selective 11β-HSD1 inhibitors decreased blood glucose in diabetes by reducing 
glucose production in both rodents and humans (Alberts, Engblom et al. 2002; Barf, 
Vallgarda et al. 2002; Andrews, Rooyackers et al. 2003; Tiwari 2010). 
 
1.6 11β-HSD1 and inflammation 
1.6.1 Expression of 11β-HSD1 in leukocytes 
It has recently been shown that 11β-HSD1 is expressed in immune cells and 
regulates both innate and adaptive immune responses (reviewed in (Chapman, 
Coutinho et al. 2009; Cooper and Stewart 2009)). 11β-HSD1 is induced in human 
monocytes upon differentiation to macrophages (Thieringer, Le Grand et al. 2001). It 
is also induced upon differentiation of monocytes into dendritic cells where it acts as 
an autocrine-negative regulator of dendritic cell differentiation from monocyte 
precursors (Freeman, Hewison et al. 2005). 11β-HSD1 expression has been detected 
in human neutrophils at both the mRNA and protein levels (Kardon, Senesi et al. 
2008). With respect to the adaptive immune response, Zhang et al. showed that 
11β-HSD1 mRNA, protein, and enzyme activity are expressed in murine CD4+, 
CD8+ and B220+ lymphocytes (Zhang, Ding et al. 2005). 
 
1.6.2 Inflammatory responses of 11β-HSD1-deficient mice  
Most data show that during an acute inflammatory response, mice deficient in 




In vivo, in sterile peritonitis, more peritoneal cells are recruited to the peritoneum in 
11β-HSD1-deficient mice than in control mice (Gilmour 2002), and following LPS 
administration, 11β-HSD1-deficient mice exhibited higher serum levels of TNF-α, 
IL-6 and IL-12p40 compared to WT controls (Zhang and Daynes 2007). Importantly, 
preliminary data in a mouse model of pleurisy suggested a greater influx of 
inflammatory cells in the pleural cavity of 11β-HSD1-deficient mice than in control 
mice following intrapleural injection of carrageenan (Coutinho 2009). In vivo, during 
sterile peritonitis, macrophages from 11β-HSD1-deficient mice showed delayed 
acquisition of phagocytic competence compared to WT mice, with more free 
apoptotic neutrophils 2 days following injection with thioglycollate (Gilmour, 
Coutinho et al. 2006) suggesting 11β-HSD1 may potentially contribute to the 
reduction of inflammation, although both genotypes resolved the peritoneal 
inflammation at the same time (Gilmour, Coutinho et al. 2006). Ex vivo, 
macrophages lavaged from the peritoneum of 11β-HSD1-deficient mice following 
thioglycollate showed a greater cytokine response to LPS stimulation (Gilmour, 
Coutinho et al. 2006; Zhang and Daynes 2007), probably due to TGF-β mediated 
up-regulation of SHIP1, a phosphatase that negatively regulates the activation of 
immune cells primarily via the phosphoinositide 3-kinase (PI3K) pathway (Zhang 
and Daynes 2007). In a model of self-resolving experimental arthritis, 
11β-HSD1-deficient mice developed clinical signs of inflammation a day earlier than 
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control mice and were slower to resolve the inflammatory response (Coutinho 2009). 
Collectively, these data suggest that endogenous GC regulated by 11β-HSD1 play an 
important role in affecting the differentiation or activation of macrophages and that 
11β-HSD1 activity may suppress acute inflammation and contribute to its successful 
resolution. 
 
1.6.3 Regulation of 11β-HSD1 in inflammation 
Several recent reports have shown that 11β-HSD1 expression is increased by 
pro-inflammatory stimuli or at sites of inflammation (reviewed in (Chapman, 
Coutinho et al. 2009) ).  
 
In human and animal colitis, colonic 11β-HSD1 activity and mRNA expression were 
strongly increased (Vagnerova, Kverka et al. 2006; Zbankova, Bryndova et al. 2007). 
In rheumatoid arthritis, within the joint, synovial inflammation was positively 
correlated with cortisone reactivation, suggesting increased synovial 11β-HSD1 
activity (Schmidt, Weidler et al. 2005) and in rat adjuvant arthritis, which is similar 
to human rheumatoid arthritis, synovial 11β-HSD1 mRNA and reductase activity 
was increased (Ergang, Leden et al. 2010). This is consistent with increased 
11β-HSD1 activity and mRNA levels in synovial tissues of patients with rheumatoid 
arthritis (Hardy, Rabbitt et al. 2008) and synovial fibroblasts highly express 
11β-HSD1 following treatment with IL-1β or TNF-α (Hardy, Filer et al. 2006). In 
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sterile peritonitis, 11β-HSD1 expression was markedly increased in peritoneal cells 
(mainly immune cells) following in vivo injection of thioglycollate (Gilmour, 
Coutinho et al. 2006). IL-1β and TNF-α are potent stimulators of 11β-HSD1 
expression in various cells. They induce mRNA and activity of 11β-HSD1 in human 
aortic smooth muscle cells, glomerular mesangial cells, ovarian surface epithelial 
cells and preadipocytes (Escher, Galli et al. 1997; Handoko, Yang et al. 2000; Cai, 
Wong et al. 2001; Tomlinson, Moore et al. 2001; Yong, Harlow et al. 2002), as well 
as all types of fibroblasts examined to date (Sun and Myatt 2003; Hardy, Rabbitt et al. 
2008). 
 
1.7 Regulation of 11β-HSD1 
1.7.1 Promoters of 11β-HSD1 
The 11β-HSD1 gene is transcribed from 3 promoters; P1, P2 and P3 (Moisan, 
Edwards et al. 1992; Bruley, Lyons et al. 2006). Lung mainly uses an upstream 
promoter, P1, which in mice, is located approximately 23 kb 5’ to exon 2, whereas 
most other tissues (liver, brain, adipose tissue) use the downstream promoter, P2 
(Bruley, Lyons et al. 2006) (Figure 1.5). P3, described in rat kidney, is located within 
the intron between exon 2 and 3 (Moisan, Edwards et al. 1992). It encodes a 
truncated protein, which doesn’t show 11β-HSD1 enzyme activity (Mercer, 
















Figure 1.5 Schematic representation of the 11β-HSD1 promoter region  
11β-HSD1 can be transcribed from the P1 promoter (transcribing exon 1A), from the 
P2 promoter (exon 1B), or from the P3 promoter in the intron between exons 2 and 3 
(Moisan, Edwards et al. 1992; Bruley, Lyons et al. 2006). Transcription starts 
associated with each promoter are shown by curved arrows. Rectangular boxes 
indicate exons (numbers in boxes indicate the exon). An asterisk indicates the normal 
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The regulation of the P1 and P3 promoters has not been characterized, although 
expression of 11β-HSD1 in lung (mainly from the P1 promoter) is 
C/EBPα−independent and the P1 promoter is not regulated by C/EBPα in transfected 
cells (Bruley, Lyons et al. 2006). The P2 promoter has been shown to be regulated by 
the CCAAT/enhancer binding protein (C/EBP) family of transcription factors.  
C/EBPs are major regulators of cell proliferation and terminal differentiation 
(reviewed in (McKnight 2001)). There are 6 members of the family; 
C/EBPα, β, γ, δ, ε and C/EBPζ (also known as CHOP) (Lekstrom-Himes and 
Xanthopoulos 1998). C/EBPα and C/EBPβ have both been implicated in the 
regulation of 11β-HSD1 transcription (reviewed in (Chapman, Coutinho et al. 2009)). 
C/EBPα plays a major role in energy metabolism (McKnight, Lane et al. 1989) and 
haematopoietic lineage determination (Iwasaki, Mizuno et al. 2006). C/EBPβ 
regulates inflammatory and native immunity functions (reviewed in (Poli 1998)). In 
vivo, C/EBPα is a major regulator of 11β-HSD1 P2 promoter activity in liver and 
brown adipose tissue (Williams, Lyons et al. 2000; Bruley, Lyons et al. 2006) as well 
as mature adipocytes (Dr Cristina Esteves, personal communication). C/EBPβ is also 
important for 11β-HSD1 expression in white adipose tissue (Payne, Au et al. 2007) 
and adipocytes (Dr Cristina Esteves, personal communication). In vitro, in 3T3-L1 
preadipocytes, C/EBPβ is implicated in the basal level expression of 11β-HSD1 and 
its induction in response to cAMP, as 3T3-L1 preadipocytes are differentiated into 
adipocytes (Gout, Tirard et al. 2006). Similarly, when 3T3-L1 preadipocytes were 
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treated with ceramide or the AMPK activator, AICAR, 11β-HSD1 expression and 
enzyme activity was increased, and was dependent upon C/EBPβ binding to the P2 
promoter (Arai, Masuzaki et al. 2007). In A549 lung epithelial cells, dex increased 
11β-HSD1 expression, and it was dependent on C/EBPβ and associated with 
C/EBPβ binding to the P2 promoter of 11β-HSD1 (Sai, Esteves et al. 2008). Dex has 
also been shown to increase 11β-HSD1 activity in human skin fibroblasts (Hammami 
and Siiteri 1991) an effect which might also depend on C/EBPβ, which is regulated 
by GC (Berg, Didon et al. 2005; Yang, Mammen et al. 2005). 
 
The P2 promoter is also regulated by cytokines. TNF-α increased 11β-HSD1 
expression by inducing the binding of C/EBPβ to the P2 promoter of 11β-HSD1 in 
HepG2 (hepatoma) cells (Ignatova, Kostadinova et al. 2009). Similarly, the dramatic 
induction of 11β-HSD1 expression by IL-1 in human fetal lung fibroblasts required 
C/EBPβ binding to the P2 promoter of 11β-HSD1 (Yang, Zhu et al. 2009).  
 
1.7.2 Expression of 11β-HSD1 in lung 
11β-HSD1 is expressed in lung of all species examined to date, including rat, mouse, 
rabbit and human (Torday, Olson et al. 1976; Monder and Lakshmi 1990; Soldan, 
Nagel et al. 1999; Speirs, Seckl et al. 2004).  
 
In rat lung, 11β-HSD enzyme activity is mainly reductase (Nicholas and Lugg 1982) 
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and the presence of the protein in lung has been confirmed by western blots after 
producing an antibody against rat liver 11β-HSD1 (Monder and Lakshmi 1990). In 
humans, expression of 11β-HSD1 varies widely between individuals, with an almost 
20-fold range in 11β-HSD1 mRNA levels between different subjects (Soldan, Nagel 
et al. 1999) which suggests large inter-individual differences. Within lung, expression 
of 11β-HSD1 has been identified by IHC in fibroblasts and type II alveolar cells 
(Brereton, van Driel et al. 2001; Suzuki, Tsubochi et al. 2003). The IHC result is 
consistent with activity assays in isolated lung fibroblasts. Both human and rat lung 
fibroblasts in vitro show 11β-HSD reductase activity (Abramovitz, Branchaud et al. 
1982; Torday, Post et al. 1985). 
 
Very little 11β-HSD1 is expressed in rodents prior to birth (Speirs, Seckl et al. 2004). 
However, studies in the mouse, rat and rabbit have demonstrated a rise in conversion 
of 11-dehydrocorticosterone to corticosterone by the fetal lung in late pregnancy 
(Torday, Olson et al. 1976; Hundertmark, Ragosch et al. 1994; Suzuki, Tsubochi et al. 
2003). In mouse lung, 11β-HSD1 mRNA expression is observed at E15 and increases 
strongly later in development (Speirs, Seckl et al. 2004).  
 
Given the effects of GC on fetal lung maturation, these studies suggested that 
11β-HSD1 may be important in the fetal development of lung. Consistent with such a 
role, 11β-HSD1 deficient mice exhibited delayed fetal lung development, with lower 
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surfactant protein (SP)-A levels and significant depletion of lung surfactant 
(Hundertmark, Dill et al. 2002). Chemical inhibition of fetal 11β-HSD1 activity also 
reduced the gestation-dependent accumulation of SP-A and decreased lamellar body 
content in alveolar type II cells in lung (Hundertmark, Dill et al. 2002). These data 
suggest 11β-HSD1 plays an important role in regulating GC levels in fetal lung to 
enhance lung maturation.  
 
1.8 Lung inflammation and fibrosis  
1.8.1 Lung structure 
Lung is the main organ for air exchange, extracting oxygen from the air into the 
blood circulation and releasing CO2. Lung can be divided into two components, 
airways and alveoli (Figure 1.6A). The airways comprise the upper airway (trachea) 
and lower airways (bronchi). At the end of the bronchi are the alveoli, which are 
surrounded by capillaries and are the site of gas exchange. There are 4 main kinds of 
cells in and around alveoli. Type I alveolar cells comprise ~95% of the alveolar 
surface area and are the major cell type in alveoli. They are thin, squamous epithelial 
cells that cover the pulmonary capillaries, and are required for effective gas exchange. 
Type II alveolar cells cover only about 5% of the alveolar surface area and their main 
function is to produce and secret surfactant to reduce surface tension of the alveolar 
wall. Fibroblast cells are present in the connective tissue of the alveoli to form the 
structure and alveolar macrophages are located inside the alveolar spaces to clear 






Figure 1.6 Lung structure 
(A), basic structures of lung from trachea to alveoli, and the basic structure of alveoli 
(enlarged circle). (B), the detailed structure of alveolar sacs. CT represents 
connective tissue.  
[Taken from http://education.vetmed.vt.edu/Curriculum/VM8054/Labs/Lab25/lab25.htm] 
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Lung is one of the few tissues or organs which are exposed to air directly. Due to the 
moist environment, it is an ideal place for bacteria to grow. Alveolar macrophages 
comprise about 85% of free cells in the alveoli and they are a distinctive cell type in 
a unique environment where they function to phagocytose and neutralize the large 
daily burden of foreign organisms and particles that reach the distal airways (Brody 
1998). Clearance of these particles must be achieved without excessive inflammation 
that could compromise gas exchange, suggesting that alveolar macrophages are 
specialized phagocytes (Hu, Sonstein et al. 2000). It is well established that resting 
alveolar macrophages help to create an immunosuppressive environment in which 
the initiation of immune responses and the activation of antigen-specific T cells in 
the lung are limited (Strickland, Kees et al. 1996).  
 
Minor lung injury is usually resolved by cycles of the normal physiological response 
of inflammation and repair. However, when injury is repetitive or larger in magnitude, 
the repair process is exaggerated and usually widespread and frequently results in 
scarring or fibrosis (Martinet, Menard et al. 1996).  
 
1.8.2 Bleomycin-induced lung injury and fibrosis 
Bleomycin belongs to a family of glycopeptides isolated from Streptomyces 
verticillus and is used clinically as a cancer chemotherapeutic agent for the treatment 
of several types of tumors, notably squamous cell carcinomas and malignant 
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lymphomas (Blum, Carter et al. 1973), probably because of its ability to mediate 
dioxygen activation and affect the degradation of DNA substrates (Hamamichi, 
Natrajan et al. 1992). It binds to DNA and iron which induces free radical formation, 
resulting in death of cells (Kane, Natrajan et al. 1994). Bleomycin has also been 
shown to mediate the oxidative degradation of all major classes of cellular RNA 
(reviewed in (Hecht 2000)). The main side effect of treatment with bleomycin is 
dose-dependent pulmonary toxicity and pulmonary fibrosis (reviewed in (Cooper, 
Zitnik et al. 1988)). Bleomycin increases total lung collagen content possibly 
resulting from an inflammatory response to lung injury (Sikic, Young et al. 1978). 
The symptoms following bleomycin treatment in animal models resemble human 
idiopathic pulmonary fibrosis (Giri, Nakashima et al. 1985). The bleomycin model 
includes four phases; an initial injury phase, an inflammatory phase, a proliferative 
phase involving connective tissue cells and other cells and a remodeling-repair phase. 
Typically, intratracheal instillation of bleomycin causes necrosis of type I alveolar 
cells up to one day post instillation, followed by acute alveolitis on day two or three, 
then an intense interstitial inflammation (Piguet, Collart et al. 1989). And the lung 
starts to express chemokines, such as CXCL-12 and CCL-18 to recruit inflammatory 
cells (Phillips, Burdick et al. 2004; Pochetuhen, Luzina et al. 2007). Overexpression 
of those chemokines worsens the severity of lung inflammation and fibrosis (Phillips, 
Burdick et al. 2004; Pochetuhen, Luzina et al. 2007). During the inflammation phase, 
fibroblasts start to proliferate and differentiate into myofibroblasts in an attempt to 
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repair the damaged alveolus, resulting in ECM accumulation. The collagen content 
can be elevated by 2-fold after three weeks of treatment (Bowden 1984). Fibrosis is 
seen within the interstitium and the alveolar spaces, and finally leads to extensive 
diffuse pulmonary fibrosis (Swaisgood, French et al. 2000). In normal wound healing, 
the number of myofibroblasts gradually declines as the healing process is 
successfully completed and it has been suggested that myofibroblast disappearance 
occurs via apoptosis (Gabbiani, Hirschel et al. 1972; Desmouliere, Redard et al. 
1995).  
 
TGF-β1 is one of the most important factors in inducing fibrosis in lung (Shukla, 
Meisler et al. 1999) and production of this cytokine has been widely demonstrated in 
bleomycin-induced pulmonary fibrosis (Zhang, Flanders et al. 1995). Bleomycin 
treatment increases the transcription of TGF-β mRNA, total cellular TGF-β mRNA, 
and total cellular type I procollagen mRNAs in rat lung fibroblasts (Cutroneo, Breen 
et al. 1991). C/EBP-β also plays a significant role in the development of pulmonary 
fibrosis (Hu, Ullenbruch et al. 2007) and it stimulates the expression of α-SMA 
during myofibroblast differentiation (Hu, Wu et al. 2004). C/EBP-β–/– mice were 
resistant to bleomycin induced fibrosis (Hu, Ullenbruch et al. 2007), demonstrating a 





1.9 Hypothesis and Aims of this study 
Hypothesis: 
Amplification of endogenous intracellular GC levels by 11β-HSD1 represents an 




This thesis aimed to test the above hypothesis, by determining the contribution of 
11β-HSD1 to an inflammatory response, using 11β-HSD1-deficient mice subjected 
to experimental models of lung inflammation and fibrosis. Furthermore, to provide 
new insights into its role in the inflammatory response, the regulation of 11β-HSD1 
was investigated in wild-type (WT) control mice. In particular the specific aims 
were: 
 Firstly, to characterize the expression of 11β-HSD1 in lung and identify the cell 
types that express 11β-HSD1. 
 Secondly, to identify the 11β-HSD1 gene promoter used in lung fibroblasts and 
determine if 11β-HSD1 is regulated by cytokines in these cells. 
 Thirdly, to investigate whether there is a difference in lung inflammation and 































Male Mice (~16-18 weeks of age) homozygous for a targeted disruption of the 
Hsd11b1 gene encoding 11β-HSD1 (backcrossed >8 generations on a C57BL/6 
background) (Kotelevtsev, Holmes et al. 1997) (Morton, Paterson et al. 2004) and 
age-matched C57BL/6 control mice (Hsd11b1+/+) were used. Mice were bred on-site 
and were housed in groups of 2-6 per cage under controlled conditions (12h 
light/dark cycles, at 21ºC) with unlimited access to water and standard rodent chow. 
All experiments on animals were approved by the local ethics committee and were 
performed in accordance with the U.K. Home Office Animals (Scientific Procedures) 
Act of 1986.  
 
2.1.2 Tissue culture materials 
Attachment medium 500ml RPMI-1640 supplemented with 10 ml 




500ml RPMI-1640 supplemented with 10ml 
penicillin/streptomycin (5000U/ml), 0.5ml 50 
mM 2-mercaptoethanol, 50ml FBS 
Dissociation solution 12.5mg DNase I in 50ml of Phosphate buffered 
saline (PBS) (without calcium and magnesium), 
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containing 500μg gentamycin and 800μg 
tylosine, filter sterilized, kept at room 
temperature and used fresh each time. 
Fibroblast culture medium 500ml DMEM supplemented with 5ml 
penicillin/streptomycin (5000U/ml) and 50ml 
NBFS 
GM-CSF solution Reconstitute to 10μg/ml and store at –20°C in 
40μl aliquots (for 10μg lots, dissolve in 100 μl 
sterile water, then add 900 μl sterile PBS) 
Conditioned L929 media  Gift of Dr Jeremy Hughes lab 
Macrophage medium DMEM/F12 Glutmax (Invitrogen) 
supplemented with 50ml FBS, 5ml 
penicillin/streptomycin (5000U/ml) and 10% 
conditioned L929 medium  
Trypsin solution 65mg Trypsin type I into 26ml PBS with 
calcium and magnesium. The solution dissolved 
slowly.  After dissolve, solution was filter 
sterilized and used fresh at 37°C. 
 
 
2.1.3 Tissue culture media and reagents 
Cell strainer BD Biosciences, The Danby Building, Edmund 
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Halley Road, Oxford Science Park, OX4 4DQ 
Oxford, UK 
Collagenase from Clostridium 
histolyticum, Type IA-S 
Sigma-Aldrich Company Ltd. 
The Old Brickyard, New Road, Gillingham, 
Dorset, SP8 4XT 
Dimethyl Sulphoxide (DMSO) 
D2650 
Sigma-Aldrich (see above) 
DMEM/F12 Glutmax medium Invitrogen Ltd, 3 Fountain Drive,  
Inchinnan Business Park, Paisley, PA4 9RF 
Dulbecco's Modified Eagle's 
Medium (DMEM)  
Lonza Group Ltd, Muenchensteinerstrasse 38 
CH-4002 Basel, Switzerland 
F-12K Nutrient Mixture, Kaighn's 
Modification (1X), liquid 
Invitrogen (see above) 
Fetal bovine serum (FBS) Lonza (see above) 
Gentamicin solution (10mg/ml) Sigma-Aldrich (see above) 
Granulocyte-Macrophage Colony 
Stimulating 
Factor (GM-CSF) REC MS 
(BioSource™) 
Invitrogen (see above) 
L-Glutamine (200mM) Lonza (see above) 
2-mercaptoethanol Sigma-Aldrich (see above) 
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NucleoCassette ChemoMetec, Gydevang 43, DK-3450 Allerod, 
Denmark 
NucleoCounter ChemoMetec (see above) 
Penicillin and streptomycin 
solution (5000U/ml) 
Lonza (see above) 
Petri dish Barloworld ScientificBeacon Road, Stone, 
Staffordshire, ST15 0SA, UK 
Phosphate buffered saline (PBS) 
(without calcium and magnesium) 
Sigma-Aldrich (see above) 
Phosphate buffered saline (PBS) 
(with calcium and magnesium) 
Sigma-Aldrich (see above) 
RPMI 1640 medium with 
L-glutamine 
Lonza (see above) 
Tissue culture flasks (25cm2 and 
75cm2) 
Corning Limited, The Guildway, Old 
Portsmouth Road, Artington, Surrey GU3 1LR, 
United Kingdom 
Trypsin/ EDTA (trypsin 500mg/L, 
EDTA 200mg/L) 
Lonza (see above) 
Trypsin type I, from Bovine 
pancreas 
Sigma-Aldrich (see above) 




6,12 well plates Corning (see above) 
 
2.1.4 General reagents  
All general reagents were purchased from Sigma-Aldrich, or were purchased as 
detailed below:  
Acetone（99.5%） Sigma-Aldrich (see above) 
Aqueous picric acid solution Sigma-Aldrich (see above) 
LE Agarose Lonza (see above) 
Antibody diluent Dako UK Ltd. Denmark House, Angel Drove, 
Ely, Cambridgeshire CB7 4ET 
Avidin/biotin blocking kit Vector Laboratories, Ltd., 3 Accent Park, 
Bakewell Road, Orton Southgate, Peterborough, 
PE2 6XS, England 
Chloroform  Fisher Scientific UK Ltd, Bishop Meadow 
Road, Loughborough, Leicestershire, LE11 5RG
Diethyl Phyocarbonate (DEPC) Sigma-Aldrich (see above) 
Direct red 80 Sigma-Aldrich (see above) 
Deionised formamide Sigma-Aldrich (see above) 
Dexamethasone  Sigma-Aldrich (see above) 




Diff-quick red staining solution Dade Behring, Inc. Corporate Headquarters, 
1717 Deerfield Road, Deerfield, Illinois 
Diff-quick blue staining solution Oy Reagena Ltd, Takojantie 18, FIN-70900 
Toivala, Finland          
Ethanol Fisher Scientific (see above) 
Fast green Sigma-Aldrich (see above) 
Formalin solution, 4% Sigma-Aldrich (see above) 
Hydrogen peroxide  VWR International Ltd, Hunter Boulevard, 
Magna Park, Lutterworth, Leicestershire, LE17 
4XN 
Harris' hematoxylin Thermo, anatomical pathology international, 
93-96 Chadwick Road, Astmoor, Runcorn, 
Cheshire, WA7 1PR, UK 
Isopropyl alcohol Fisher Scientific (see above) 
Kodak MS-1 autoradiographic 
film 
Sigma-Aldrich (see above) 
Liquid Diaminobenzidine (DAB) 
+ substrate chromogen system 
Dako (see above)  
Lipopolysaccharide (LPS) Sigma-Aldrich (see above) 
Methanol Fisher Scientific (see above) 
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Mowiol 4-88 Reagent MERCK CHEMICALS LTD, Padge Road, 
Beeston, Nottingham NG9 2JR, UK 
NICK columns Amersham Pharmacia Biotech UK Ltd 
Pepsin from porcine gastric 
mucosa 
Sigma-Aldrich (see above) 
Phosphate buffered saline (PBS) 
tablets 
Oxoid Ltd, Wade Road, Basingstoke, 
Hampshire, RG24 8PW, UK 
Protein assay dye reagent 
concentrate 
Bio-Rad Laboratories Ltd, Bio-Rad House, 
Maxted Road, Hemel Hempstead, Hertfordshire, 
HP2 7DX, UK 
Protein assay reagent A Bio-RAD (see above) 
Protein assay reagent B Bio-RAD (see above) 
Protein block Dako (see above) 
Proteinase K Promega UK Ltd, Delta House, Enterprise 
Road, Chilworth Research Centre, Southampton 
SO16 7NS 
R.T.U. vectorstain kit (ABC 
reagent) 
Vector (see above)  
Sircol Dye Reagent Biocolor Ltd, 8 Meadowbank Road, 




20xSSC Sigma-Aldrich (see above) 
Xylene Fisher Scientific (see above) 
 
2.1.5 Antibodies 
1) Primary antibodies:  
Anti-mouse F4/80 antigen, rat, 
1:50 dilution 
AbD Serotec, Endeavour House, Langford 
Business Park, Langford Lane, Kidlington, 
Oxford, OX5 1GE, UK 
11β-HSD 1 polyclonal antibody, 
rabbit, 1:100 dilution 
Cayman Chemical, 1180 E.Ellsworth Road, Ann 
Arbor, Michigan, 48108, USA 
11β-HSD 1 polyclonal antibody, 
sheep, 1:1000 dilution 
A gift from Dr Scott Webster, Endocrinology 
Unit, Queen’s Medical Research Institute, 47 
Little France Crescent, Edinburgh, EH16 4TJ. 
Anti-Mouse CD11c, Hamster 
(Biotin-labeled), 1:50 dilution 
Invitrogen (see above) 
Ms X β-tubulin, 1:1000 dilution CHEMICON, 290 Concord Road, Billerica, MA 
01821, USA 
GR polyclonal antibody (M20), 
rabbit, 1:100 dilution 
Santa Cruz Biotechnology, Inc, Bergheimer Str. 
89-2, 69115 Heidelberg, Germany 
  
2) Secondary antibodies:  
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Goat anti-Rabbit IgG, 
Biotin-labeled, 1:50 dilution 
Dako (see above) 
Rabbit anti-Rat IgG, 
Biotin-labeled, 1:200 dilution 
AbD Serotec (see above) 
Rabbit anti-Sheep IgG, HRP 
conjugate, 1:400 dilution 
Millipore (U.K.) Limited, Units 3&5 The 
Courtyards, Hatters Lane, Watford, WD18 8YH, 
England 
IRDye 800 conjugated 
Anti-mouse IgG, 1:1000 dilution 
Rockland Immunochemicals, Gilbertsville, PA 
19525, USA 
Alexa 680 conjugated Anti-sheep 
IgG, 1:1000 dilution 
Invitrogen (see above) 
 
2.1.6 Molecular biology general reagents 
Denhardt’s solution Sigma-Aldrich (see above) 
Deoxynucleotide Triphophates 
(dNTPs) 
Promega (see above) 
DNA size markers (1000 
base-pair ladder)  
Invitrogen (see above) 
Dnase I Promega (see above) 
GoTaq DNA polymerase Promega (see above) 
Kpn I restriction enzyme Promega (see above) 
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Lightcycler 480 Probes Master 
Mix 
Roche Diagnostics Ltd, Charles Avenue, Burgess 
Hill,  RH15 9RY, United Kingdom 
Not I restriction enzyme Promega (see above) 
Nuclease-free water Promega (see above) 




Promega (see above)  
RNaseOUT Invitrogen (see above) 
RNaseZAP Ambion, Applied Biosystems, Lingley House 
120 Birchwood Boulevard, Warrington WA3 
7QH, UK 
35S-dUTP GE healthcare, Pollards Wood, Nightingales 
Lane, Chalfont St Giles, BUCKS, HP8 4SP  
SP6 RNA polymerase Promega (see above) 
SuperScript™ III Reverse 
Transcriptase 
Invitrogen (see above) 
T7 RNA polymerase Promega (see above) 




2.1.7 Primers used for PCR 





Primers used to amplify 
total 11β-HSD1, 470bp 
product. (Rajan, Chapman 
et al. 1995) 
Maser 1.4L 5’- GGAGCCGCACTTATCTGAA -3’ Primer used to amplify 
from mouse promoter 1 
with P868; 627bp product. 
Down stream 
Ex1 specific 
5’- GGAGGTTGTAGAAAGCTCTG -3’ 
 
Primer used to amplify 
from mouse promoter 2 
with P868; 646bp product. 
P31 intron 5’- GTATGGAAAGCAAGACAAGG -3’ 
 
Primer used to amplify 
from mouse promoter 3 





Primer used to amplify 
from human promoter 1 




5’-GGAGGTTGTAGAAAGCTCTG-3’ Primer used to amplify 
from human promoter 2 
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5’-TTCTGCAAACGAGGAATTCAG-3’ Primers used to amplify 





5’-GTAGAGTTTCTTTTGACCTCG-3’ Human reverse primer 
 
2.1.8 Equipment 
Wallac 1450 MicroBeta TriLux 
Liquid Scintillation Counter 
Perkin Elmer, 940 Winter Street, Waltham, 
Massachusetts 02451, USA 
Chamber Slide™ NUNC™ 
Lab-Tek™ II 
VWR International Ltd, Hunter Boulevard, 
Magna Park, Lutterworth, Leicestershire, 
LE17 4XN 
Cover slips  VWR (see above) 
Cover plate Thermo (see above)  
Cytocentrifuge cytospin 3 Thermo (see above) 
Cytoclip  Thermo (see above) 
Eppendorf centrifuge Eppendorf UK Limited, Endurance House, 
Vision Park, Chivers Way, Histon, 
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Cambridge, CB4 9ZR 
Filter card Thermo (see above) 
Fuji Film FLA-2000 phosphorimager 
and Fuji BAS phosphorimager tritium 
screen 
Raytek Scientific Ltd, Sheffield, UK. Fuji 
photofilm Company Ltd, Tokyo, Japan.  
Gene Quant RNA/DNA calculator GE healthcare (see above) 
Light cycler 480 Roche (see above) 
OPTI max microplate reader Molecular Devices Corporation, 1311 
Orleans Drive, Sunnyvale, CA 94089-1136, 
U.S.A. 
Sequenza staining Racks Thermo (see above) 
Superfrost plus microscope slides VWR (see above) 
 
2.1.9 Preparation of buffers and solution 
Borate Buffer 8.25g Boric acid, 2.7g NaOH, and 3.5ml HCl (33M) 
was made up to 1L with H2O (pH 7.4), then 0.5% 
BSA (0.5g/100ml) was added and stored at -20°C 
Citrate Buffer, pH 6.0 1.92g Citric acid (anhydrous) made up to 1L with 
dH2O and pH to 6.0, then 0.5 ml of Tween 20 added 
and solution autoclaved. 
Deionised Formamide 150ml formamide mixed with 15g mixed bed 
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ion-exchange resin for >1hr, filtered twice and stored 
protected from light 
DEPC-treated H2O 100ml dH2O with 1 drop diethylpryocarbonate, left 
O/N before autoclaving 
DNA ladder in loading 
buffer 
30μl 1kb DNA ladder, 60μl TE and 30μl loading 
buffer. 
10X MOPS buffer 200mM 3-(N-morpholino) propanesulfonic acid, 
50mM sodium acetate, 10mM EDTA, pH to 7 then 
autoclaved. 
Methyl-Carnoy fixative 60:30:10 (v/v) of methanol, chloroform and glacial 
acetic acid, respectively 
RNase buffer 1ml 5M NaCl, 100μl 1M Tris and 40μl 250mM 
EDTA, made up to 10ml with Dep H2O 
PBST 0.5ml Tween 20 dissolved in 1000ml PBS 
2X prehybridization 
solution 
5.88ml Dep H2O, 2.4ml 5M NaCl, 200μl 1M Tris (pH 
7.5), 400μl 50x Denhardt’s solution, 80μl 250mM 
EDTA, 1ml 10mg/ml sonicated salmon sperm DNA 
and 40μl 50mg/ml yeast tRNA  
Prehybridization solution 6.68ml Dep H2O, 2.4ml 5M NaCl, 200μl 1M Tris (pH 
7.5), 400μl 50x Denhardt’s solution, 80μl 250mM 
EDTA, 200μl 10mg/ml sonicated salmon sperm 
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1ml 30% H2O2 added to 9ml 1X PBS, mix well and 
store at 4ºC, stable for 3 months. 
Scott’s Tap Water Substitute 
(STWS) 
100g magnesium sulphate and 17.5g sodium 
bicarbonate, made to 5L in H2O 
10X TBE buffer 108.9g Trizma base, 55.7g boric acid, 4.7g EDTA, 
made to 1L in DEPC H2O and autoclaved. 
TE buffer 10mM Tris-HCl pH8, 1mM EDTA, made to 1L with 
dH2O, then autoclaved. 
 
2.1.10 Steroids and radiolabeled steroids  
Dexamethasone (DEX) (FW=392g) was dissolved in 100% ethanol to a stock 
concentration of 10mM and stored at –20°C 
Corticosterone (B) (FW=346.5g) was dissolved in 100% ethanol to a 
stock concentration of 10mM and stored at –20°C 
11-Dehydrocorticosterone 
(A) 
(FW=344.4g) was dissolved in 100% ethanol to a 
stock concentration of 10mM and stored at –20°C 
[3H]-Corticosterone Commercial stock solutions of [3H4]-Corticosterone 
(specific activity ~37 Ci/mmol; Amersham Pharmacia 
Biotech, Buckingham, UK) in ethanol (with 
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concentrations of 13.7nmol/ml) were stored at -20°C 
[3H]-11-Dehydrocorticoster
one 
[3H4]-11-Dehydrocorticosterone was synthesized 
in-house (preparation described in detail in Section 
2.2.23.1), re-suspended in ethanol (for final 
concentrations of ~10-15nmol/ml) and stored at -20°C
 
2.1.11 Software 
Gel electrophoresis (UVI pro) UVItec Limited, Avebury House, 36a Union Lane, Cambridge CB4 1QB, 
United Kingdom 
Phosphorimage analysis (Aida) Raytek Scientific Ltd (see above) 
Statistical analysis (Excel) Microsoft Corporation 
GraphPad Prism 4.00 GraphPad Software 
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cell lines; maintenance of HFL-1 and A549 cells in culture 
A549 cells were derived from a human lung adenocarcinoma cell line and resemble 
type 2 alveolar cells (Lieber M, Smith B et al. 1976). HFL-1 cells were derived from 
human fetal lung fibroblast cells (Breul, Bradley et al. 1980). HFL-1 and A549 cells 
were brought up from liquid nitrogen from one of the original passages then these 
cells were passaged, split and stored in liquid nitrogen to ensure that cells maintain 
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the original character and were not excessively passaged. If cells were passaged more 
than 15 times, the cells took on the appearance of quiescent cells and did not 
proliferate.  
 
A549 cells were maintained in 75cm2 corning flasks in DMEM containing 50U/ml 
penicillin/streptomycin and 10% FBS. HFL-1 cells were maintained in 75cm2 
corning flasks in F-12K Nutrient Mixture containing 50U/ml penicillin/streptomycin, 
1.5mg/ml sodium bicarbonate and 10% FBS. Cells were passaged every week. 
Medium was aspirated and cells were washed with DMEM medium supplemented 
with 50U/ml penicillin/streptomycin to remove traces of serum. Cells were immersed 
in 2ml trypsin/EDTA for 5min in an incubator at 37°C, 5%CO2. The flask was gently 
shaken to assist cell detachment from the surface of flask. Trypsin was neutralized by 
8ml medium containing 10% FBS. Approximately 2.5ml cells were left for further 
culture, the rest were aspirated. 10ml fresh medium was added into the flask. Cells 
were incubated at 37°C and 5%CO2 until the next passage. Two 75 cm2 corning 
flasks were maintained and required for each experiment. 
 
2.2.1.2 Primary cells; generation of murine bone marrow derived 
macrophages (BMDM) 
Male mice were killed by cervical dislocation and immersed in 75% ethanol. A 
lateral incision was made in the skin midway down the abdomen and skin removed 
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from the lower abdomen and legs. The tissue surrounding the hip point and muscle 
on the femur was dissected using autoclaved surgical instruments. The femurs were 
removed by cutting through the knee joint and the hip joint (flexing the limb helped 
to pinpoint the spot to cut). The femurs were placed into PBS on ice and transported 
to a tissue culture hood. The tissues surrounding the femur were removed with a 
sterile scalpel. Any remaining connective tissue was removed with disinfectant wipes. 
The femurs were rinsed in 70% ethanol and placed in a small Petri dish with some 
medium. The proximal and distal ends of each femur were cut just below each joint. 
A 25G green needle was inserted into the bone cavity. The bone marrow were 
flushed out in 5ml medium and collected into a 30ml sterile container. This was 
repeated once from the opposite end of the bone. The cells were resuspended 3 times 
through a wider bore needle then transferred into 60ml Teflon pots and cultured in 
30ml L929 medium in an incubator at 37°C, 5%CO2. Half of the medium was 
replenished every other day. Macrophages were harvested for experiment at day 7. 
Usually the macrophage yield was about 1-2X107 per femur and purity, assessed by 
F4/80 staining of cytospin, was generally more than 90%. 
 
2.2.1.3 Primary cells; generation of bone marrow derived dendritic cells 
Bone marrow cells were isolated as above session 2.2.1.2, counted by 
haemocytometer and viability assessed by trypan blue exclusion. Dendritic cells (DC) 
were differentiated from bone marrow according to described methods (Lutz, 
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Kukutsch et al. 1999). On day 0, cells were seeded on bacteriological petri dishes at 
2X105/ml in 10ml DC medium containing 20ng/ml GM-CSF. Cells (200μl) were 
added dropwise to the centre of each petri dish containing medium. On day 3, 10ml 
of DC medium containing 20ng/ml GM-CSF was added to the petri dish. On day 6 
and 8, the procedure was the same as day 3. On day 10, floating cells were harvested 
by gentle pipetting, counted and centrifuged at 300g for 5 min at room temperature. 
Cells were resuspended at 2X106/ml in DC medium containing 5ng/ml GM-CSF to 
mature DC. On day 11, cells were harvested for experiment. The maturation of DCs 
was assessed by CD11c staining. 
 
2.2.2 Cytocentrifugation  
Cells were adhered onto Superfrost Plus microscope slides by cytocentrifugation in a 
cytoclip centrifuge (Thermo). Approximately 2X105 cells in 120-140μl PBS 
containing 10% FBS were loaded into a cytospin chamber and the cells were adhered 
onto a glass slide by centrifugation at 300 rpm for 3min. Slides were then air dried 
and fixed in methanol for 2min. Diff-quick staining was performed by immersion 
into diff-quick red for 1min followed by diff-quick blue for 1min. For 
immunocytochemistry, slides were fixed in a combination of 9:1 (v/v) acetone: 




2.2.3 Bleomycin model 
Bleomycin was administered by intra-tracheal (i.t.) instillation of 50µl of 0.025U 
bleomycin solution. This was carried out by Dr Rodger Duffin (CIR, QMRI). Mice 
were killed at various time points; 0d (untreated mice), 2d, 7d, 14d and 28d 
following bleomycin instillation. In same experiments, prior to termination, blood 
samples were collected by tail nick (section 2.2.16) for measurement of plasma 
corticosterone level and blood cell phenotype.  
 
Mice were then anaesthetised by i.p injection of 150μl pentobarbital. The body was 
sprayed with 75% ethanol and the skin was removed by blunt dissection. BALF was 
collected as described in section 2.2.4. The lung and heart were isolated from the 
main body as described (section 2.2.4), preserved in formalin or in dry ice. Further, 
lungs were homogenated for RNA or protein extraction (section 2.2.8 and 2.2.23.2) 
or used to measure collagen content by Sircol assay (section 2.2.20). Formalin fixed 
lung were subjected to histology analysis (section 2.2.17). Adrenal glands were 
collected for weighing into 0.5ml tube with 0.2ml formalin. Subsequently adrenal 
glands were dissected to remove surrounding tissues and weighed.  
 
2.2.4 Bronchial alveolar lavage + collection of cells + perfusion + 
preparation of lung 
Bronchial alveolar lavage fluid (BALF) was collected according to described 
 
 63
methods (Oreffo, Morgan et al. 1990; Fitch 2005). Mice were anesthetized using a 
lethal intraperitoneal injection of 0.5ml pentabarbitone (Sagatal) (Merial Animal 
Health, UK). Fur was washed with 70% ethanol and then deflected from the skin, 
from the abdomen to the throat, on the ventral surface. The abdominal cavity was 
opened and the liver and other abdominal organs were removed without puncturing 
the diaphragm. The diaphragm was lifted up with forceps and carefully punctured to 
deflate the lungs. The rib cage over the lungs and heart were removed. The peritoneal 
cavity and neck were then exposed and a set of watchman scissors used to expose, 
stretch and lift the trachea, which was then incised at its top using a fresh scalpel. A 
blue 23G needle covered in a 1inch stretch of flexible tubing was then inserted into 
the trachea for approx 2cm, and tied off mid-cartilage ring via a fine suture.  
 
0.8ml of PBS was then inserted into the lungs and withdrawn. Another 3 lavages, 
each 0.8ml, were used to maximize recovery of alveolar cells. Isolated cells were 
pooled and kept on ice at all times to reduce cellular activity and macrophages loss 
through adherence to the 50ml falcon tube. The purity of alveolar macrophages was 
assessed by F4/80 staining. The right ventricle of the heart was then cut, and 
cannulation tubing inserted. Saline was perfused through the lungs via the right 
ventricle under gravitational pressure. The lungs and heart were then carefully 
removed from the body. For immunohistochemistry, lungs were inflated with 
formalin via the tracheal tube and immersed in formalin. For cell culture, lungs were 
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inflated with PBS and preserved in PBS on ice before transporting to the lab.  
 
2.2.5 Isolation of fibroblast and epithelial cells from mouse lung 
The isolated lung was suspended in PBS at 37°C and expanded with 0.8ml trypsin 
solution which was rapidly withdrawn. The lungs were then filled completely with 
5ml trypsin solution and left for 15min. During this time, the trypsin solution was 
topped up continuously. After 15min, the heart was removed and the lung transferred 
to a petri dish and chopped into 1-2mm cubes using a scalpel and scissors in 1ml 
FBS (Figure 2.1). The pieces were then transferred using a sterile transfer pipette to a 
15ml tube with 4ml dissociation solution. After swirling for 4min, the solution was 
filtered through the cell strainer and a final volume of 4mls were centrifuged at 32G 
for 6 min at 10°C. The supernatant was removed to another tube and the pellet was 
resuspended in dissociation solution and recentrifuged. The pellet was then 
resuspended in 3ml attachment medium and placed in a petri dish at 37°C, 5% CO2 
for 1.5h. During this time, macrophages and fibroblasts attached to the bottom of the 
petri dish. The epithelial cells, consisting mainly of Clara cells could be isolated as 
clumped balls of cells by gently rocking the dish. Epithelial cells were counted and 














Figure 2.1 Diagram of lung cells isolation 
Lung was chopped into cubes after trypsin digestion and then was filtered through 
the cell strainer. The cells were plated on a Petri dish. Purple color indicate floating 
cells, which is mainly epithelial cells, blue color indicate adherent cells, which are 






None adherent cells, epithelial cells 




2.2.6 Fibroblast culture and passage  
Following isolation of epithelial cells, the remaining pieces on the cell strainer were 
plated into a 50ml tube with 20ml Collagenase Type IA-S and FBS solution (50mg 
Collagenase Type IA-S with 11ml FBS in 89ml PBS). The tubes were rotated for 
10min at 37°C and the media was passed through pipette several times to dissociate 
cells. Then the tubes were rotated for another 10min and then the media was 
centrifuged at 300G for 5min at 4°C. Further the pellet was resuspended with 
DMEM with 10% FBS and was cultured at flask. Medium was replaced 24h after 
plating. After one week, fibroblasts were washed with PBS and trypsinized with 10% 
trypsin/EDTA diluted in PBS without calcium or magnesium at 37°C, 5% CO2 for 
30min. Trypsin was neutralized using DMEM containing 10% FBS and the cells 
were plated in a new flask. Fibroblasts were then cultured in DMEM with 10% 
NBFS and passaged every week. 
 
2.2.7 TGF-β treatment on fibroblast cells 
For TGF-β treatment, fibroblast cells were trypsinized and resuspended in medium. 
Cell density was determined using a haemocytometer and adjusted to 1X105 cells/ml. 
Cell viability was determined by adding 100μl cells to 100μl 0.4% (w/v) Trypan blue 
and counting the number of cells taking up dye (dead cells) and those not. Viability 
was typically 90-95%. 2ml of suspended cells were plated per well in 6 well plates at 
2X105/well and placed in an incubator at 37°C with 5% CO2, where they were 
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maintained for the entire culture period. 1d after plating, the medium was aspirated 
from the cells and 4ml starving medium containing 2% NBFS was added. 1d after 
starving, cells were treated with 2ng/ml TGF-β for 72h. Control groups were treated 
with appropriate concentration of DMSO.  
 
2.2.8 RNA extraction and analysis 
All instruments used for RNA extraction were autoclaved or treated with RNaseZap 
before use. All solutions were made with DEPC H2O. Lung tissues were put into 
aluminum foil, placed on dry ice and broken into small pieces using a hammer. 
Tissues were weighed before homogenization. About 50mg of tissue or 5X106 cells 
were added into 1ml TRIzol for RNA extraction. RNA was extracted following 
homogenization in TRIzol, according to the manufacture’s instructions. Samples 
were incubated for 5min at room temperature to permit the complete dissociation of 
nucleoprotein complexes. 0.2ml chloroform per 1ml of TRIzol was added to the 
sample. Samples were vortexed vigorously for 15s, incubated at room temperature 
for 3min and then centrifuged at 12,000g at 4°C for 15min. The upper (aqueous) 
phase was transferred to a fresh tube and RNA precipitated by mixing with 0.5ml of 
isopropyl alcohol per 1ml of TRIzol. Samples were incubated at room temperature 
for 10min and then centrifuged at 12,000g at 4°C for 10min. The supernatant was 
removed and the RNA pellet was washed with 1ml ice cold 75% ethanol and 
centrifuged at 7,500g at 4°C for 5min. The pellet was air dried on ice and dissolved 
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in 30μl DEPC H2O by pipetting up and down. Samples were stored at -80°C until 
required.  
 
A GeneQuant RNA/DNA calculator was used to measure the optical density of RNA 
samples to quantify RNA concentration. 1μl RNA sample was diluted in 99μl DEPC 
H2O and quantified by UV absorbance at 260nM. The ratio of A 260: A280 was also 
measured as an indicator of RNA purity. Generally, the ratio was between 1.6-1.8. 
RNA integrity was checked by denaturing gel electrophoresis. An aliquot of total 
RNA was electrophoresed in a 100ml 1.2% agarose/ formaldehyde denaturing gel. 
1.2g of agarose was dissolved in 88ml DEPC water in a microwave oven. The 
mixture was allowed to cool slightly and then, in a fume hood, 2ml formaldehyde, 
10ml 10X MOPS buffer and 2-5μl of 10mg/ml ethidium bromide were added. 
RNaseZAP was sprayed on combs, gel tray and electrophoresis tank. The molten gel 
was poured into a sealed tray with combs in place and allowed to set. The solidified 
gel was presoaked in an electrophoresis tank filled with 1X MOPS buffer. 2μg RNA 
sample was adjusted to 10μl with DEPC H2O and 2.5μl formaldehyde, 2.5μl 10X 
MOPS and 10μl deionised formamide added in a fume hood. Samples were mixed, 
briefly centrifuged then incubated at 65°C for 15min. After denaturing, 2μl loading 
buffer was added to each sample. Then samples were loaded on the gel and 
electrophoresed at 100V for about 1-2h, until the leading dye was about 2/3 of the 
way along the gel. Ethidium bromide-stained RNA was visualized under UV at 
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260nm and integrity judged from relative intensities of 28S RNA and 18S RNA. 
 
2.2.9 RT-PCR to detect specific mRNAs 
Reverse transcriptase synthesizes single-stranded cDNA from total RNA, and the 
cDNA can be used directly in a PCR reaction. Invitrogen’s SuperScript™ III Reverse 
Transcriptase system was used for generation of cDNA. Reactions (20μl) contained 
1μg total RNA, 0.5μl 0.5μg/μl random hexamers, 1μl 10mM dNTPs and RNase free 
water. Reactions were heated at 65°C for 5min then incubated on ice for 2min. Tubes 
were briefly centrifuged and the following added: 4μl 5X First-Strand Buffer 
(supplied with SuperScript™ III RT), 1μl 0.1M DTT (supplied with SuperScript™ 
III RT), 1μl RNaseOUT and 1μl of SuperScript™ III RT. Samples were incubated at 
25°C for 5min, then 50°C for 60min and 70°C for 15min. Negative controls 
containing RNase free water instead of either reverse transcriptase (no RT) or total 
RNA (no RNA) were used in parallel. Reverse transcription reactions were used 
directly as a template for amplification in PCR.  
 
Promega GoTaq DNA polymerase was used for PCR amplification. 50μl reactions 
contained 4μl RT reaction, 0.4μl 5U/μl GoTaq, 10μl 5X Green GoTaq Reaction 
buffer (supplied with the polymerase), 1μl 2.5μM upstream primer, 1μl 2.5μM 
downstream primer, 1μl 10mM dNTPs and 32.6μl H2O. Negative controls containing 
H2O instead of RT reactions were used in parallel. 
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Initial denaturation was at 95°C for 5min. The cycle conditions were 95°C for 30s, 
60°C for 30s, 72°C for 90s. Normally a total of 30 cycles were carried out followed 
by a 7min final extension at 72°C, before holding at 4°C.  
 
RT-PCR products were normally separated on a 1.5% Agarose/0.5X TBE gel and 
visualized with ethidium bromide. The weight of agarose is 1.5g per 100ml of gel. 
Agarose was dissolved in 0.5X TBE solutions by boiling in a microwave oven. 1μl 
ethidium bromide per 50ml gel was added to detect DNA. The molten gel was then 
poured into a sealed tray with the appropriate comb, and allowed to solidify. The 
solidified gel was submerged in a gel electrophoresis tank containing 0.5X TBE 
solutions and the comb was removed to create loading wells for the DNA samples. 
9μl PCR reaction products were loaded onto the gel directly after amplification. 4μl 
1kb DNA ladder was used in order to confirm sizes of amplified products. 
Electrophoresis was carried out in 0.5X TBE at 120V for 50min, then the gel was 
viewed under UV light (wavelength 260nm) and imaged using an UVI Tec imager 
and printed on Mitsubishi video printer paper. DNA fragment size was estimated by 
comparison to 1kb ladder. 
2.2.10 Real-time PCR 
For all quantitative PCR (qPCR) experiments, real time-PCR was carried out using a 
LightCycler 480 (Roche). Primer-probe sets used to measure transcripts are listed in 




Table 2-1 Commercially available primer-probe sets. 
 
Catalogue  Amplification gene 
Mm00433832_m1 Glucocorticoid receptor, nuclear receptor subfamily 3, 
group C, member 1 
Mm01241596_m1 Mineralocorticoid receptor, nuclear receptor subfamily 3, 
group C, member 2   
Mm00516005_m1 heme oxygenase 1 
Mm01204962_gH actin, alpha 2, smooth muscle 
Mm00476182_m1 hydroxysteroid 11-beta dehydrogenase 1 
Mm00786711_s1 CCAAT/enhancer binding protein (C/EBP), delta 
Mm00492541_g1 hydroxysteroid 11-beta dehydrogenase 2 
Mm99999064_m1 interleukin 6 
Mm01165187_m1 collagen, type I, alpha 2  Collagen Type I α 2 (COL1A2) 
Mm00441726_m1 transforming growth factor, beta 1 
Mm00446971_m1 TATA box binding protein 
Mm00468869_m1 hypoxia inducible factor 1, alpha subunit 
Mm00475988_m1 arginase 
Mm01309902_m1 nitric oxide synthase 2, inducible 
Mm00443258_m1 tumor necrosis factor 
Mm00843434_s1 CCAAT/enhancer binding protein (C/EBP), beta 









Table 2-2 In-house designed primers and probe for 11β-HSD1 promoter 
detection 
 
Gene Forward primer (5’ to 3’) Common reverse 
primer (5’ to 3’) 
Common probe (5’ 













The primers and probe are for mouse 11β-HSD1 and were designed by Dr Julie 










For all the amplification of transcripts a commercial 20xassay primer-probe set 
(Applied Biosystems) and a LightCycler 480 Probes Master mix was used (Roche). 
Each real-time PCR reaction consisted of 0.5μl 20x primer/probe mixes, 5μl 
LightCycler 480 Probes Master mix, 2.5μl dH2O and 2μl cDNA. Each sample was 
measured in triplicate. The Lightcycler 480 PCR programme was as follows: 
pre-incubation at 95oC, 5min, amplification for 50 cycles of (95oC, 10s; 60 oC, 30s; 
72oC, 1s) and cooling, 40 oC, 30s. Data were calculated by the 2nd derivative 
maximum method. According to manufacture’s software application, this method 
determined the Cp of a sample as the point where the sample’s fluorescence curve 
turns sharply upward. This turning point indicates the maximum of the second 
derivative of the amplification curve and the value were calculated by the 
LightCycler ® 480 Software automatically. The ratio of tested gene divided by the 
housekeeping gene (TBP) concentrations was determined for each sample.  
 
The internal control used to correct for equal RNA concentrations between samples 
in the animal experiments (chapters 4 and 5) was TBP. 2 internal controls, TBP and 
18S were tested. TBP showed good linear relationship with gene of interest and 18S 
did not have good linear relationship with gene of interest as TBP, so finally, TBP 
was used as an internal control for all experiments. Table 2-3 list the correlation of 






Table 2-3 Correlation of coefficient of TBP and GR or 18S and GR 
 
 GR/18S GR/TBP 
WT 0D 0.91 0.92 
WT 2D -0.12 0.85 
WT 7D -0.45 0.96 
WT 14D 0.03 0.92 
WT 28D -0.92 0.09 
KO 0D -0.21 0.92 
KO 2D 0.74 0.64 
KO 7D 0.46 0.89 
KO 14D 0.01 0.97 










2.2.11 In situ mRNA hybridization 
Fresh frozen tissue was prepared by injecting 2ml of OCT embedding medium 
diluted in PBS (1:1, v/v) into lung through the trachea, then placing the lungs in a 
small container containing OCT on dry ice. 50% OCT/ 50% PBS was continually 
injected into the lung until the OCT solidified. The tissue was preserved at -80°C 
before processing. 10µm lung sections were cut using a cryostat and thaw-mounted 
onto poly-L-lysine slides. Sections were then stored at -80°C until use. 
 
In situ 11β-HSD1 mRNA hybridization was performed according to a standard 
protocol used in the lab (Seckl et al., 1990). Tissue sections were fixed in cold 
paraformaldehyde for 10min followed by 2 washes for 5min each in PBS made up in 
DEPC H2O. Sections were then incubated in 0.1M triethanolamine for 10min and 
dehydrated in serial ethanol solutions, from 50% to 100%. Both fixation and washing 
treatments were carried out in sterilized glassware.  
 
Sufficient pre-hybridization mix was made to apply 200μl to each slide. The 
pre-hybridization mix consisted of 50% deionised formamide and 50% 2X 
pre-hybridization solution. Tissue sections were dried around, the edges with lens 
tissue before adding 200μl pre-hybridization mix to each slide and ensuring each 
tissue section was covered. Sections were placed flat in plastic boxes containing 3M 
paper (Whatman) soaked with box buffer consisting of 20% 20xSSC, 20% DEPC 
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H2O and 50% deionised formamide (Sigma), for 3h at 50°C. 
 
The 11β-HSD1 probe was transcribed in vitro from a PVL105 plasmid encoding a 
470bp 11β-HSD1 mouse cDNA. For anti-sense probe, the plasmid was linearized 
with Not I and cRNA was transcribed with SP6 RNA polymerase, in a 10µl reaction 
containing 1.1µg linearized plasmid and 4µl 37MB/µl [35S]-UTP. For sense probe, 
the plasmid was linearized with Kpn I and cRNA was transcribed with T7 RNA 
polymerase, in a 10µl reaction containing 1.1µg linearized plasmid and 4µl 37MB/µl 
[35S]-UTP. Both anti-sense and sense probe were digested with Dnase I and purified 
through Nick column. Then 1µl probe was added into 1ml scintillation fluid and 
counted in Microbeta liquid scintillation counter. 
 
Sufficient hybridization mix was made up to apply 200μl to each slide. The 
hybridization mix consisted of 50% deionised formamide, 10M counts/ml of 
radioactive cRNA probe, made up to a final volume with 2x hybridization solution. 
This hybridization mix was denatured at 70°C for 10min, cooled on ice and 10μl/ml 
of 1M DTT added. Tissue sections were dried around the edges with lens tissue 
before adding 200μl hybridization mix to each slide and ensuring each tissue section 
was covered. Sections were placed flat in plastic boxes containing 3M paper soaked 
with box buffer. These boxes were then sealed with autoclave tape and incubated at 
50°C overnight. Following hybridization, slides were rinsed twice in 2x SSC for 
 
 77
10min at room temperature prior to RNase digestion with 200μl of RNase buffer at 
37°C for 1h. Slides were then washed in 2x SSC at room temperature for 1h followed 
by a more stringent wash of 0.1x SSC at 60°C for 1h. After dehydration in 50%, 70% 
and 90% ethanol in 0.3M ammonium acetate for 2min each, slides were air dried 
overnight in a fume hood before being exposed to autoradiographic film for 2 weeks, 
then dipped in photographic emulsion and stored at 4°C for 2 weeks. Films were 
developed in D19 developer (Kodak) for 2min and fixed in a 1:5 dilution of Amfix 
fixative (Kodak), for 2min. For microscopic localization, slides were dipped in 
photographic emulsion (NTB2, Kodak), exposed in a light-tight box for 3 weeks. 
Then the slides were developed for 3min in D19 developer, rinsed in dH2O, fixed in 
Amfix fixative for 3min and washed 5times in dH2O for 5min each. In order to 
visualize silver grains clearly, slides were also counterstained with hematoxylin and 
eosin and coverslipped using DPX as a mountant. 
 
Hybridization with sense cRNA probes under the same conditions as above was 
performed as controls for in situ hybridization. 
 
Visualisation of hybridisation 
The hybridization signal was quantified by measuring the density in the 
autoradiographic film under bright field using a computer driven image analysis 
system (Carl Zeiss, Welwyn Garden City, UK). Semiquantitative analysis by optical 
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densitometry measurements was carried out blind to genotype. For each lung section, 
10 circular area were measured by the image analysis system after an appropriate 
calibration. Results were calculated as mean number of density per slides after 
background counted over non-specific areas was subtracted. 
 
2.2.12 Immunohistochemistry 
Two methods were used to fix lung specimens: 4% formalin solution and 
Methyl-Carnoy fixative. For formalin fixation, the lung was inflated with formalin 
and incubated overnight at room temperature before dehydration and embedding in 
paraffin. For Methyl-Carnoy fixative, lungs were inflated and immersed in 
Methyl-Carnoy fixative overnight at 4°C, then embedded in paraffin. For both 
methods, 5µm thick sections were cut using cryostat (Leica) and floated onto slides. 
The sections were heated on a slide warmer overnight (37°C). Before staining, 
sections were deparaffinized by immersion in xylene twice for 5min, and then 
rehydrated in 100% ethanol for 2min, 100% ethanol 2min, 95% ethanol 1min, 90% 
ethanol 1min, 80% ethanol 1min. Sections were rinsed in dH2O before antigen 
retrieval.  
 
Formalin fixation forms protein cross-links that may mask antigenic sites in tissue 
sections, thereby giving weak staining for immunohistochemical detection of certain 
proteins (Puchtler and Meloan 1985). Antigen retrieval can be used to unmask the 
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antigen in formalin-fixed and paraffin embedded tissue sections, thus enhancing 
staining intensity of antibodies. Antigen retrieval was carried out in citrate buffer 
pre-heated to 100°C. Slides were plated in a staining rack and put into 100°C citrate 
buffer for 30min, then cooled to room temperature for 20min before loading onto 
sequenza racks for staining.  
 
Slides were washed in PBS containing 0.05% Tween 20 (PBST) 2 times for 3min 
each. 3 drops of Protein Block (Dako) was added to each slide for 30min to inhibit 
non-specific binding and then slides were washed 2 times in PBST. Sections were 
blocked with 3 drops of Vector Avidin Block for 10min at room temperature, then 
washed in PBST and blocked with 3 drops of Vector Biotin Block for 10min then 
washed in PBST to block non-specific binding of Avidin/Biotin system reagents, 
after which they were incubated with primary antibody diluted in Dako antibody 
diluent overnight at 4°C. After 2 PBST washes, endogenous peroxidase activity was 
blocked by incubation in 150µl Peroxidase blocking solution for 10min. The slides 
were subsequently washed in PBST and incubated with biotinylated secondary 
antibody for 30min. Two PBST washes were performed before adding 150µl Vector 
ABC reagent 30 min to form avidin and biotinylated horseradish peroxidase complex. 
After 3 PBST washes, the immune complexes were localized by incubation with 
150µl Dako DAB for 5min in a dark room. Upon oxidation, DAB formed a brown 
end-product at the site of target antigen. Sections were washed in PBST and 
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counterstained by immersion into Harris' hematoxylin for 15s and Scott’s Tap Water 
Substitute (STWS) for 2min. Finally, sections were mounted in a solution of Mowiol 
4-88 Reagent (MERCK) and viewed under a light microscope (Carl Zeiss). A KS300 
software (Carl Zeiss), and a JVC camera were used to capture images of sections. 
 
2.2.13 Immunocytochemistry 
The procedure of immunocytochemistry is slightly different from 
immunohistochemistry. First, cytocentrifugation slides were immersed in 0.15% 
H2O2 in methanol for 10min to block endogenous peroxidase activity, before 
washing in PBST and loading into sequenza racks. Then slides were blocked with 3 
drops of Vector Avidin Block for 10min at room temperature, then washed in PBST 
and blocked with 3 drops of Vector Biotin Block for 10min, then washed in PBST. 
Slides were incubated with Protein Block (Dako) for 30min, after which they were 
incubated with 150µl primary antibody diluted in Dako antibody diluent overnight at 
4°C. The slides were subsequently washed in PBST and incubated with 150µl 
biotinylated secondary antibody for 30min. Two PBST washes were performed 
before incubation in Vector ABC reagent for 30min to form avidin and biotinylated 
horseradish peroxidase complex. After 3 PBST washes, the immune complexes were 
visualized with Dako DAB in 5min in a dark room and processed further as 




2.2.14 Protein assay 
Protein concentrations were estimated using the BioRad protein assay, based on the 
Bradford method. The BioRad protein assay dye reagent concentrate was diluted 1:5 
with dH2O to give a working solution. A standard protein curve was constructed in 
duplicate by preparing standards containing 0, 0.5, 1, 1.5, 2 and 2.5μg Bovine Serum 
Albumin (BSA) (made up to 10μl with dH2O) in a standard 96-well plate. A range of 
sample concentrations were also prepared in duplicate (adjusted to 10μl with dH2O), 
and 200μl BioRad reagent A was added to both controls and samples, then 50μl 
BioRad reagent B was added into each well before incubation at room temperature 
for 5min. The plate was then inserted into an OPTI Max microplate reader 
(Molecular Devices, Sunnyvale, CA) and absorbance at 595nm was measured. A 
calibration curve was obtained from the standards, against which sample protein 
concentrations could be calculated. 
 
2.2.15 Antibody purification 
HiTrap is designed for purification and isolation of monoclonal and polyclonal IgG 
from serum. It was used to purify the sheep anti-11β-HSD1 antibody. Protein G is a 
Type III Fc receptor that binds to the Fc region of IgG by a non-immune mechanism. 
Protein G has strong affinity with IgG at pH 7.0 and IgG can be eluted at pH 2.7. 
Fast protein liquid chromatography (FPLC) system was used to sustain the supply of 
binding buffer or elution buffer. 1ml of sheep anti-11β-HSD1 antiserum was injected 
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into the Protein G column with syringe and adaptor. The column was washed with 
binding buffer (20mM sodium phosphate, pH 7.0) at 1ml/min for 20min, then the 
column was washed with elution buffer (0.1M glycine-HCl, pH 2.7) at 1ml/min for 
27min. 47 X 11ml tubes (Sarstedt) were used to collect fractions of 1ml containing 
IgG. Each tube contained 200μl 1M Tris-HCl pH 9.0 to raise the IgG solution pH to 
7.0. 
 
The concentration of each fraction was assayed by protein assay. The highest 
concentrations were in tube 1 and 2, but these two fractions comprised non-binding 
protein. The IgG was eluted in fractions 29 to 33, with highest concentration of IgG 
in fraction 29 (Figure 2.2A). Fractions of highest concentration were dialyzed against 
PBS containing 50% glycerol in the cold room overnight with gentle stirring. 
Following dialysis, the concentration of dialyzed IgG was tested and the purified IgG 
was 0.75 mg/ml. IgG was preserved at 4°C for required use.  
 
To test the specificity of the purified sheep anti-11β-HSD1 antibody, dilutions of 
antibody (1:500, 1:1000, 1:2000, 1:4000 and unpurified antibody at 1:2000) were 
tested for ability to recognize 11β-HSD1 in 5μg liver protein by western blotting. 
The purified antibody only detected 11β-HSD1 in liver protein at 1:500 dilution, but 


























Figure 2.2 Protein concentration in each fraction following elution from protein 
G column. 
(A), the concentration of each fraction was assayed by protein assay, as described in 
2.2.14. 
(B), western blot technique was used to test the specificity of purified 11β-HSD1 
antibody in WT liver protein. 5μg liver protein was loaded per well. 11β-HSD1 





IgG dilution: 1/500 1/1000 1/2000 1/4000               unpurified 1/2000   











2.2.16 Tail nick blood collection 
For measurement of basal plasma corticosterone levels, peripheral blood was 
collected under non-stressed conditions via tail nick between 0730h and 0830h. 
Briefly, one mouse at a time was quickly taken off from its cage and a tiny cut was 
made at the base of tail with a sterile scalpel. Approximately 25µl of blood was then 
collected into EDTA coated microvettes (Sarstedt Inc., UK) and placed on ice. Then 
another 25µl of whole blood was collected by tail nick into a 0.5ml tube and 
immediately mixed with 25µl of sodium citrate and stored on wet ice for flow 
cytometry analysis. Samples were centrifuged at 4˚C for 10min at 12,000rpm and 
plasma stored at -20ºC until further analysis (see section 2.2.21). The procedure was 
performed with help from Dr Agnes Coutinho. For analysis of blood leukocytes by 
flow cytometry was described at section 2.2.22 
 
2.2.17 Assessment of lung inflammation and fibrosis 
Comparative assessment of inflammation between WT and 11β-HSD1-deficient 
mice was achieved by measuring total cell number (by Chemometec NucleoCounter) 
and protein concentration in BALF. Greater infiltration of cells was used to infer 
greater inflammation. In addition, cells were cytocentrifuged (Section 2.2.22) to 
confirm cell identification and ratio. Flow cytometry was used to quantify the 
percentage of apoptotic and necrotic cells as well as cell types (using inflammatory 
cell markers described in Table 2-5. Histological assessment of lungs was performed 
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by Dr David Brownstein to identify the degree of tissue damage at various stages of 
disease. Picrosirius red staining (section 2.2.19) and Masson’s trichrome staining and 
H&E staining (by histology lab) were used to identify fibrosis and Sircol assay 
(section2.2.20) was used to quantify collagen in lung. 
 
2.2.18 Score of bleomycin induced damage 
In order to assess the inflammatory reaction in the lungs and to compare the WT and 
11β-HSD1-deficient mice, a scoring system was devised based on the method 
described in (Fisher, Ahmad et al. 2005). The scoring of peripheral lung 
inflammation was performed blind to genotype at x200 magnification over 10 
random fields in which lungs were completely, but not overly inflated and where the 
field contained a complete transection of at least one bronchiole less than half a field 
width in diameter, and a blood vessel as well as an alveolar airway. Large 
bronchioles were ignored. As the lungs were all perfused and lavaged before fixation, 
no comment can be made on infiltrate in the alveolar airspaces. The scoring system is 











Table 2-4 Method for scoring peripheral inflammation in bleomycin treated 
lungs. 
 
Score Area scored  
1 2 3 4 
(A) Perivascular 
compartment  
<10 cells 10-20 cells 20-50 cells >50 cells 
(B) Peribronchiolar 
alveolar tissue  
<10 cells 10-20 cells 20-50 cells >50 cells 
(C) Alveolar Walls No 
infiltration 
2-3 cells 4-5 cells >5 cells 
 
The scoring system was devised based on the method described in (Fisher, Ahmad et 
al. 2005). The scoring of peripheral lung inflammation was performed at x200 
magnification over 10 random fields. Cells were counted in 3 different compartments 
in each microscope field. 
(A), Cells around blood vessel walls 
(B), Defined as sub-bronchiolar tissue, beneath basement membrane and smooth 
muscle, not immediately adjacent to a blood vessel 







For each section, 10 fields were scored. In each field, the number of inflammatory 
cells was counted in perivascular compartment, peribronchiolar alveolar tissue and 
inside alveolar walls. Then according to the number of cells, it converted into a score 
scale from 1-4 based on Table 2-4. Further, the score for each compartment for the 10 
fields were averaged to give the score for the section. Then the averaged scores for 






















Figure 2.3 H&E stained sections of WT mouse lung 14d after bleomycin.  
Typical fields used to score bleomycin induced lung damage. 14d following 
bleomycin installation, mouse lung was fixed and processed as described in section 
2.2.4. Original magnification X100. Scoring was carried out as described in the text 
from 10 fields per section. The field fulfilled all the requirements: a complete 
transaction of at least one bronchiole less than half the field width in diameter, a 
blood vessel, and an alveolar airway. The perivascular compartment, indicated by v, 
shown above was given a score of “4” in pervascular compartment as there was 
cellular infiltrate, and more than 50 cells around the blood vessel walls. The 
peribronchiolar alveolar tissue, indicated by b, was given a score of “3” as there were 
more than 20 but fewer than 50 cells in this area. Finally, in the alveolar walls there 
was evidence of focal expansion by 4 to 5 cells, indicating a score of “3”. A 
combined score of “10”, calculated by adding all the scores in the field, was then 
given for that field. This process was repeated over nine additional random fields, 





2.2.19 Picrosirius red staining 
Picrosirius red staining is commonly used for the assessment of fibrosis as the Sirius 
Red stain is specific for polymeric and monomeric collagen matrix (Junqueira, 
Bignolas et al. 1979). Picrosirius red staining for collagen was performed on 5μm 
methyl carnoy fixed lung sections. The tissue sections were deparaffinised, 
rehydrated and stained with Picro Sirius red/ fast green stain (equal volume of 0.1% 
Direct red 80 and 0.1% Fast green were mixed and then 1 in 9 diluted with Aqueous 
Picric acid solution) for 2h at room temperature in dark room. The sections were then 
rinsed briefly in running water. The sections were then dehydrated and cleared in 
Xylene. Then the sections were mounted with DPX and coverslipped. 
 
2.2.20 Sircol assay 
Collagen content was estimated using Sircol assay. The Sircol dye reagent (Biocolor 
Ltd) contains Sirius Red. Sirius Red is anionic dye with sulphonic acid side chain 
groups. These groups react with the side chain groups of the basic amino acids 
present in collagen.  
 
The left lobe of lung was removed from mice and placed on dry ice. 3mg/ml pepsin 
solution was prepared in 0.5M acetic acid. Lungs were wet weighted just prior to 
sircol assay. Each lung was cut into small cubes with scissors and then placed into a 
7ml bijou with 5ml pepsin solution. Samples were placed in a roller at 4˚C for 24h. 
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After the digestion, 200μl supernatant, containing solubolised collagen, was removed 
from the centre of the bijou to a 1.5ml tube. The concentration of collagen standard 
reagent was 1mg/ml. A standard curve of collagen was constructed in duplicate by 
dilution of a stock reagent (1mg/ml) to give standards containing 0, 12.5, 25, 37.5 
and 50μg collagen (made up to 200μl with 0.5M acetic acid) in 1.5ml tubes. 200μl of 
each sample was also prepared in duplicate and 1ml sircol dye reagent was added to 
both controls and samples before gentle mixing on a Stuart SB2 rotator at room 
temperature for 30min. The tubes were then centrifuged at 12,000g for 10min. The 
collagen with dye was centrifuged to the bottom of tube, the supernatant was 
removed and the pellet cleaned using cotton buds. Next, 1ml sircol assay alkali 
(0.5M NaOH) was added into each tube. The tube was vortexted for 15s to dissolve 
the pellet. 200μl solution was retrieved and placed in a 96 well plate. The plate was 
then inserted into an OPTI Max microplate reader (Molecular Devices, Sunnyvale, 
CA) and absorbance at 540nm was measured. A calibration curve was obtained from 
the standards, against which the sample collagen concentration could be calculated. 
 
2.2.21 Corticosterone radioimmunoassay 
Plasma corticosterone levels were measured by radioimmunoassay, in which, 
unlabeled sample corticosterone and [3H]-corticosterone compete for 
anti-corticosterone antibody. Plasma samples were diluted 1:10 in borate buffer, 
heated for 1h at 75˚C then centrifuged for 2min at 13,000rpm at RT. A series of 
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corticosterone standard (0-500nM) were prepared to produce a standard curve. In a 
96 well plate, 20μl standard and sample was added in duplicate to 50μl borate buffer 
containing [3H]-corticosterone (10,000cpm per sample) and corticosterone antibody. 
The rabbit-anti-rat corticosterone antiserum (kindly provided by Dr Chris Kenyon) 
was added at 1:10,000 dilution in borate buffer. This mix was incubated at RT for 2h. 
Next, 50μl of anti-rabbit scintillation proximity assay (SPA) beads were added to 
each well and incubated for 16h at dark at RT. Then, the samples were detected by 
β-scintillation counter. The SPA beads can bind to the rabbit antibody, if that rabbit 
antibody also binds to [3H]-corticosterone, the radioactive signal is detected by the 
beads and the scintillation signal was detected by β-scintillation counter. The 
corticosterone concentration in each sample was determined from a standard curve 
and calculated using Multicalc software (Wallac, Milton Keynes, UK). 
 
2.2.22 Flow cytometric analysis for phenotyping the Cells: 
2.2.22.1 Flow cytometry general information 
Flow cytometry have been commonly used for counting and examining cells. The 
cells are suspended in a stream of fluid and at a point the cells were passed through a 
light beam. A number of detectors are used to catch the scattered or emitting light 
(from fluorescent chemicals). It allows simultaneous multiparametric analysis of the 
physical and chemical characteristics of cells. The data from forward scatter indicate 
the size of cells. The data from side scatter indicate the granularity and structural 
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complexity inside the cell. The data from fluorescent detector show the intensity of 
the staining of antibody on single cell. All experiments were carried out on FACS 
Calibur flow cytometer (Becton Dickinson, San Jose, CA). 
 
Flow cytometric analysis was performed on blood and digested lung. Prior to flow 
cytometric analysis, cells in polystyrene tubes were incubated on ice for 10min in 
PBS with Fc blocker, CD16/CD32 (Fcg III/II Receptor), (BD) (to block non-specific 
binding). In general, 0.5μl conjugated antibodies were added to the cells (unless 
otherwise specified by the manufacturer) and incubated on ice for 20min in the dark. 
Then cells were washed in 2ml PBS and recovered by centrifugation at 300g for 
5min then resuspended in 400μl PBS prior to analysis.  
 
2.2.22.2 Phenotyping blood cells 
Blood were collected as described at section 2.2.16. 25μl red blood cells were lysed 
with 500μl FACS Lysis buffer for 8min prior to final wash with PBS. Cells were 
washed by adding 3ml of PBS, collected by centrifugation at 300g for 5min at 4ºC 
and fixed with 100μl 10% formalin per sample. Fixed cells were stored (for 24-48h) 
at 4ºC until analysis. 
 
Prior to flow cytometric analysis, 50μl fluorescent Flow-Check fluorospheres 
(Beckman Coulter) was added to each sample and specific number of events were 
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collected in the bead gate (i.e. 5000 events for blood samples and 2500 events for 
bone marrow samples) enabling accurate calculation of the ratio of cells to beads 
used to calculate the absolute number of any cell type in the cell suspensions 
(performed by Dr Tiina Kipari). A combination of antibodies specific for neutrophils, 
monocytes and lymphocyte was used for blood (Table 2-5) harvested from each 
mouse. CD11b was marker for neutrophils and monocytes, in CD11b positive cells, 
neutrophils were identified as Ly6(G) and 7/4 positive cells, 7/4 only positive cells 
are monocytes.  
 
2.2.22.3 Phenotyping lung cells 
Lungs were isolated as described in section 2.2.4. Then lung tissue was minced into 
small pieces by scissors in a Petri dish. Pieces were incubated and rotated in a 15ml 
tube with 5ml Collagenase Type IA-S and FBS solution (50mg Collagenase Type 
IA-S with 11ml FBS in 189ml PBS). After 50min incubation, cells were released 
from pieces by using a 5ml syringe and a 21G needle to flush the suspension from 
the syringe against the tube wall. Then all cells were filtered through cell strainer, 













Table 2-5 Summary of cell markers used to phenotype blood cells. 
 
1) Master mix specific for lymphocytes 
 B220, PE, eBioscience 
 CD11b, FITC, BioLegend 
 CD4, PerCP/Cy5.5, BioLegend 
 CD8, APC, eBioscience 
2) Master mix specific for neutrophils and monocytes 
 7/4, Alexa 647, AbD Serotec 
 CD11b, PerCP/Cy5.5, BioLegend 
 Ly6(G), FITC, BioLegend 







To phenotype recruited inflammatory cells in WT and 11β-HSD1-deficient mice lung 
7d following bleomycin instillation, four different master mixes each containing 3 
antibodies were prepared, each aimed at identifying specific immune cells, described 
in Table 2-6. Lung macrophage have very strong autofluorescence (Garn 2006). To 
exclude the natural autofluorescence of cells, unstained samples were processed in 
parallel to experimental samples. To confirm the specific binding of each antibody, 
pooled samples of lung cells obtained following collagenase digestion from all 
groups were stained with specific isotope controls. Single antibody controls were 
used to set gates and compensation during collection and subsequent analysis. The 
data collected from flow cytometry (BD FACArray Bioanalyser) were analysed using 
WinMDI V2.8 software (Joseph Trotter). Flow cytometry was performed with help 













Table 2-6 Summary of cell markers used to phenotype lung cells. 
  
1) Master mix specific for lymphocytes 
 B220, FITC 
 CD3, PE 
 CD8, APC 
2) Master mix specific for neutrophils 
 CD11b, PerCP/Cy5.5 
 Ly6(C), FITC 
 Ly6(G), PE 
3) Master mix specific for Dendritic cells and inflammatory macrophages 
 CD11c, APC 
 CD11b, PE 
 MHCII, FITC 
4) Master mix specific for leukocytes and 11β-HSD1 
 CD45, PerCP/Cy5.5 








2.2.22.4 Phenotyping apoptotic and necrotic cells 
Apoptosis is normal physiologic process and the loss of plasma membrane is of one 
the earliest features. In normal cells, membrance phospholipid phosphatidylserine 
(PS) is contained in the inner leaflet of cytoplasmic membranes. When cells undergo 
apoptosis, PS residues flip to the outer leaflet of the membrane and are exposed to 
the external cellular environment (Vermes, Haanen et al. 1995). Annexin V is a 
35-36kDa calcium-dependent phospholipid-binding protein with a high affinity for 
PS (Vermes, Haanen et al. 1995). Thus, annexin V positive cells indicate early 
apoptosis. However, the translocation of PS also occurs during necrotic processes. 
Therefore staining with Annexin V has to be performed in conjunction with a dye 
exclusion to test the integrity of the cell membrane. 7-Amino-Actinomyxin (7-AAD) 
is a vital dye which can indicate membrane disruption. Viable cells with intact 
membrane are both 7-AAD and Annexin V negative, cells in early apoptosis are 
Annexin V positive and 7-AAD negative and cells that have progressed to 
post-apoptotic necrosis or have undergone primary necrosis are both Annexin V and 
7-AAD positive. Thus apoptosis and necrosis can be detected by labeling cells with 
Annexin V and 7-AAD and analysis by flow cytometry.  
 
Flow cytometry was used to quantify the percentage of apoptotic and necrotic cells in 
digested lung cells. Prior to flow cytometric analysis, cells in polystyrene tubes were 
incubated on ice for 10min in PBS with Fc blocker, CD16/CD32 (Fcg III/II 
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Receptor), (BD) (to block non-specific binding). After the Fc Block, 106 cells were 
resuspened in 1ml 1X binding buffer, then 100μl cell suspension was transferred to a 
5ml polystyrene tube. 2.5μl of PE conjugated Annexin V and 5μl 7-AAD were added 
to cells. The samples were gently vortexed and incubated for 15 min at RT in the 
dark. 400μl of 1X binding buffer were added to each tube and the cells were detected 
within 1h by flow cytometry.  
 
2.2.23 Measurement of 11β-HSD1 activity 
2.2.23.1 Synthesis of [3H]-11-Dehydrocorticosterone 
[3H]-11-Dehydrocorticosterone was made using homogenized rat placental extract as 
previously described (Low, Chapman et al. 1994). Rat placenta expresses 11β-HSD2 
with very low 11β-HSD1 (Waddell, Benediktsson et al. 1998) so it is efficient at 
producing 11-dehydrocorticosterone from corticosterone. Briefly, 50μl of 
[3H]-corticosterone (37Mq/μl) was added to 200μl of 25mM NAD+ (the 11β-HSD2 
specific cofactor), 300μl of rat placental homogenate (gift from Ms Lynne Ramage) 
and 4.45ml of C buffer, and gently shaken at 37°C for 4h. Then, 4ml of ethyl acetate 
were added; the solution was vortexed and then centrifuged (Eppendorf 5810R 
Centrifuge) at 1,700rpm for 5min. The organic (upper) layer containing the steroid 
was transferred into a borosilicate tube and dried under nitrogen. Dried steroid was 
reconstituted in 100μl of 100% ethanol and then 1μl of the resuspended steroid was 
subjected to HPLC to determine the purity of [3H]-A which was routinely >95%. 
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Specific activity was measured by counting a 1μl aliquot in 1ml scintillation fluid 
(Pico-fluor 40, Canberra Packard, Berkshire, UK) in a β-counter (Wallac 1450 
Microbeta Plus liquid scintillation counter, Milton Keynes, UK). The 
[3H]-11-dehydrocorticosterone was stored at -20°C for future use. 
 
2.2.23.2 Measurement of 11β-HSD1 activity in homogenised lung 
In homogenate, 11β-HSD1 mainly shows dehydrogenase reaction direction thus in 
homogenised lung, the assays were performed in the 11β-dehydrogenase direction. 
Lung samples which had been rapidly frozen on dry ice and stored at -80°C were 
homogenised in 1ml C buffer with an Ultra-Turrax T8 auto-homogenizer (Ika) in 2ml 
tube and protein concentration of each lung homogenization sample was determined 
as describes above (section 2.2.14). 11β-dehydrogenase assays contained 
homogenate (0.5mg/ml protein), 10nM 3H-corticosterone and 400μM NADP. Initial 
trials were carried out to establish protein concentration and time that gave 
conversion of 20-40% of subtract within a relatively short time period (less than 
20min). For all further experiment, samples were incubated for 10min at 37oC; 
steroids were extracted by ethyl acetate and quantified by HPLC as described below. 
 
2.2.23.3 Measurement of 11β-HSD1 activity in fibroblast cells 
11β-HSD1 activity was measured in intact cells as previously reported (Low, 
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Chapman et al. 1994). Conversion of [3H]-corticosterone to 
[3H]-11-dehydrocorticosterone (11β-dehydrogenase activity) or 
[3H]-11-dehydrocorticosterone to [3H]-corticosterone (11β-reductase activity) was 
measured in intact primary cells. Normally, 106 cells were seeded per well of a 
24-well plate in 1ml of medium and incubated at 37ºC for the duration of the 
experiment (1h to 24h). A trace amount of [3H]-A or B (normally 5nM) was diluted 
with unlabelled steroid and added to the cell medium to give a final concentration of 
200nM steroid. Aliquots of medium (200μl) were collected at various times after 
addition of [3H]-11-dehydrocorticosterone or [3H]-corticosterone. Steroids were 
extracted with >4x vol ethyl acetate. The upper layer was removed into 12X75cm 




Steroids from 11β-HSD1 activity assays were measured by high-performance liquid 
chromatography (HPLC), which was carried out by Dr Ruth Andrew. Briefly, dried 
steroids were resuspended in 600μl of mobile phase, (60% water, 25%methanol and 
15% acetonitile). Then the solution was moved into HPLC assay tube and then 
measured by dual λ absorbance detector (Waters 2487). Each sample was measured 




2.2.24 Western Blot   
Frozen lung tissues were homogenized on ice using cold buffer (100g glycerol, 
300mg Tris, 186mg EDTA, and 7.7mg DTT made up to 500ml in H20, pH to 7.5). 
Total protein concentration was determined as described in section 2.2.14 and 15 μg 
of total protein was adjusted to 6.5 μl using H2O and added to 6 μl of a pre-prepared 
mix of 5 μl NuPAGE® LDS sample buffer (Invitrogen) and 1μl of NuPAGE® 
Reducing agent (Invitrogen). 10μl of Plus2® pre-stained protein standard (Invitrogen) 
and all samples were incubated at 80ºC for 10min to denature the protein. According 
to manufacturer’s instructions, samples were loaded into a 15 well 4-12% Bris-Tris 
Novex® pre-cast gel (Invitrogen) in the Invitrogen XCell II Blot Module. The inner 
chamber was filled with 200ml of 1X Novex® MOPS running buffer (Invitrogen) 
and 500μl of NuPAGE® antioxidant (Invitrogen) and the outer chamber filled with 
600ml of 1X Novex® MOPS running buffer. Samples were electrophoresed at 200V 
for ~40min until the bromophenol blue band migrated to the bottom of the gel. The 
gel was then removed to the plastic cassette and proteins transferred from the gel to a 
nitrocellulose membrane (Invitrogen) using a wet transfer system which include pad, 
3M paper membrane and gel in Invitrogen XCell II Blot Module. Transfer was 
carried out at 30V for 75min. To reduce non-specific antibody binding, immediately 
after protein transfer, the membrane was placed in 100ml of blocking solution, 
consisting of 5% non-fat dry milk in TBST (TBS + 0.1% Tween-20) and incubated 
with gentle shaking for 1-2h at room temperature. Incubation with primary antibody, 
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diluted in blocking solution, was performed overnight at 4°C. Following incubation 
with the primary antibody, the membrane was washed 3 times at room temperature 
with wash buffer TBST for 15min per wash. The membrane was incubated with the 
secondary antibody in blocking solution with gentle shaking for 1h at room 
temperature. Following incubation with the secondary antibody, the membrane was 
washed 4 times at RT with wash buffer (same as above) for 15min per wash. The 
membrane was scanned and band intensities were quantified using the Odyssey 
infrared imaging system (Licor Biosciences; Lincoln, NE).  
 
2.2.25 Statistics 
Statistical analysis was performed using GraphPad Prism 4.00 software with P≤0.05 
as the criterion for statistical significance. All data are expressed as mean ± standard 
error of mean (SEM). Data were analysed by Student’s t-tests, Analysis of Variance 

































3.1 Introduction  
It is well established that 11β-HSD1 is expressed in lung in humans, rodents and 
rabbits (Torday, Olson et al. 1976; Monder and Lakshmi 1990; Soldan, Nagel et al. 
1999; Speirs, Seckl et al. 2004). Also, 11β-HSD1 has been shown to be expressed in 
fetal rat lung in late pregnancy (Hundertmark, Ragosch et al. 1994). In addition, 
11β-HSD1-deficient mice exhibited delayed fetal lung development (Hundertmark, 
Dill et al. 2002). Together, these data suggest 11β-HSD1 plays an important role in 
the physiological function of lung. To look at the role of 11β-HSD1 in lung 
inflammation, it is important to establish where in lung 11β-HSD1 is expressed. 
Whilst previous data have demonstrated expression in type 2 alveolar cells (Brereton, 
van Driel et al. 2001; Suzuki, Tsubochi et al. 2003), it is not clear whether other cell 
types also express the enzyme. Torday suggested fibroblasts were the only cell in the 
alveolus that express oxidoreductase activity (Torday, Post et al. 1985). IHC has also 
localized 11β-HSD1 expression to fibroblasts in rat lung (Brereton, van Driel et al. 
2001). However, although 11β-HSD1 is expressed in mouse lung (Speirs, Seckl et al. 
2004), the location of 11β-HSD1 expression in mouse lung has not been described. 
To localize the expression of 11β-HSD1 in mouse lung, in situ mRNA hybridization 
and IHC were used. Lung cell isolation was used to isolate single cell types which 
allowed confirmation of 11β-HSD1 expression in mouse lung fibroblasts, by 





3.2.1 11β-HSD1 localization in lung 
3.2.1.1 In situ mRNA hybridization to identify sites of expression of 11β-HSD1 
in lung 
To localize 11β-HSD1 mRNA within mouse lung, in situ mRNA hybridization was 
carried out on sections of wild-type (WT) mouse lung using an “antisense” 
[35S]-cRNA probe complementary to mouse 11β-HSD1 mRNA. Whilst fresh frozen 
tissues are optimal for ISH, paraffin-embedded tissues provide better morphology. 
Therefore, both paraffin-embedded and fresh-frozen tissues were hybridized. To 
prepare fresh-frozen lung sections, lungs were injected with OCT prior to freezing to 
maintain the alveolar structure. Liver highly expresses 11β-HSD1 and was used as a 
positive control. A “sense” strand cRNA probe (the same as the messenger mRNA) 
was used as a negative control.  
 
Autoradiography showed hybridization of antisense, but not sense, probe in lung and 
liver, for both paraffin-embedded and fresh frozen tissue (Figure 3.1A-E). This 
suggests specific hybridization and both fixing methods show a similar result. Heart, 
which was also preserved in the sections, showed hybridization to the antisense 
probe which was similar to the sense probe (Figure 3.1) and was therefore judged to 
be non-specific. Autoradiography showed that 11β-HSD1 mRNA was expressed 
throughout the lung and was not specifically confined to any particular part (eg blood 
vessels or alveoli). Thus, either 11β-HSD1 is expressed in cells which are present 
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throughout the whole lung, or most of the cells in lung express 11β-HSD1.  
 
For microscopic localization, slides were developed as described in Chapter 2.2.11 and 
were hematoxylin and eosin stained. Figure 3.1F shows that the density of silver 
grains on sections hybridized to “antisense” probe was greatest above cells around the 




























Figure 3.1 Representative autoradiographs showing in situ mRNA hybridization 
of 11β-HSD1 mRNA within WT mouse lung.  
(A), Fresh-frozen lung hybridized to an anti-sense [35S]-labelled 11β-HSD1 cRNA 
probe; (B), Fresh-frozen lung hybridized to a sense [35S]-labelled 11β-HSD1 cRNA 
probe (negative control); (C), Paraffin-embedded lung hybridized to an anti-sense 
[35S]-labelled 11β-HSD1 cRNA probe; (D), Paraffin-embedded lung hybridized to a 
sense [35S]-labelled 11β-HSD1 cRNA probe; arrows indicate lung lobes and white 
rectangular boxes enclose heart; (E), Paraffin-embedded liver hybridized to an 
anti-sense [35S]-labelled 11β-HSD1 cRNA probe; (F), Representative image of 
[35S]-labelled 11β-HSD1 anti-sense cRNA probe hybridized to WT mouse lung. 
Signal was visualized using photographic emulsion and sections were counterstained 
with hematoxylin and eosin. Small spots are silver grains hybridized to 11β-HSD1 


























3.2.1.2 Immunohistochemical staining of 11β-HSD1 in lung 
Cellular localization of 11β-HSD1 mRNA by in situ mRNA hybridization was not 
possible because the radiation of the [35S] probe made the silver grains appear above 
other cells around hybridized cells rather than restricted to a single cell. Therefore to 
determine the localization of 11β-HSD1 in lung, immunohistochemistry was carried 
out using different anti-11β-HSD1 antibodies: a rabbit anti-11β-HSD1 antibody, 
raised to a peptide corresponding to amino acids 78-92 of human 11β-HSD1, bought 
from Caymen, and a sheep anti-11β-HSD1 antibody which was raised against 
purified recombinant mouse 11β-HSD1 protein within the Endocrinology Unit (a gift 
from Dr Scott Webster). During the course of this work, Dr Agnes Coutinho showed 
by western analysis that the Caymen anti-11β-HSD1 antibody recognizes 11β-HSD1, 
but also cross-reacts against a number of other proteins, whilst the sheep antibody 
appeared more specific for 11β-HSD1 (Coutinho 2009). Therefore, although the 
Caymen antibody was used during initial experiments (data not shown), it was not 
used in the experiments described here. Instead, the sheep anti-11β-HSD1 antibody 
was used. This antibody has also been validated in other experiments within the 
Endocrinology Unit (De Sousa Peixoto, Turban et al. 2008). 
  
Sheep anti-11β-HSD1 IgG was purified before use and tested as described in Chapter 
2.2.15. The specificity of the antibody was determined by staining kidney section 
(detailed in Appendix I). Paraffin-embedded lung sections from C57BL/6 control 
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(WT) and 11β-HSD1-deficient mice were stained with purified sheep anti-11β-HSD1 
antibody at 1:1000 dilution. Positive staining was seen in some cells in the alveolar 
wall, which showed morphology typical of type II alveolar cells (Figure 3.2A) and in 
cells next to the basement membrane of bronchioli and blood vessels (Figure 3.2B 
and C). No staining was found on bronchiolar epithelial cells (Figure 3.2B). 
11β-HSD1-deficient mice show weak staining compared to WT mice, mainly in type 
II alveolar cells (Figure 3.2D), but there was no staining on cells next to the 


















Figure 3.2 Immunohistochemical staining of 11β-HSD1 in mouse lung shows 
expression in fibroblasts and type2 alveolar cells. 
Representative image of Immunohistochemistry carried out on lung sections from 
WT mice (A-C) or 11β-HSD1-deficient mice (D-F) with purified sheep 
anti-11β-HSD1 antibody at 1:1000 dilution and biotinylated rabbit-anti-sheep 2nd Ab 
at 1:400 dilution. Images captured at magnification, X400. A&D show alveolar 
structure, arrows indicate positive staining on type 2 alveolar cells. B&E show 
bronchi epithelium, positive staining was seen in connective tissue fibroblasts lying 
adjacent to epithelium. C&F show blood vessel, positive staining was seen in 
fibroblasts outside blood vessel in WT but not in 11β-HSD1-deficient mice. “a” 















3.2.1.3 Expression and distribution of GR in mouse lung 
Expression of 11β-HSD1 occurs primarily in GR-rich tissue (Whorwood, Franklyn et 
al. 1992; Hardy, Filer et al. 2006). Lung is a major GC target tissue and abundantly 
expresses GR (Ballard, Baxter et al. 1974; Cole, Blendy et al. 1995; Speirs, Seckl et 
al. 2004). To determine whether GR is colocalized with 11β-HSD1 in lung, and as a 
positive control for the IHC, a GR antibody was used in IHC on WT mouse lung 
sections. No staining was detected without antigen retrieval (data not shown). 
Following antigen retrieval, some alveolar cells, with morphology typical of type 2 
alveolar cells (Figure 3.3A) and endothelial cells (Figure 3.3B) showed a positive 
signal. Most of the positive staining was in the nuclei of immuno-positive cells 
(Figure 3.3A), consistent with a nuclear localization of GC-GR complexes. No 
staining was found in airway epithelial cells (Figure 3.3C). Overall, the GR 















Figure 3.3 Immunohistochemical staining of GR in mouse lung shows expression 
in type 2 alveolar cells and endothelial cells. 
Immunohistochemistry was carried out on paraffin-embedded WT mouse lung. 
Following antigen retrieval (described in Chapter 2.2.12), sections were incubated 
with rabbit anti-GR antibody at 1:100 dilution and biotinylated goat-anti-rabbit 2nd 
Ab at 1:50 dilution. (A), staining in type 2 alveolar cells (arrowheads); (B), GR 
immuno-staining in endothelial cells (arrow indicates an endothelial cell); (C), no 
staining in bronchiolar epithelial cells (arrow indicates bronchiolar epithelial cell); 
(D), Negative control: WT lung with 2nd Ab alone. Images captured at magnification, 













3.2.1.4 11β-HSD1-deficient mice have detectable 11β-HSD1 activity in lung 
During the course of this work, Dr Agnes Coutinho showed that 11β-HSD1 can be 
detected by western blotting in 11β-HSD1-deficient mouse lung (Coutinho 2009). 
Therefore to investigate whether the weak staining in lung of 11β-HSD1-deficient 
mice was due to cross reactivity with another protein or was due to residual 
11β-HSD1 activity in lung of “KO” mice, 11β-HSD1 activity was assayed in 
homogenate of WT and 11β-HSD1-deficient lung as described in Chapter 2.2.23.2. A 
selective inhibitor of 11β-HSD1 which does not inhibit the function of 11β-HSD2 
(gift from Dr Scott Webster) was used to demonstrate that 11β-HSD activity detected 
in lung was due to 11β-HSD1. Kidney highly expresses 11β-HSD2 (Krozowski, 
Albiston et al. 1995) and so was included as a control for the selectivity of the 
inhibitor. 
 
As expected, 11β-HSD activity in WT lung homogenate was readily detectable ~0.5 
pmolproduct/mg/min (Figure 3.4); although lower than in kidney homogenates 
(Figure 3.4). However, lung from 11β-HSD1-deficient mice showed approximately 
one third the level of 11β-HSD activity of WT lung homogenate (Figure 3.4). 
Addition of the selective 11β-HSD1 inhibitor resulted in inhibition of all the 
11β-HSD activity in “KO” lung, but kidney was unaffected (Figure 3.4), 
demonstrating that the 11β-HSD activity detected in “KO” mouse lung was due to 
residual expression of 11β-HSD1 (kidney highly expresses 11β-HSD2). Therefore 
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11β-HSD1 immunostaining in KO mouse lung may be due to residual 11β-HSD1 
expression. Homogenates of liver from “KO” mice (the tissue that most highly 























































Figure 3.4 Residual 11β-HSD1 enzyme activity in lung of 11β-HSD1 KO mice 
11β-HSD activity was measured by conversion of [3H-B] to [3H-A] in a 10 min assay 
with 0.5mg/ml lung homogenate or kidney homogenate from WT or 
11β-HSD1-deficient (KO) mice. 50 μM 11β-HSD1 inhibitor (CC002054) was added 
to the homogenate before the reaction. Steroids were extracted by ethyl acetate and 
quantified by HPLC as described in Chapter 2.2.24. 11β-HSD activity is expressed as 
pmol of corticosterone (B) converted into 11-dehydrocorticosterone (A)/mg protein 
/min. Values are mean ± SEM of 3 lungs. A single kidney was analysed as control, 
with assay carried out in duplicate. ND, not detected. There is significant difference 






3.3 11β-HSD1 expression in isolated alveolar macrophages, lung epithelial cells, 
and fibroblasts in vitro 
IHC suggests 11β-HSD1 expression in lung is mainly in fibroblasts and type 2 
alveolar cells. To further examine this, individual lung cells were isolated. Alveolar 
macrophages were isolated by cytocentrifugation of lung lavages and identity 
confirmed by F4/80 staining (Figure 3.5A). Following lavage, lungs were subject to 
trypsin digestion as described in Chapter 2.2.5. This enabled epithelial cells (mainly 
clara cells) to be isolated as clumps of non-adherent or loosely adherent cells (Oreffo, 
Morgan et al. 1990). Cells which firmly attached to the bottom of the culture dish 
were largely fibroblasts and interstitial macrophages. Fibroblasts could be removed 
by mild trypsin digestion and further passaged. In contrast, interstitial macrophages 
did not proliferate on further passage.  
 
RNA was extracted from isolated lung cells. Semi-quantitative RT-PCR showed that 
all cells express 11β-HSD1, with similar levels of 11β-HSD1 PCR product from the 
non-adherent cells (containing epithelial cells) (Figure 3.6, lane 2) and alveolar 
macrophages (Figure 3.6, lane 3). However, the adherent cells, containing fibroblasts 
and interstitial macrophages, gave more 11β-HSD1 PCR product (Figure 3.6, lane 4) 
suggesting a higher level of expression. In further experiments, greater proliferation 
and characterization of the adherent cells (largely fibroblasts) was achieved (detailed 












Figure 3.5 F4/80 staining in cytocentrifuged alveolar macrophages 
Immunohistochemistry was carried out with rat anti-mouse F4/80 antibody at 1:50 
dilution and HRP conjugated rabbit-anti-rat 2nd Ab at 1:200 dilution. Brown indicates 
positive staining. Both images (A and B) show cytocentrifuged cells from alveolar 
lavages. (A) cells stained for F4/80; more than 95% cells are positive; (B) negative 















                  
                 
 
 
Figure 3.6 11β-HSD1 is expressed in different lung cell populations 
RNA was extracted from the indicated lung cells. 1μg of RNA was used in an RT 
reaction and 4μl RT reaction used in 30 cycles of PCR. Lane 1, 1kb marker. Lane 2, 
RT-PCR reaction carried out on RNA extracted from non-adherent and loosely 
adherent cells, which contain epithelial cells. Lane 3, RT-PCR reaction carried out on 
alveolar macrophage RNA. Lane 4, RT-PCR reaction carried out on RNA isolated 
from firmly adherent cells. Lane 5, minus RT reaction used as a negative control. An 
















3.4 11β-HSD1 is present in lung fibroblasts  
11β-HSD1 expression has been demonstrated in rat lung fibroblasts (Brereton, van 
Driel et al. 2001). To confirm my IHC findings, 11β-HSD1 expression in mouse lung 
fibroblasts was investigated. Lung fibroblasts were isolated and cultured according to 
the method described in Chapter 2.2.6. Fibroblasts were characterized 
morphologically by a spindle phenotype following inspection under the light 
microscope (Tarin and Croft 1969). RT-PCR, IHC and activity assay were used to 
confirm expression of 11β-HSD1. 
 
3.4.1 11β-HSD1 expression in primary lung fibroblasts 
Examination of passage 1 fibroblasts showed predominantly spindle shaped cells 
(Figure 3.7A), typical of the morphology of fibroblasts in culture (Tarin and Croft 
1969). Following trypsinization, cells were cultured on cover-slips overnight then 
subjected to IHC as described in Chapter 2.2.13. Staining with antibody raised 
against recombinantly expressed 11β-HSD1 showed that the majority of cells were 












Figure 3.7 Immunohistochemical staining of 11β-HSD1 in primary lung 
fibroblasts (passage 1) 
(A), A confluent monolayer of primary lung fibroblast cells was evident after 7 days 
of culture and exhibited a characteristic spindle morphology, typical of lung 
fibroblast (Tarin and Croft 1969). Cells were stained with Diff-Quick red and blue as 
described in Chapter 2.2.2. These cells were confirmed as fibroblasts on the basis of 
stellate morphology and ability to propagate in the medium (Hu, Wu et al. 2004). (B), 
11β-HSD1 staining with anti-11β-HSD1 Ab at 1:1000 dilution and biotinylated 
goat-anti-rabbit 2nd Ab at 1:400 dilution; (C), Negative control: biotinylated 








3.4.2 Mouse lung fibroblasts have 11β-HSD reductase activity 
To measure 11β-HSD1 activity in primary fibroblasts, cells from WT mice were 
assayed for 11β-HSD dehydrogenase and reductase activity. Only 11β-reductase 
activity was detected, with little dehydrogenase activity, suggesting the presence of 

























































Figure 3.8 11β-HSD1 activity in primary fibroblasts 
11β-HSD reductase and dehydrogenase activities in primary fibroblasts were 
measured by adding [3H]-substrate 11-dehydrocorticosterone or corticosterone, 
respectively to the medium, removing aliquots at various times up to 24h and 
calculating conversion of substrate to product (see Chapter 2.2.23.3 for details). Data 
are expressed as % conversion of 200nM substrate by 1x106 cells, over time. Black 
bars indicate reductase activity (conversion of 11-dehydrocorticosterone to 
corticosterone) and white bars indicate dehydrogenase activity (conversion of 
corticosterone to 11-dehydrocorticosterone). Values are mean ± SEM of triplicate 







The data contained in this chapter show unequivocally that lung expresses functional 
11β-HSD1 in fibroblasts, alverolar macrophages and epithelial cells. In primary 
fibroblasts, 11β-HSD1 transcripts were obvious by RT-PCR and 11β-HSD activity 
assay showed exclusively the reductase direction.   
 
In situ hybridization showed strong hybridization to 11β-HSD1 mRNA in lung, with 
silver grains localized to certain cells rather than all cells in lung. To more 
specifically identify the cells expressing 11β-HSD1, IHC was used. WT lung showed 
positive staining on type II alveolar cells and fibroblasts. These results are similar to 
11β-HSD1 IHC in rat lung (Brereton, van Driel et al. 2001). However, 
11β-HSD1-deficient mice also showed positive staining on lung although to a lesser 
extent than WT. 11β-HSD activity assay confirmed the presence of low levels of 
11β-HSD1 in 11β-HSD1-deficient lung. When lung homogenate was treated with 
11β-HSD1-specific inhibitor, the 11β-dehydrogenase activity in WT or 
11β-HSD1-deficient lung was abolished, which confirmed that 11β-HSD1-deficient 
mice express functional 11β-HSD1 in lung. However, no activity was detected in 
livers (K. Chapman, unpublished result), consistent with previous data at this line of 
mice (Kotelevtsev, Holmes et al. 1997). Although it was not appreciated at the time 
this line of mice were generated, it is likely that the homologous recombination event 
designed to disrupt the 11β-HSD1 gene did not occur exactly as expected (K. 







Figure 3.9 Targeted inactivation of the 11β-HSD1 gene 
A, predicated recombination event for generating 11β-HSD1 KO mice, showing (top) 
the targeting vector; (middle), the Hsd11b1 locus and predicted sites of homologous 
recombination and (bottom) the predicted targeted allele. The targeting vector was 
designed to replace exons 4 and 5.  
B, likely recombination event. The targeting vector has inserted into the Hsd11b1 
locus rather than replacing exons 4 and 5. Due to the strong β-actin promoter and the 
disruption to the Hsd11b1 gene, the 11β-HSD1 transcription from the P2 promoter is 
abolished, with the P1 promoter less affected because the P1 promoter is >20kb 
upstream of the targeted sequence.  
Transcription starts associated with each promoter are shown by curved arrows. 
Rectangular boxes indicate exons (numbers in boxes indicate the exon). Neo, 
neomycin. pA, simian virus 40 polyadenylation signal sequence. pβ-actin, β-actin 




(previously designated 3 and 4; Kotelevtsev et al, 97) (Figure 3.9A), all the exons are 
still present and in the correct order (Figure 3.9B). Therefore, RNA splicing can 
generate correct 11β-HSD1 transcripts in 11β-HSD1 “KO” mice. Whilst this happens 
at a very low frequency from transcripts initiated at the P2 promoter (probably 
because of promoter interference from the strong β-actin promoter present on the neo 
cassette in the opposite orientation to the 11β-HSD1), because the 11β-HSD1 P1 
promoter is >20kb upstream to the neo cassette (see Chapter 1.7.1 for description of 
the 11β-HSD1 promoters), the interference may be less, allowing some 11β-HSD1 
mRNA to be made in tissues such as lung that use the P1 promoter. 
 
Cell separation was used to isolate single cells to further identify the cells expressing 
11β-HSD1. Analysis of RNA by RT-PCR was consistent with the IHC finding, with 
alveolar macrophages and epithelial cells expressing 11β-HSD1 and fibroblasts 
highly expressing 11β-HSD1. All of those cells contribute to the 11β-HSD activity in 
lung. Primary cultured fibroblasts showed exclusively 11β-reductase activity, similar 
to human fibroblasts (Abramovitz, Branchaud et al. 1982). Abramovitz et al 
incubated human fetal lung at midgestion (at stage when 11β-HSD2 expression is 
likely to be high and 11β-HSD1 to be low (Stewart, Whorwood et al. 1995)) in 
monolayer cultures or as explants. Explants mainly converted cortisol to cortisone 
(dehydrogenase activity). In monolayer cultures consisting almost entirely of 
fibroblast-like cells, cortisol to cortisone conversion was low, but cortisone to 
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cortisol conversion steadily increased to 85% and plateaued at confluence 
(Abramovitz, Branchaud et al. 1982). Thus, cortisone to cortisol conversion only 
happened in human fetal lung fibroblast-like cells in culture, and apparently not in 
the in vivo (explant) system (Abramovitz, Branchaud et al. 1982). In vivo or in 
explants, 11β-HSD2 is expressed and not 11β-HSD1, as suggested by Stewart et al 
1995. However, upon culture and outgrowth of fibroblasts, 11β-HSD1 may be 
expressed, with its associated reductase activity. This suggests that fibroblast cells 
express 11β-HSD1 and mainly exhibit 11β-reductase activity. 
 
11β-HSD1 generates ligand for GR. GR staining appears mainly on type 2 alveolar 
cells which was colocalised with 11β-HSD1 expression. The staining of GR is 
mainly on nuclear of the cells, it is either because that endogenouse GC occupy the 
GR or because that the antibody only recognize nuclear GR but not cytoplasmic GR 
(Sarabdjitsingh, Meijer et al. 2010). However, the antibody I used for the GR IHC 
could pick up both nuclear and cytoplasmic GR, so the mice may be stressed before 
the cull. 
 
These data show that lung fibroblasts demonstrate potential for the amplification of 











4  Chapter Four: The regulation of 11β-HSD1 
















In lung, 11β-HSD1 mRNA is transcribed from 2 promoters in the Hsd11b1 gene, P1 
and P2, with the majority of the mRNA expressed from the P1 promoter (Bruley, 
Lyons et al. 2006) (see Chapter 1.7.1). In addition, a further promoter (P3) has been 
described in rat kidney (Moisan, Edwards et al. 1992), which is also used in mouse 
and human kidney (Ms V. Kelly, Prof K. Chapman, unpublished results). To test the 
hypothesis that lung epithelial cells express 11β-HSD1 from the P2 promoter 
whereas lung fibroblast cells use the P1 promoter, individual lung cell types were 
tested. Two human lung cell lines, representative of fibroblast and epithelial cells, 
were first used to test the hypothesis. In addition, cell separation was undertaken to 
isolate epithelial and fibroblast cells from lung to test the hypothesis in primary cell 
culture. Recent work has established that bone marrow-derived mast cells 
exclusively use the P1 promoter (Dr Agnes Coutinho, unpublished data) and 
lymphocytes (B220+ and CD4+) also predominately use the P1 promoter (Dr Agnes 
Coutinho, unpublished data), so the promoter usage of other immune cells was also 









4.2.1 The P1 promoter of Hsd11b1 predominates in lung 
4.2.1.1 Both the P1 and P2 promoters of Hsd11b1 are used in lung 
To validate the PCR assay and confirm that mouse lung mainly uses the P1 promoter 
to transcribe Hsd11b1, RNA was extracted from lung of wild-type mice and subject 
to RT-PCR, using primers that were specific for each of the 3 promoters; P1, P2 and 
P3. Figure 4.1 shows that lung uses both the P1 promoter and the P2 promoter with 
only a very small amount of transcription from the P3 promoter. 
 
4.2.1.2 Validation of real-time PCR assay to measure Hsd11b1 transcripts 
initiated at the P1 and P2 promoters 
To quantify the promoter usage of the mouse Hsd11b1 gene, real-time PCR assays 
for the P1 and P2 promoters were developed by Dr Julie Nixon (Endocrinology Unit, 
University of Edinburgh). To validate the real-time PCR assay, WT lung and liver 
cDNA were used to compare the promoter usage in each tissue, as well as in 
mixtures of cDNA from the 2 tissues, prepared as outlined in Figure 4.2. Real-time 
PCR results showed that liver mainly uses the P2 promoter and around 90% of lung 














Figure 4.1 11β-HSD1 promoter usage in mouse lung. 
RNA was extracted from the lung of WT mice. 1μg of RNA was used in an RT 
reaction and 4μl RT reaction used in 30 cycles PCR with primers specific for 
transcripts initiating at each of P1, P2 and P3 promoters as well as primers that detect 
all 11β-HSD1 transcripts (see Chapter 2.1.7). Lane 1 contains a 1 kb ladder, labeled 
with L. The positions of the 543bp P3 product, the 627bp P1 product and the 646bp 
P2 product are indicated, as is the position of the 470bp product derived from total 
11β-HSD1 mRNA. A control reaction (-RT) gave no product with primers to amplify 













470bp total 11β-HSD1 

































Figure 4.2 Comparison of promoter usage of the Hsd11b1 gene in lung and liver 
Total RNA extracted from lung and liver of WT mice was analysed for P1 and P2 
mRNA by real-time PCR. 5 groups of cDNA were prepared by mixing different 
proportions of lung and liver cDNA as detailed below the graph. The values shown in 
the graph are mean concentration of each group derived from the standard curve, 
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4.2.2 Human lung cell lines (A549, HFL-1) express endogenous 11β-HSD1 
using the P2 promoter  
Initially, 2 human lung cell lines were used to test the hypothesis that lung epithelial 
cells express 11β-HSD1 from the P2 promoter whereas lung fibroblast cells use the 
P1 promoter. A549 cells were derived from a human lung adenocarcinoma cell line 
and resemble type 2 alveolar cells (Lieber M, Smith B et al. 1976). HFL-1 cells were 
derived from human fetal lung fibroblast cells and resemble fibroblast cells (Breul, 
Bradley et al. 1980), although there is some evidence that they also have 
myofibroblast characteristics (Kawamoto, Matsunami et al. 1997)  
  
A549 and HFL-1 cells were cultured as described in Chapter 2.2.1. RT-PCR showed 
that endogenous 11β-HSD1 was expressed in both A549 and HFL-1 cells (Figure 
4.3), confirming previous findings in A549 (Sai, Esteves et al. 2008) and more 
recently in HFL-1 (Yang, Zhu et al. 2009). In both cell lines, Hsd11b1 was 
predominately transcribed from the P2 promoter with a lower level of transcription 
from the P3 promoter (Figure 4.3). Neither cell line used the P1 promoter of 
Hsd11b1 (Figure 4.3). A positive control for the P1 promoter was not included due to 
difficulties in obtaining human tissue, but suitable controls would be lung, kidney or 
placenta and previous work has established that these P1 primers amplify the correct 














Figure 4.3 11β-HSD1 promoter usage in human A549 and HFL-1 cells. 
RNA was extracted from human A549 and HFL-1 cells. 1μg of RNA was used in an 
RT reaction and 4μl RT reaction used in 35 cycles PCR with primers specific for 
transcripts initiating at each of P1, P2 and P3 as well as primers that detect all 
Hsd11b1 transcripts. Lane 1 contains a 1 kb ladder, labeled with L. A black arrow 
indicates the position of the 285bp P2 product and a white arrow indicates the 152bp 
P3 product from human 11β-HSD1 mRNA. A negative control reaction (-RT) gave 
no product with primers to amplify total 11β-HSD1. The predicted size for the P1 
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4.2.3 Promoter usage of 11β-HSD1 in primary alveolar macrophages, lung 
epithelial cells, lung fibroblasts and interstitial macrophages 
The result from the lung cell lines indicates that the Hsd11b1 gene is transcribed 
from the P2 promoter in both epithelial and fibroblast cell lines. Given that lung 
mainly uses the P1 promoter, this suggests either that another cell type other than 
fibroblasts or type 2 alveolar cells expresses 11β-HSD1 from the P1 promoter or that 
the cell lines behave differently in this respect to the primary lung cells. Therefore 
lung cell isolation was carried out to investigate Hsd11b1 promoter usage in different 
primary cell populations in lung. Lung alveolar macrophages, epithelial cells (as 
clumps of non-adherent or loosely adherent cells), fibroblasts and interstitial 
macrophages (adherent cells) were isolated as detailed in Chapter 3.3. 
 
RNA was extracted from the indicated lung cell preparations. RT-PCR showed that 
the non-adherent cells (containing epithelial cells) used both P1 and P2 (Figure 4.4, 
lanes 2-4). Alveolar macrophages mainly used P2 (Figure 4.4, lanes 5-7) and the 
adherent cells, containing fibroblasts and interstitial macrophages, predominantly 
used P1 (Figure 4.4, lanes 8-10). Because the P3 promoter is a very minor promoter 
in lung (Figure 4.1) and the truncated enzyme encoded by the P3 promoter lacks 
11β-HSD1 activity (Mercer, Obeyesekere et al. 1993), only the P1 and P2 promoters 














Figure 4.4 Hsd11b1 promoter usage in different lung cell populations. 
RNA was extracted from the indicated primary lung cells. 1μg of RNA was used in 
an RT reaction and 4μl RT reaction used in 30 cycles PCR with primers specific for 
transcripts initiating at each of P1 and P2 as well as primers that detect all Hsd11b1 
transcripts. Lane 1, 1kb marker. Lanes 2-4, RT-PCR reactions carried out on RNA 
extracted from non-adherent and loosely adherent cells, which contain epithelial cells. 
Lanes 5-7, RT-PCR reactions carried out on alveolar macrophage RNA. Lanes 8-10, 
RT-PCR reactions carried out on RNA isolated from firmly adherent cells. Lane 11, A 
control reaction (-RT) on adherent cell RNA gave no product with primers to amplify 
total 11β-HSD1. Arrows indicate the similar sized products from the P1 (627bp) and 












Non-adherent &       alveolar      adherent cells     
loosely adherent cells  macrophages  (fibroblasts and macrophages) 
Lane: 1   2   3   4   5   6  7   8   9  10   11 






4.2.4 Hsd11b1 promoter usage in bone marrow-derived myeloid cells 
The experiments described above (4.2.3) show alveolar macrophages mainly use the 
Hsd11b1 P2 promoter. To investigate Hsd11b1 promoter usage in a more pure 
population of macrophages and to explore promoter usage in other innate immune 
cells present in lung tissue, bone marrow-derived myeloid cells were used. Bone 
marrow-derived macrophages (BMDM) were differentiated from bone marrow, 
prepared from femurs of C57BL/6 mice as described in Chapter 2.2.1.2 and used to 
test whether all macrophages predominately use the P2 promoter. In addition, 
dendritic cells (DC) were differentiated from bone marrow by culture with 
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF). As DC have 
previously been shown to express 11β-HSD1 (Freeman, Hewison et al. 2005), 
promoter usage in these cells was also examined. 
 
4.2.4.1 Both P1 and P2 but not P3 are used to transcribe Hsd11b1 in bone 
marrow derived macrophages and dendritic cells 
RT-PCR on RNA from freshly isolated bone marrow cells from C57BL/6 mice 
showed that both P1- and P2-initiated 11β-HSD1 mRNAs were present in bone 















Figure 4.5 Promoter usage of 11β-HSD1 in freshly isolated mouse bone marrow 
cells. 
RNA was extracted from freshly isolated bone marrow cells from C57BL/6 mice. 
1μg of RNA was used in an RT reaction and 4μl RT reaction used in 30 cycles PCR 
with primers specific for transcripts initiating at each of P1, P2 and P3 as well as 
primers that detect all Hsd11b1 transcripts. Lane 1, 1kb marker. Lanes 2-4, RT-PCR 
reactions carried out to detect transcripts initiating from P1 (lane 2, 627bp product), 
P2 (lane 3, 646bp product) and P3 (lane4, 543bp product). Lane 5 shows the 470bp 
product from total 11β-HSD1. Lane 6, contains a PCR reaction in which RT was 
omitted from the RT reaction (-RT). The positions of the 627 bp P1 product and the 
646bp P2 product are indicated, as is the position of the 470bp product derived from 
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4.2.4.2 Bone marrow derived macrophages mainly use the P2 promoter 
To confirm macrophage differentiation, immunocytochemical staining for F4/80 was 
carried out on BMDM as described in Chapter 2.2.13. Generally, more than 90% 
BMDM cultures were macrophages (Figure 4.6A). Diff-Quick staining was also used 
to assess morphology (Figure 4.6B). To verify that GR is co-expressed with 
11β-HSD1 in BMD macrophages, immunocytochemical staining for GR was also 
carried out. Intensity of GR staining was variable between BMDM, with most cells 




















Figure 4.6 Phenotyping of BMDM by F4/80, Diff-Quick and GR staining 
Immunohistochemistry was carried out on cytocentrifuged preparations of BMDM 
cells from WT mice to check maturation. (A), rat anti-mouse F4/80 antibody (1:100 
dilution) and biotinylated rabbit-anti-rat 2nd Ab (1:200 dilution); (B), Diff-Quick 
staining; (C), rabbit anti-GR antibody (1:100 dilution) and biotinylated 
goat-anti-rabbit 2nd Ab (1:50 dilution); (D), negative control in which primary 
antibody was omitted with biotinylated goat-anti-rabbit 2nd Ab (1:50 dilution). 









To establish which promoter of Hsd11b1 was used in BMDM and to test whether 
activation of macrophage by LPS altered expression levels and/or promoter usage of 
Hsd11b1, BMDM were treated with 100ng/ml LPS for 24h. Previous studies have 
suggested that macrophage activation by lipopolysaccharide (LPS) may regulate 
levels of 11β-HSD1 mRNA in a macrophage cell line (Thieringer, Le Grand et al. 
2001), although there may be no effect in primary macrophages (Gilmour 2002). 
 
RT-PCR to examine P1 promoter and P2 promoter usage showed that BMDM use the 
P2 promoter (Figure 4.7), consistent with data in alveolar macrophages (Section 
4.2.3). No difference was seen in promoter usage following LPS (Figure 4.7), nor 
was there an obvious difference in levels of 11β-HSD1 mRNA initiated from the p2 




















Figure 4.7 BMDM use the 11β-HSD1 P2 promoter and promoter usage is not 
affected by LPS treatment 
BMDM were differentiated and cultured in Teflon pots. 7d after differentiation of 
BMDM, one pot of BMDM was treated with 100ng/ml LPS for 24h. RNA was 
extracted from BMDM with or without 24h LPS stimulation. 1μg of RNA was used 
in an RT reaction and 4μl RT reaction used in 30 cycles PCR with primers specific 
for transcripts initiating at each of P1, P2 and P3 as well as primers that detect all 
Hsd11b1 transcripts. Lane 1, 1kb marker. Lanes 2 to 5, RT-PCR reactions carried out 
on RNA of BMDM without LPS. Lane 6, 1kb marker. Lanes 7 and 8, RT-PCR 
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4.2.4.3 Bone marrow derived dendritic cells express 11β-HSD1 from the P2 
promoter  
Previous data has shown that 11β-HSD1 expression is induced in immature human 
DC then decreases as DC are matured (Freeman, Hewison et al. 2005). To determine 
which promoter is used in DC cells and whether promoter usage is altered by 
maturation of DC, DC were differentiated from bone marrow cells as described in 
Chapter 2.2.1. On d10 of differentiation, DC were resuspended in medium containing 
GM-CSF to mature. Control cells were left without GM-CSF treatment and 
considered immature DC. On d11, cells were harvested for RNA extraction. The 
maturation of DCs was assessed by CD11c staining, which was similar in mature and 
immature DCs with 65% cells staining positively (Figure 4.8A&B). 
 
IHC showed that expression of 11β-HSD1 decreased with maturation (Figure 
4.8C&D). Interestingly, GR immunoreactivity showed the opposite pattern to 
11β-HSD1 and was higher in mature DC than in immature DC (Figure 4.8E&F).  
 
RT-PCR showed that both mature and immature DC predominantly used the P2 







Immature DC Mature DC 
 
Figure 4.8 Immunohistochemical staining of 11β-HSD1 (rabbit Ab), GR and 
CD11c on DC  
(A-B), DC stained with biotinylated hamster anti-mouse CD11c (1:50 dilution); (A) 
11 days immature DC; (B) 11 days mature DC; (C-D), immunohistochemistry was 
carried out with rabbit anti-11β-HSD1 antibody and biotinylated goat-anti-rabbit 2nd 
Ab on (C) 11 days immature DC; (D) 11 days mature DC. (E-F), DC stained with 
rabbit anti-GR antibody (1:100 dilution) and biothylated goat-anti-rabbit 2nd Ab (1:50 
















      
 
Figure 4.9 Promoter usage of 11β-HSD1 in mature and immature DC. 
RNA was extracted from mature and immature DC. 1μg of RNA was used in an RT 
reaction and 4μl RT reaction used in 30 cycles PCR with primers specific for 
transcripts initiating at each of P1 and P2 as well as primers that detect all Hsd11b1 
transcripts. Lane 1, 1kb marker. Lane 2-5, RT-PCR reactions carried out on immature 
DC RNA. Lane 6, minus RT. Lane 7-10, RT-PCR reactions carried out on mature DC 
RNA. Lane 11, contains a PCR reaction in which RT was omitted from the RT 
reaction, minus RT. The position of the 627 bp P1 product and the 646bp P2 product 
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4.2.5 Further characterization of 11β-HSD1 promoter usage in primary lung 
fibroblasts  
11β-HSD1 expression has been demonstrated in rat lung fibroblasts (Brereton, van 
Driel et al. 2001) and Chapter 3 shows that 11β-HSD1 is also expressed in mouse 
primary lung fibroblasts. Moreover, the experiments above suggest that freshly 
isolated lung fibroblasts mainly use the P1 promoter with the P2 promoter used to a 
much lesser extent. However, there are still macrophages present in freshly isolated 
fibroblasts (identified by F4/80 staining), raising the possibility that the small amount 
of P2 promoter usage in the adherent cells (fibroblasts and macrophages) might be 
due to macrophage contamination, because macrophages mainly use the P2 promoter 
(Figure 3.6 and see Chapter 4.2.4.2). As primary macrophages do not proliferate 
(Stewart, Lin et al. 1975), but fibroblasts proliferate very quickly in culture, further 
culture was carried out to decrease the possible macrophage contamination, as 
described in Chapter 2.2.7. However, RT-PCR showed that 11β-HSD1 promoter 
usage was changed and both the P1 and P2 promoters are used in passage 2 


















Figure 4.10 Primary lung fibroblasts use similar amount of the P1 and P2 
promoter of Hsd11b1 in passage2 
RNA was extracted from lung fibroblasts at passage 2 and subject to PCR with 
primers specific for Hsd11b1 transcripts initiating at the P1 promoter (627bp 
product), the P2 promoter (647bp product) or the P3 promoter (predicted product of 
542bp). Total 11β-HSD1 mRNA was amplified to give a product of 470bp (lanes 
marked total). Control reactions omitted RT (-RT). 1μg of RNA was used in an RT 
reaction and 4μl RT reaction used in 30 cycles PCR. Lanes 1, 1kb marker. Lanes 2-5, 
RT-PCR reactions carried out on passage 2 fibroblast RNA. The position of the 627 
bp P1 product and the 646bp P2 product is indicated, as is the position of the 470bp 
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To determine whether any macrophage contamination cause the increase of the P2 
promoter usage, IHC was carried out with anti-F4/80 antibody to identify 
macrophages in primary lung fibroblasts following 6 passages. As shown in Figure 
4.11A very few (<1%) cells stained with F4/80 suggesting there is little macrophage 
contamination.  
  
As HFL-1 cells are reported to have myofibroblast characteristics and primary 
fibroblasts may have transformed to myofibroblasts with passage, passage 6 cells 
were stained with anti-α-SMA antibody to address this possibility. The majority of 
cells were positive for α-SMA (Figure 4.11C), suggesting that fibroblasts had 
transformed to myofibroblasts after 6 passages in primary culture. Although the cells 



















Figure 4.11 Immunocytochemistry on primary cultured lung fibroblasts 
(passage 6) shows the majority of cells are positive for α-SMA and very few cells 
are positive for F4/80  
Immunocytochemistry showing staining of primary lung fibroblasts (passage 6) (A), 
F4/80 staining; (B), negative control for F4/80 staining, 2nd Ab only; (C), α-SMA 
staining; (D), negative control for α-SMA, 2nd Ab only. Immunocytochemistry was 
carried out with mouse anti-mouse α-SMA antibody at 1:8000 dilution and 
biotinylated goat-anti-mouse 2nd Ab at 1:400 dilution or rat anti-mouse F4/80 at 
1:400 dilution and biotinylated goat-anti-rat 2nd Ab at 1:400 dilution. Brown 









4.2.5.1 The promoter usage of Hsd11b1 changes during culture and passage 
The discovery that passaged fibroblasts (which stained positively for α-SMA) and 
HFL-1 cells use the P2 promoter of Hsd11b1 whereas freshly isolated fibroblasts 
appear to mainly use the P1 promoter suggested that promoter usage of Hsd11b1 may 
switch with continuous cell culture. To determine whether fibroblast cells switch 
from the P1 promoter to the P2 promoter after continuous passage, RNA was 
extracted from fibroblasts after 5 passages and subject to RT-PCR. Control reverse 
transcription-PCR reactions from lung mRNA served as positive controls for the 
transcription of 11β-HSD1 from the P1 promoter. Almost no PCR product was 
obtained with cDNA from the passaged fibroblasts with the primers specific for the 
P1 promoter (Figure 4.12). At this time, the number of macrophages (identified by 





















Figure 4.12 Primary lung fibroblasts mainly used the P2 promoter of Hsd11b1 
after 5 passages 
RNA was extracted from lung fibroblasts at passage 5 and subject to PCR with 
primers specific for Hsd11b1 transcripts initiating at the P1 promoter (627bp 
product), the P2 promoter (647bp product). Total 11β-HSD1 mRNA was amplified to 
give a product of 470bp (lanes marked total). Control reactions omitted RT (-RT). 
1μg of RNA was used in an RT reaction and 4μl RT reaction used in 30 cycles PCR. 
Lanes 1, 1kb marker. Lane 2, RT-PCR carried out on RNA from whole lung used as a 
positive control for the P1 promoter product. Lanes 3-8, RT-PCR reactions carried 
out on RNA isolated from 2 independent cultures of fibroblasts (passage 5; pool 1 
and pool 2). The position of the 627 bp P1 product and the 646bp P2 product is 
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4.2.5.2 Quantification by real-time PCR of 11β-HSD1 promoter usage in 
primary lung fibroblasts cultured for 2 weeks, 4 weeks or 22 weeks  
To quantify mRNA initiating from the P1 and P2 promoters of 11β-HSD1 in primary 
lung fibroblasts and to confirm the switch in promoter usage, specially designed 
primers were used in real-time PCR (validation of assay at 4.2.1.2). Three 
independent cultures were established, each from a pool of cells from 2 mice. RNA 
was extracted from fibroblasts at passage 0 (in culture for 2 weeks), passage 3 (in 
culture for 4 weeks) and passage 12 (in culture for 22 weeks) and subject to real-time 
PCR. 
 
After 22 weeks of culture (12 passages), only 11β-HSD1 mRNA initiating at the P2 
promoter was detected (Figure 4.13). In contrast, after 2 weeks (passage 0) P1 
predominated whereas after 4 weeks of culture (passage 3), P1 and P2 were used to a 
similar extent with P2 possibly predominating (Figure 4.13). These results confirm 
that at early passages lung fibroblasts mainly use the P1 promoter, but undergo a 
































Figure 4.13 The promoter usage of the Hsd11b1 gene switches from P1 to P2 
following extended primary culture. 
Total RNA was extracted from 3 independent cultures of primary lung fibroblasts 
grown for 2 weeks (0 passages), 4 weeks (3 passages), or 22 weeks (12 passages) and 
analysed for P1-and P2-initiated 11β-HSD1 mRNA as well as total 11β-HSD1 
mRNA by real-time PCR. mRNA Levels are expressed relative to the level of TBP 
mRNA and are in arbitrary units (AU). Data at 2 and 4 weeks are from 2 different 










4.2.5.3 TGF-β regulates 11β-HSD1 expression during fibroblast to 
myofibroblasts differentiation  
TGF-β plays an important role in inducing fibroblast to myofibroblast differentiation 
(Hu, Wu et al. 2004). To determine whether TGF-β induces the promoter switch of 
Hsd11b1, primary fibroblasts in passage 1 were treated with 2ng/ml TGF-β or 10μM 
SB431542 (a TGF-β receptor antagonist) for 72h, as described in Chapter 2.2.7. 
After removal of the culture medium, cells were washed with PBS, then subject to 
RNA extraction or IHC. Type 1 collagen and α-SMA expression, two markers of 
fibroblast activation and myofibroblast differentiation (Liu, Dhanasekaran et al. 
2004), were assessed by IHC and the encoding mRNAs measured by real-time PCR 
to confirm the transformation and to validate the effect of TGF-β.  
 
α-SMA IHC showed that before TGF-β treatment, cells were already positive for 
α-SMA (Figure 4.14A). TGF-β treatment caused fibroblasts to proliferate and 
become more spindle-shaped, with cells aligned parallel to one another (Figure 
4.14B) and exhibiting increased α-SMA expression (Figure 4.14B), all typical 
features of myofibroblasts (Hu, Wu et al. 2004). Fibroblasts treated with SB431542 
showed similar fibroblast morphology and α-SMA expression to control untreated 
cells (compare Figure 4.14C with Figure 4.14A). The results confirm that TGF-β 








Figure 4.14 α-SMA expression in primary cultured lung fibroblasts confirms a 
TGF-β−mediated fibroblast to myofibroblast transformation.  
Immunohistochemistry was carried out with mouse anti-mouse α-SMA antibody at 
1:8000 dilution and biotinylated goat-anti-mouse 2nd Ab at 1:400 dilution. Brown 
indicates positive staining.  
(A), control fibroblasts without treatment (passage 1); (B), fibroblasts treated for 72h 
with 2ng/ml TGF-β; (C), fibroblasts treated for 72h with 10μM SB431542, a TGF-β 
receptor antagonist; (D), negative control for α-SMA, mouse IgG only. Images 




B, TGF-βA, Untreated 
C, SB431542 D, negative control 
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Real-time PCR showed that type 1 collagen expression was increased with TGF-β 
treatment and decreased with TGF-β receptor antagonist (Figure 4.15A), consistent 
with a TGF-β–induced differentiation (from fibroblasts to myofibroblasts). α-SMA 
mRNA levels showed a similar trend to Type 1 collagen (Figure 4.15B). However, 
this difference did not reach significance (P=0.15). Nevertheless, these results 
confirm the effect of TGF-β on the cells and its antagonism by TGF-β receptor 
antagonist. 
 
Levels of 11β-HSD1 mRNA were markedly decreased by TGF-β whereas 11β-HSD1 
mRNA levels were increased by TGF-β receptor antagonist (Figure 4.15C). Levels of 
P1-initiated 11β-HSD1 transcripts were repressed by TGF-β, to barely detectable 
levels (Figure 4.15D). Importantly, addition of SB431542 markedly increased levels 
of P1-initiated mRNA. TGF-β decreased levels of mRNA initiating at the P2 
promoter, an effect that was antagonised by SB431542 (Figure 4.15E). However, 
levels of P2-initiated transcripts were similar in TGF-β receptor antagonist-treated 
cells and in control cultures (Figure 4.15E).  
 
Because C/EBPβ regulates the P2 promoter (Chapman, Coutinho et al. 2009) and is 
implicated in the differentiation of fibroblast to myofibroblasts (Hu, Ullenbruch et al. 
2007), levels of C/EBPβ mRNA were measured. However, C/EBPβ mRNA levels 





















































































































































Figure 4.15 TGF-β switches off the P1 promoter of Hsd11b1  
Total RNA was extracted from passage 1 (9d) fibroblasts following 72h treatment 
with TGF-β or  SB431542 or without treatment (control), reverse transcribed and 
subject to real-time PCR to measure (A) typeI α2 collagen mRNA levels; 
(B) α-SMA mRNA levels; (C) total 11β-HSD1 mRNA; (D) mRNA initiating at the 
P1 or (E) P2 promoter of 11β-HSD1; and (F) C/EBPβ mRNA. Levels are expressed 
relative to the level of TBP mRNA and are in arbitrary units (AU). Data are mean ± 
SEM from 3 independent cultures. Data were analysed by ANOVA followed by 







In the majority of tissues, 11β-HSD1 can be transcribed from 2 promoters although 
in mouse the P2 promoter predominates (Bruley, Lyons et al. 2006). Data in this 
chapter confirmed that lung expresses 11β-HSD1 mainly from the P1 promoter and 
showed that, in contrast to macrophages and dendritic cells which mainly used the P2 
promoter, this was likely to be due to expression of Hsd11b1 from the P1 promoter in 
lung fibroblasts. A549 cells, an alveolar cell line (Lieber M, Smith B et al. 1976), 
expressed 11β-HSD1 from the P2 promoter. However, HFL-1, a fibroblast cell line 
(Breul, Bradley et al. 1980), expressed 11β-HSD1 from the P2 promoter as well. 
Although primary lung fibroblasts predominantly used the P1 promoter of 11β-HSD1, 
they completely switched to the P2 promoter after a few passages. Interestingly, total 
11β-HSD1 expression was decreased upon initial passage, then was increased 
thereafter. This might be due to differentiation and/or proliferation of a 
sub-population of fibroblasts that highly express 11β-HSD1 from the P2 promoter, or 
may be an adaption to culture shown by all the fibroblasts in the population.  
  
In passage 2 lung fibroblasts, almost all cells were α-SMA positive, which means 
that fibroblasts had started to transform to myofibroblasts. But compared to TGF-β 
stimulated myofibroblasts, these passage 2 cells were still like fibroblasts in 
morphology and had low α-SMA expression. Some groups are using plasma-derived 
serum to culture fibroblasts, to decrease the transformation to myofibroblast during 
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culture (Hu, Wu et al. 2004). Fetal Bovine Serum (FBS) has been shown to stimulate 
lung fibroblast proliferation (Yano, Yoshida et al. 2006) and primary culture with 
FBS will induce α-SMA expression (personal communication, Dr Sem Phan, 
University of Michigan, USA). Early passaged fibroblasts were subject to real-time 
PCR to measure α-SMA mRNA expression, showing that the level of α-SMA was 
much higher in the first passage, and decreased gradually thereafter (data not shown). 
It may represent an autocrine regulation mechanism of α-SMA expression. The 
culture medium and especially serum content may therefore induce the 
differentiation of fibroblast to myofibroblast. 
 
TGF-β is the key inducer of fibroblast to myofibroblast transformation (Hu, Wu et al. 
2003), so early passaged fibroblasts were treated with TGF-β to test whether TGF-β 
regulates 11β-HSD1 expression and promoter usage. 72h treatment with TGF-β 
increased expression of collagen type1 α2 and α-SMA, markers of myofibroblast 
differentiation, and decreased 11β-HSD1 expression, an effect which was not only 
reversed by SB431542, a TGF-β  receptor antagonist, but in fact SB431542 increased 
11β-HSD1 expression above control levels. This increase in 11β-HSD1 expression 
after SB431542 treatment compared to untreated cells, suggests either that the 
fibroblasts themselves secrete TGF-β or that culture medium containing new born 
calf serum contains TGF-β; thus antagonism of TGF-β  receptors increased 
11β-HSD1 mRNA levels relative to untreated cells. Whilst TGF-β reduced levels of 
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mRNA initiating at the P2 promoter, initiation from the P1 promoter was completely 
repressed. Treatment with TGF-β receptor antagonist markedly increased levels of 
P1-initiated 11β-HSD1 mRNA above levels in untreated cells. These data suggest 
that higher levels of TGF-β are required to decrease the P2 promoter than are present 
in the culture medium/secreted by the cells and that the P1 promoter may be sensitive 
to lower dose of TGF-β. A dose response experiment could test this hypothesis. 
These data suggest that a switch in 11β-HSD1 promoter usage may be regulated by 
TGF-β during an inflammatory response. TGF-β has been shown to regulate 
C/EBP-β and C/EBP-δ (Choy and Derynck 2003) and it may regulate 11β-HSD1 
expression through those transcription factors. 
 
C/EBP-β regulates 11β-HSD1 expression and is a key regulator of α-SMA 
expression and myofibroblast differentiation in isolated lung fibroblasts, binding to a 
C/EBP-β binding element identified in the α-SMA promoter (Hu, Wu et al. 2004; Hu, 
Ullenbruch et al. 2007). In the experiments reported here, the overall pattern of 
C/EBP-β expression after TGF-β stimulation was the same as for the 11β-HSD1 P2 
promoter, but the treatment effects did not achieve significance. Small changes in 
transcription factor levels can have large effects on target genes, so perhaps there 
were changes in C/EBP-β levels that were missed here. Also C/EBP-β is regulated 
translationally and post-translationally, e.g. by phosphorylation (Park, Qiang et al. 










5  Chapter Five: The consequences of 















5.1 Introduction and aim 
Previous data from our lab have suggested that 11β-HSD1 is important in 
inflammation, with 11β-HSD1-deficient mice showing earlier and more severe 
inflammation in three experimental models; peritonitis, pleurisy and arthritis 
(reviewed in 1.1.6.2). In the peritonitis model, 11β-HSD1-deficient mice showed 
greater recruitment of inflammatory cells than WT mice, but the inflammation 
resolved at a similar time in WT and 11β-HSD1-deficient mice (Gilmour 2003). In 
the pleurisy model, 11β-HSD1-deficient mice similarly showed greater recruitment 
of inflammatory cells and also hints of early fibrosis, that were not seen in WT 
control mice, 2d following carrageenan (Coutinho 2009). This suggests that 
11β-HSD1 may regulate the inflammatory response in lung by modulating local 
glucocorticoid action. Because the work described in Chapter 3 showed that in lung 
11β-HSD1 is mainly expressed in the fibroblast cells, and Chapter 4 showed lung 
fibroblast express 11β-HSD1 from the P1 promoter, and TGF-β suppresses 
11β-HSD1 expression, these suggested a role in lung fibrosis associated with 
inflammation. 
 
To delineate the role of 11β-HSD1 in pulmonary inflammation and fibrosis, the 
bleomycin model was used. Pulmonary fibrosis is the most severe adverse effect 
associated with clinical use of bleomycin, a cytotoxic chemotherapeutic agent (Sikic, 
Young et al. 1978), and intratracheal instillation of bleomycin is a commonly used 
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experimental model of lung inflammation and fibrosis (Borzone, Moreno et al. 2001). 
Unlike the previous 3 inflammatory models tested, the bleomycin model can 
investigate both inflammation and fibrosis, which also has features in common with 
human idiopathic pulmonary fibrosis (IPF) syndrome (Giri, Nakashima et al. 1985). 
Intratracheal instillation of bleomycin induces inflammatory cell infiltration into 
interstitial and alveolar lung (Borzone, Moreno et al. 2001). The first 14d following 
bleomycin installation comprises the acute phase of inflammation, with 
inflammatory cell recruitment, then the tissue progresses to a fibrotic response which 
resolves slowly (Borzone, Moreno et al. 2001). The experiments described in this 
chapter were carried out in collaboration with Dr Rodger Duffin, who performed the 
intratracheal instillation of bleomycin.  
 
5.2 Experimental plan 
Age matched mice were treated with 0.025U bleomycin/mouse, and were killed 2d, 
7d, 14d, 28d or 35d after installation of bleomycin. Mice were weighed regularly to 
assess general response to bleomycin. At each time point, lung tissues were 





5.3.1 WT and 11β-HSD1-deficient mice showed similar weight loss over 28d 
following bleomycin treatment 
Mice were weighed on a regular basis following bleomycin treatment. 
Repeated-measures ANOVA showed there is no difference in weight between 
genotypes at any time point. And, there was no effect of bleomycin treatment on 











































Figure 5.1 Bleomycin treatment for 28d had no effect on body weight of either 
WT or 11β-HSD1-deficient mice. 
Repeated-measures ANOVA showed no difference in body weight between wild-type 
(WT; squares) and 11β-HSD1-deficient (KO; triangles) mice. Data are mean ± SEM 









5.3.2 Characterization of bronchial alveolar cells recovered from bronchial 
alveolar lavage fluid (BALF) 
In order to assess the effects of bleomycin, mice were killed 2d, 7d, 14d, 28d and 35d 
after treatment and lungs were lavaged to collect cells. Inflammation was assessed by 
total cell count using a nuclear counter machine and differential cell counts on 
Diff-Quick stained BALF cells (described in Chapter 2.2.4).  
 
5.3.2.1 Total cell counts were similar between WT and 11β-HSD1-deficient mice 
after bleomycin treatment 
Figure 5.2 compares the total cell count in BALF of bleomycin-treated WT and 
11β-HSD1-deficient mice at each of the time points. No significant difference in the 
total mean cell count was seen between genotypes at any time point. The total cell 
number gradually increased from d2 through d28 and was significantly higher at d7 
and d14 than in untreated mice. After 28d, total cell counts from both groups were 












































Figure 5.2 Comparison of the total cell number in BALF from WT and 
11β-HSD1-deficient mice over the course of bleomycin-induced lung 
inflammation. 
BALF was collected at the time points indicated from both WT and 
11β-HSD1-deficient mice, and cells counted. Two-way ANOVA did not reveal any 
difference in total cell number between wild-type (WT; black bars) and 
11β-HSD1-deficient (KO; white bars) mice, but did show a significant effect of time 
(p<0.01). There was not a significant interaction between genotype and time 









5.3.2.2 Differential cell counts did not reveal any differences between WT and 
11β-HSD1-deficient mice after bleomycin treatment 
In order to assess whether the types of inflammatory cells present in the BALF 
differed between WT and 11β-HSD1-deficient mice, BALF cells were 
cytocentrifuged and Diff-Quick stained as described in Chapter 2.2.4.  
 
In cytocentrifuge preparations, the typical morphology of macrophages and 
neutrophils was obvious (Figure 5.3A&B). Similar numbers of macrophages and 
neutrophils were recovered in BALF from each genotype, 2d after bleomycin 
instillation (Figure 5.3C). However, almost all the neutrophils were cleared by 7d 
(Figure 5.3D), after which time the majority of inflammatory cells in BALF were 
macrophages (Figure 5.3E). The rest of the cell population consisted of either 
lymphocytes or neutrophils. There were no statistically significant differences 
between genotypes in the proportion of cell types (neutrophils, macrophages or 
lymphocytes) at any time point after bleomycin treatment (Figure 5.3C-E).  
 
Total protein levels in BALF are an indication of the severity of lung inflammation 
(Duffin, Tran et al. 2007). Total protein in BALF recovered 14d after bleomycin 
installation was measured as described in Chapter 2.2.14. The BALF protein level 
was similar between the genotypes (Figure 5.4), which is consistent with the 







Figure 5.3 Similar inflammatory cell 
types are present in BALF from WT 
and 11β-HSD1-deficient mice after 
bleomycin treatment. 
(A+B): Typical microscopic fields of 
Diff-Quick stained BALF cells from 
bleomycin-treated mice, collected 2d (A) 
or 7d (B) following bleomycin. Large 
arrows indicate macrophages. Neutrophils 
are indicated by arrowheads. (C-E): 
BALF was collected and cells recovered 
2d (C), 7d (D) or 14d (E) following 
bleomycin. 
Following cytocentrifugation and Diff-Quick staining, relative numbers of cell types 
were assessed microscopically (blind to genotype). Differential counts were 
performed by counting 300 cells per slide on random fields at x100 magnification. 
Data are mean ± SEM, n = 5-8. No significant differences were found between wild 
type (WT; black bars) and 11β-HSD1-deficient (KO; white bars) mice (Student’s 
t-test).  
A, 2d B, 7d  
C, 2d  D, 7d







































































































































Figure 5.4 The protein concentration of BALF recovered 14d after bleomycin 
installation was similar between the genotypes.  
Measurement of BALF protein from wild type (WT; black bars) and 
11β-HSD1-deficient (KO; white bars) mice, 14d after bleomycin instillation. Data 
are mean ± SEM with n = 5-8. The results were compared by unpaired Student’s 








5.3.3 Plasma corticosterone levels did not differ between WT and 
11β-HSD1-deficient mice following bleomycin installation 
On a C57BL/6 background, 11β-HSD1-deficient mice show normal basal plasma 
corticosterone levels (Yau, McNair et al. 2007). To investigate if levels differ 
between genotypes following bleomycin which could indicate differential activation 
of the HPA axis, nadir (morning) plasma corticosterone levels were measured in tail 
blood. Morning plasma corticosterone levels did not significantly differ between 
genotypes at d0 (Figure 5.5). However, morning corticosterone levels above 
50-70nM indicate stress (Kotelevtsev, Holmes et al. 1997; Carter, Paterson et al. 
2009), suggesting that the levels measured at d0 are elevated due to stress caused by 
blood collecting. Levels in WT were lower at d10, d14 and d28 than at d0, so that at 
d10 and d14 they were within the basal range (Figure 5.5), suggesting that at these 
later collections, the mice were less stressed and that bleomycin treatment did not 
result in HPA activation d10 later. Although not significant, there was a trend for 
higher plasma corticosterone levels in 11β-HSD1-deficient mice at d10, d14 and d28, 
suggesting a possible greater HPA axis response in 11β-HSD1-deficient mice. 









































Figure 5.5 Plasma corticosterone levels measured after bleomycin treatment. 
Plasma corticosterone levels in WT and 11β-HSD1-deficient mice were measured at 
different time points following bleomycin installation, as described in Chapter 2.2.21. 
Two-way ANOVA showed a significant interaction (P<0.05), but no genotype 
(P=0.34) or time difference (P=0.17) in plasma corticosterone levels between wild 
type (WT; black bars) and 11β-HSD1-deficient (KO; white bars) mice. Data are 







5.3.4 Adrenal gland weights differ between WT and 11β-HSD1-deficient mice 
Irrespective of genetic background, 11β-HSD1-deficient mice have larger adrenal 
glands than WT mice (Kotelevtsev, Holmes et al. 1997; Carter, Paterson et al. 2009). 
Both adrenal glands (formalin fixed) were weighed for each mouse killed 0d, 7d, 14d 
or 28d following bleomycin treatment. Two-way ANOVA showed significant 
genotype differences in the total adrenal gland weight between WT and 
11β-HSD1-deficient mice (Figure 5.6). At 0d, 7d and 14d adrenal glands from 
11β-HSD1-deficient mice were significantly heavier than those from WT mice 
(Figure 5.6). However, no significant difference was found at 28d between the 
genotypes (Figure 5.6). One-way ANOVA showed there was no difference between 
d0 and other time points in WT mice, although there was a difference between d0 
and d28 in 11β-HSD1-deficient mice, which suggests the size of adrenal glands 









































Figure 5.6 Comparison of total adrenal gland weight between WT and 
11β-HSD1-deficient mice following bleomycin. 
Adrenal glands from either WT or 11β-HSD1-deficient mice at different time points 
following bleomycin installation were weighed. Weights indicated in graph are the 
combined weight of both adrenal glands from each animal. Two-way ANOVA 
showed a significant genotype difference (P<0.0001), interaction (P<0.01) and time 
(P=0.01) in weight of adrenal glands between wild type (WT; black bars) and 
11β-HSD1-deficient (KO; white bars) mice. Data are mean ± SEM with n = 3-8. *** 






5.3.5 Histological assessment indicates more severe inflammation and fibrosis 
in 11β-HSD1-deficient mice 14d after bleomycin 
Lungs (half or whole) were dissected from mice 2d, 7d, 14d or 28d following 
instillation of bleomycin, fixed in Methyl-Carnoy fixative as described in Chapter 
2.2.4, and embedded. Sections (5μm thick) were stained with haematoxylin and 
eosin (H&E) to assess pathology, and the remaining sections were used for 
Picrosirius red staining (Chapter 2.2.19) or for immunohistochemistry (IHC) 
(Chapter 2.2.12). The H&E stained sections were examined by Dr David Brownstein 
of the CVS Pathology Core Facility. The objective was to determine whether there 
were differences in inflammation and fibrosis within lung between WT and 
11β-HSD1-deficient mice at any stage following instillation of bleomycin. 
 
There was histological variability within groups at every time point. The distribution 
of inflammation in the lung was patchy, probably due to unequal distribution of 
bleomycin with the instillation method. Some parts of lung showing normal structure 
could be found at all time points, but some parts of lung showed the expected 
inflammatory cell infiltration, thickening of the alveolar walls and deposition of 
fibrous tissue. 
 
There were no differences in lung histology between untreated WT and 
11β-HSD1-deficient mice (data not shown). At 2d following bleomycin treatment 
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there was noticeable inflammation in both genotypes with similar infiltration of 
inflammatory cells (Figure 5.7A and B). By 7d, inflammation had worsened in the 
lungs of both genotypes, but there were no obvious qualitative differences between 

























Figure 5.7 2d and 7d following instillation of bleomycin, inflammation is 
noticeable in both genotypes with inflammatory cell infiltration. 
Representative images of H&E stained sections of lung tissue from WT and 
11β-HSD1-deficient mice killed 2d or 7d after bleomycin treatment. (A) WT mouse, 
2d bleomycin treated; (B) 11β-HSD1-deficient mouse, 2d bleomycin treated. H&E 
staining shows inflammation within alveolar areas and small areas of thickened 
alveolar walls (arrows); (C) WT mouse, 7d bleomycin treated; (D) 
11β-HSD1-deficient mouse, 7d bleomycin treated. All were photographed at X100 
magnification. H&E, hematoxylin and eosin. “b” indicates bronchioli and “v” 
indicates a blood vessel. 
  
 
A, 2d  










At 14d, many areas of the lung had thickened alveolar walls and some tissues 
showed loss of architecture. However, whilst WT mice showed relief of 
inflammation compared to 7d (Figure 5.8A), inflammation was still severe in 
11β-HSD1-deficient mice, with more interstitial inflammatory cells (Figure 5.8B). 
11β-HSD1-deficient mice showed extensive thickening of alveolar walls, evidence of 
continued inflammation (Figure 5.8B). Also, 11β-HSD1-deficient mice showed areas 
of fibrosis with obliteration of alveolar wall architecture and fibrous deposits, 
adjacent to areas of normal lung tissue (Figure 5.8B).  
 
The final time point examined was 28d after bleomycin. Although the majority of 
inflammatory cells had cleared in both genotypes, some inflammatory cells were still 
evident within 11β-HSD1-deficient mouse lungs (Figure 5.8C and D). Both WT and 
11β-HSD1-deficient mice showed the expected extensive dense lung fibrosis, 
characterized by increased interstitial wall thickness and interstitial collagen 
deposition (Figure 5.8C and D). The fibrotic changes were greater in extent and 
severity in 11β-HSD1-deficient mice than in WT mice with fibrotic lesions more 
narrowly confined to central peribronchial and perivascular areas in WT mice 
compared with 11β-HSD1-deficient mice (Figure 5.8C and D). Thus histopathology 
suggested that 11β-HSD1 deficiency is associated with increased bleomycin-induced 
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Figure 5.8 Compared to WT mice, 11β-HSD1-deficient mice show a more severe 
inflammatory response 14d following bleomycin instillation and more fibrosis at 
28d  
Representative images of H&E stained sections of lung tissue from WT and 
11β-HSD1-deficient mice killed 14d or 28d after bleomycin instillation. (A) WT 
mouse, 14d after bleomycin; (B) 11β-HSD1-deficient mouse, 14d after bleomycin, 
showing strong inflammation around airways, blood vessels and in the interstitum, 
indicated by arrows; (C) WT mouse, 28d after bleomycin; (D) 11β-HSD1-deficient 
mouse, 28d after bleomycin. All images were obtained at X100 magnification. “b” 















In order to semi-quantify the inflammatory reaction in the lungs of WT and 
11β-HSD1-deficient mice, lung sections from mice killed 14d and 28d after 
bleomycin instillation were scored for the severity of inflammation, blind to 
genotype, as described in Chapter 2.2.18. The scoring system assessed inflammation 
in the following compartments: perivascular compartment, peribronchiolar alveolar 
tissue and alveolar walls. At both time points, 11β-HSD1-deficient mice showed a 
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Figure 5.9 Quantification of inflammation in tissue sections shows more severe 
inflammation in lungs of 11β-HSD1-deficient mice compared to WT, 14d or 28d 
following bleomycin. 
Tissue sections from bleomycin treated lung were scored blind to genotype according 
to the method described in Chapter 2.2.18. Data are mean ± SEM with n = 5-8. 
Two-way ANOVA showed a significant genotype (P=0.03) and time (P<0.01) 
difference but not an interaction (P=0.73) in inflammation score between wild type 







5.3.6 Lungs of 11β-HSD1-deficient mice show greater collagen accumulation 
28d following bleomycin treatment 
To investigate whether the greater fibrosis observed in histology was associated with 
increased collagen deposition in lungs of 11β-HSD1-deficient mice, picrosirius red 
staining was used to identify collagen (Chapter 2.2.19). The staining showed 
deposition of collagen in thickened alveolar walls and around vessels or bronchi after 
bleomycin treatment (Figure 5.10B and D) and further suggested that 
11β-HSD1-deficient mice showed more severe fibrosis compared with WT mice 
(Figure 5.10A and C). 
 
To confirm and quantify the fibrotic changes observed, lung collagen was measured 
by Sircol assay (described in Chapter 2.2.20) using the left lobe of the lung from 
naïve mice or mice 14d or 28d after bleomycin treatment. Interestingly, untreated 
(naïve) 11β-HSD1-deficient mice had significantly lower levels of collagen in lung 













Figure 5.10 Picrosirius red staining showed 11β-HSD1-deficient mice have more 
severe fibrosis 28d following bleomycin instillation 
Representative images of Picrosirius red-stained lung sections from mice, 28d after 
bleomycin treatment, showing increased collagen deposition in 11β-HSD1-deficient 
mice. Sections of lung from WT and 11β-HSD1-deficient mice, at 28d following 
intratracheal instillation of bleomycin, were stained with Picrosirius red and viewed 
under polarized light (A&B) or bright field (C&D) (X100 magnification). Collagen 
appears as a yellowish orange color under polarized light and red under bright field. 
A and C are the same section from a WT mouse, B and D are the same section from 











































Figure 5.11 Naïve 11β-HSD1-deficient mice have significantly lower levels of 
lung collagen than WT mice  
The left lung lobe was removed from 4 month old male mice, enzyme digested, acid 
hydrolysed and collagen content measured as described in Chapter 2.2.20. The lungs 
were not lavaged or perfused prior to digestion. Sircol assay was used to measure the 
total collagen content of lung. The results are expressed as total collagen per left lobe 
of lung. The difference between wild type (WT; black bars) and 11β-HSD1-deficient 
(KO; white bars) mice was statistically significant, compared by unpaired Student’s 








Because collagen in the bronchial-alveolar space accounts for a significant amount of 
collagen in lung (Michael Gibbons, personal communication), lungs were lavaged 
and perfused prior to collagen measurement to exclude those factors. The collagen 
content of 11β-HSD1-deficient mouse lung remained significantly lower than WT 
mouse lung following BAL and perfusion (Figure 5.12).   
 
To determine whether collagen levels differed between WT and 11β-HSD1-deficient 
mice 14d after bleomycin treatment, lungs were lavaged and perfused prior to 
collagen measurement. Both WT and 11β-HSD1-deficient mice had increased levels 
of lung collagen after bleomycin, compared to naïve mice. Levels in 
11β-HSD1-deficient mice still appeared lower than in WT, although this did not 
achieve significance (Figure 5.12).  
 
However, by 28d after bleomycin treatment, although both genotypes still expressed 
significantly higher levels of collagen than naïve mice, the difference between WT 
and 11β-HSD1-deficient mice in levels of collagen had disappeared (Figure 5.12), 
suggesting that the increase in collagen content following bleomycin treatment was 










































Figure 5.12 Following BAL and perfusion, naïve 11β-HSD1-deficient mice have 
lower levels of lung collagen than WT mice but not after bleomycin treatment 
The left lung lobe was removed, enzyme digested, acid hydrolysed and collagen 
content measured as described in Chapter 2.2.20. The lungs were lavaged and 
perfused prior to digestion. Sircol assay was used to measure the total collagen 
content of lung. The results are expressed as total collagen per left lobe of lung. Data 
are mean ± SEM with n = 6-8. Wild type (WT; black bars) and 11β-HSD1-deficient 
(KO; white bars) mice. Within each time point, mice are age-matched. Mice used for 
d0 were culled at 3 months of age, mice used for 14d bleomycin treatment were 
culled at 4.5 months and mice used for 28d bleomycin treatment were culled at 5 
months of age. Therefore, each time point was analysed separately for significance 
by t-test. The difference between WT and KO mice at d0 was statistically significant, 






5.3.7 Quantification of blood leukocytes in WT and 11β-HSD1-deficient mice 
after bleomycin installation. 
Because the histology at 14d suggested more inflammatory cells in lung of 
11β-HSD1-deficient mice following installation of bleomycin, blood leukocytes 
were examined to see if there were differences in number or type of blood leukocytes 
following treatment. Blood were collected at each time point and cells from blood 
were subject to flow cytometry to identify different types of blood leukocytes.  
 
5.3.7.1 11β-HSD1-deficient mice have fewer blood monocytes than WT mice, 
14d after bleomycin treatment 
To monitor monocytes in blood, antibodies to label CD115, CD11b and 7/4 were 
used in flow cytometry to identify total monocytes (CD115+ CD11b+), the subset of 
inflammatory monocytes (CD115+ CD11b+ 7/4hi) and resident monocytes (CD115+ 
CD11b+ 7/4lo) as described in Chapter 2. By 2d after bleomycin instillation, the 
number of monocytes in blood was increased in both genotypes, peaking around 14d 
(Figure 5.13). Although not statistically significant (2 way ANOVA), there was a 
trend to fewer monocytes in the blood of 11β-HSD1-deficient mice than in WT mice 
14d following bleomycin instillation (Figure 5.13) with reduced numbers of both 























































































Figure 5.13 Bleomycin treatment have fewer monocytes in blood of 
11β-HSD1-deficient mice at 14d compared to WT mice. 
Cells collected from blood of either WT or 11β-HSD1-deficient mice at different 
time points following bleomycin installation were analysed for CD115, CD11b and 
7/4 expression by flow cytometry. (A) CD115, CD11b+ monocytes; (B) CD115, 
CD11b+ and 7/4hi monocytes; (C) CD115, CD11b+ and 7/4lo monocytes. Levels are 
expressed as cell number X105 per ml blood. Two-way ANOVA showed an effect of 
time (p<0.001) and a trend to genotype difference (p=0.07) in total monocyte 
numbers between wild type (WT; black bars) and 11β-HSD1-deficient (KO; white 
bars) mice. Two-way ANOVA showed an effect of time (p<0.01) and a trend to 
genotype difference (p=0.06) in 7/4lo monocyte numbers. Two-way ANOVA showed 
an effect of time (p=0.0001) but no effect of genotype or interaction upon 7/4hi 
monocyte numbers between WT and KO mice. Data are mean ± SEM with n = 5-8. 







5.3.7.2 11β-HSD1-deficient mice have similar number of blood neutrophils to 
WT mice after bleomycin treatment 
Neutrophils were gated using CD11b and Ly6(G) markers in cells from the blood, as 
described in Chapter 2.2.22. No significant differences were observed in the number 
of CD11b+ Ly6(G)+ neutrophils in the blood between the two genotypes at any time 
point (Figure 5.14), although 2d after bleomycin treatment, WT mice had fewer 














































Figure 5.14 Blood neutrophil numbers are similar between genotypes after 
bleomycin treatment 
Cells collected from blood of either WT or 11β-HSD1-deficient at different time 
points following bleomycin installation were analysed for CD11b and Ly6(G) 
expression by flow cytometry. Levels are expressed as cell number X105 per ml 
blood. Two-way ANOVA showed no genotype difference in CD11b+Ly6(G)+ number 
between wild type (WT; black bars) and 11β-HSD1-deficient (KO; white bars) mice, 
but a significant reduction in the number of neutrophils in blood of WT mice 2d 
following bleomycin, compared to untreated controls (p<0.05; *), compared by 








5.3.7.3 Proportion of T cells and B cells in WT vs. 11β-HSD1-deficient mice: 
Anti-CD4, anti CD-8 and anti-B-220 antibodies were used to label lymphocytes in 
blood of WT and 11β-HSD1-deficient mice after bleomycin treatment. Naïve 
11β-HSD1-deficient mice had more CD4+ T cells than WT mice (Figure 5.15A), but 
there were no differences between genotypes in either CD4+ or CD8+ cells following 
bleomycin treatment (Figure 5.15A&B). Whilst no difference between genotypes 
was found in B220+ cells after bleomycin treatment, naïve (untreated) 
11β-HSD1-deficient mice had significantly more B220+ lymphocytes cells than WT 
mice (Figure 5.15C). However, levels of these cells declined in blood of 



















































































Figure 5.15 Blood CD4+, CD8+ and B220+ cell numbers were similar between 
genotypes after bleomycin treatment 
Cells collected from blood of either WT or 11β-HSD1-deficient at different time 
points following bleomycin installation were analysed for CD4, CD8 and B220 
expression by flow cytometry. Levels are expressed as cell numbers X105 per ml 
blood. Two-way ANOVA showed an effect of time (p<0.0001) and genotype (p<0.05) 
on CD4+ cell numbers between wild type (WT; black bars) and 11β-HSD1-deficient 
(KO; white bars) mice. Two-way ANOVA showed no genotype difference in B220+ 
or CD8+ cell numbers between WT and KO mice. Data are mean ± SEM with n = 5-8. 








5.3.8 Proportion of B220+, CD3+ and CD8+ cells in lung of WT and 
11β-HSD1-deficient mice 7d following bleomycin instillation 
To determine whether inflammatory cells within the lung differed between WT and 
11β-HSD1-deficient mice, collagenase digestion was used to release leukocytes prior 
to flow cytometry, to identify total leukocytes (anti-CD45), T cells (anti-CD3), 
T-cytotoxic cells (anti-CD8), and B lymphocytes (anti-B220) in lung 7d after 
bleomycin installation. Whilst no difference between genotypes was found in CD45, 
CD3 and CD8 populations 7d following bleomycin treatment, 11β-HSD1-deficient 





















Figure 5.16 11β-HSD1-deficient mice have a greater proportion of B cells but 
similar proportions of CD3+, CD8+ T cells and total CD45 leukocytes in lung, 7d 
following bleomycin installation. 
Following collagenase digestion, flow cytometry was used to estimate the proportion 
of inflammatory cells in WT and 11β-HSD1-deficient mice 7d after bleomycin 
installation. (A) Representative dot plots of unstained WT control, to show the gating 
on CD45 and FSC; (B) WT lung stained with CD45. (C) unstained WT control, to 
show the gating on CD3 and B220; (D) WT lung stained with CD3 and B220; (E) 
unstained WT control, to show the gating on CD8; (F) WT lung stained with CD8; 
Quantification from flow cytometry revealed that wild type (WT; black bars) and 
11β-HSD1-deficient (KO; white bars) mice had similar proportions of CD45 positive 
cells in digested lung cells (G). 11β-HSD1-deficient mice had significantly more 
B220 positive cells (H) but similar levels of CD3 (I) and CD8 (J) positive cells in 
lungs from WT and 11β-HSD1-deficient mice 7d after bleomycin instillation. Data 















































































































5.3.9 Lung RNA profiles in WT and 11β-HSD1-deficient mice following 
bleomycin treatment 
To investigate changes in gene expression in lung after bleomycin treatment, and to 
gain insights into the mechanisms underlying the more severe inflammation in 
11β-HSD1-deficient mice, real-time PCR was used to measure levels of mRNA 
encoding proteins important in the inflammatory response, tissue repair and GC 
action (as described in Chapter 2.2.10).  
 
5.3.9.1 Increased levels of mRNA encoding Heme oxygenase (HO)-1 and 
inducible nitric oxide synthase (iNOS) in 11β-HSD1-deficient mice 14d 
after bleomycin installation  
HO is the rate-limiting enzyme that catalyses the initial step of heme degradation, 
producing biliverdin and releasing free ion and carbon monoxide, which may induce 
lung damage (Atzori, Chua et al. 2004). HO-1 is up-regulated during oxidative stress 
and is proposed to have a role in the regulation of inflammatory process by acting as 
a cytoprotective molecule (reviewed in (Morse and Choi 2002). Analysis of lung 
RNA by real-time PCR showed that bleomycin treatment increased HO-1 mRNA 
levels in lungs of both genotypes of mice with a peak at 14d and a return to basal 
levels by 28d (Figure 5.17A). At 14d, lung from 11β-HSD1-deficient mice showed 





Nitric Oxide (NO) is an endogenous short-lived free radical that freely diffuses 
within the cells (Kalayarasan, Sriram et al. 2008). It has a biological role in 
modulating physiological and pathological processes. However, during infection and 
inflammation, in vivo formation of NO is increased and can cause damage if 
unchecked. Activated macrophages highly express inducible NO synthase (iNOS) 
(Gurujeyalakshmi, Wang et al. 2000). Bleomycin treatment caused a significant 
increase in iNOS mRNA levels in lungs of mice treated with bleomycin (Figure 
5.17B). The pattern of iNOS expression was quite similar to HO-1 gene expression 
with an increase 2d after bleomycin treatment in both genotypes, peaking at 14d and 
basal at 28d (Figure 5.17B). At 14d after bleomycin installation, 11β-HSD1-deficient 
lung showed significantly higher levels of iNOS mRNA relative to WT mice (Figure 
5.17B). 
 
IL-6 KO mice show attenuated inflammation and fibrosis compared to WT mice in 
the bleomycin model (Saito, Tasaka et al. 2008). Release of IL-6 was higher in 
LPS-stimulated macrophages from 11β-HSD1-deficient mice compared with WT 
mice (Gilmour, Coutinho et al. 2006; Zhang and Daynes 2007). However, in the 
bleomycin inflammation model, IL-6 mRNA levels did not differ between genotypes 
at any time point (Figure 5.17C). In both genotypes, levels of IL-6 mRNA were 
dramatically increased 2d after bleomycin, and then diminished at 7d and 14d, 
returning to basal levels on d28 (Figure 5.17C). 
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Tumor necrosis factor TNF-α is essential for pathogenesis in the bleomycin model of 
fibrosis (Piguet, Collart et al. 1989), being up-regulated after bleomycin treatment 
(Zhang, Gharaee-Kermani et al. 1997). To investigate whether TNF-α  was expressed 
differently between WT and 11β-HSD1-deficient mice after bleomycin instillation, 
levels of mRNA were measured. The increase in TNF-α  mRNA in both genotypes 
was evident from d2 (Figure 5.17D), remaining elevated at d7 and d14, but with 
similar levels of TNF-α expression in WT and 11β-HSD1-deficient mice. By d28, 
the level of TNF-α expression had decreased to basal levels (Figure 5.17D). There 














































































































Figure 5.17 Bleomycin treatment induced higher HO-1 and iNOS gene 
expression in 11β-HSD1-deficient mice at 14d compared to WT mice. 
Total RNA extracted from lungs of either WT or 11β-HSD1-deficient mice at 
different time points following bleomycin installation was analysed for HO-1 (A), 
iNOS (B), IL-6 (C) and TNF-α (D) mRNA by real-time PCR. Levels are expressed 
relative to the level of TBP mRNA and are in arbitrary units (AU). Two-way ANOVA 
showed significant effects of time (p<0.001) and interaction (p=0.001) upon HO-1 
mRNA expression and a trend for genotype difference (p=0.08) upon HO-1 
expression between wild type (WT; black bars) and 11β-HSD1-deficient (KO; white 
bars) mice (Post-hoc Bonferroni test showed the difference between WT and KO 
lung was statistically significant at d14 (***, p<0.001). Two-way ANOVA showed a 
significant effect of time (p<0.001) upon all mRNAs measured. There was also a 
significant interaction (p=0.05) (but no genotype effect, p=0.18) upon iNOS 
expression. There was no effect of genotype or interaction with time upon IL-6 or 
TNF-α expression between WT and 11β-HSD1-deficient mice. Data are mean ± 





5.3.9.2 11β-HSD1-deficient mice have lower levels of MR and GR mRNA in 
lung, compared to WT mice 
To test whether key parameters of glucocorticoid action differed between WT and 
11β-HSD1-deficient mice, real-time PCR was used to quantify levels of GR and MR 
mRNA. Two-way ANOVA showed a significant difference in GR (Figure 5.18A) but 
not MR (Figure 5.18B) mRNA levels between genotypes. Following bleomycin, both 
genotypes showed a significant decrease in GR and MR mRNA levels which were 
lowest at 7-14d (Figure 5.18). Levels of GR mRNA were lower in 
11β-HSD1-deficient mice at all time points examined, including in naïve mice, and 
were markedly reduced at d7 (Figure 5.18A)  
 
Similarly, in naïve mice and following bleomycin treatment, levels of MR mRNA 
were consistently slightly lower in 11β-HSD1-deficient mice than WT mice, 






























































Figure 5.18 11β-HSD1-deficient mice have lower GR and MR mRNA levels in 
lung compared to WT mice, and levels of GR and MR mRNA are reduced 
following bleomycin installation. 
Total RNA extracted from lungs of either WT or 11β-HSD1-deficient mice at 
different time points following bleomycin installation was analysed for GR (A) and 
MR (B) mRNA by real-time PCR. Levels are expressed relative to the level of TBP 
mRNA and are in arbitrary units (AU). Two-way ANOVA showed an effect of time 
(p<0.0001) and genotype (p=0.0009) (but no interaction) upon GR expression in 
wild type (WT; black bars) and 11β-HSD1-deficient (KO; white bars) mice. 
(Post-hoc Bonferroni test showed the difference between WT and KO lung at d7 was 
statistically significant (*, p<0.05)). Two-way ANOVA showed an effect of time 
(p<0.0001) and interaction (p<0.05) (but no genotype, p=0.13) upon MR expression 







5.3.9.3 TGF-β1 and α-SMA mRNA levels increased following bleomycin, but 
did not differ between the genotypes. 
Fibrosis is caused by highly proliferating fibroblasts and myofibroblasts which lay 
down collagen to repair damaged tissue. To investigate whether the histological 
difference in fibrosis observed between WT and 11β-HSD1-deficient mice are 
underpinned by differences in gene expression, a few fibrosis related genes were 
tested.  
  
Bleomycin treatment increases the transcription of TGF-β mRNA, total cellular 
TGF-β mRNA, and total cellular type I procollagen mRNAs in rat lung fibroblasts 
(Cutroneo, Breen et al. 1991) and TGF-β dose-dependently increased collagen 
synthesis in rat lung fibroblast (Cutroneo, Breen et al. 1991). Bleomycin treatment of 
rat lung fibroblast cultures increased levels of cellular TGF-β mRNA and increased 
secretion of TGF-β protein in the medium (Breen, Shull et al. 1992). Because 
TGF-β is one of the most important factors in inducing fibrosis in lung (Shukla, 
Meisler et al. 1999), levels of its mRNA were measured. In both genotypes, TGF-β 
mRNA levels increased following bleomycin installation, peaking at 7-14d, returning 
to basal levels at 28d (Figure 5.19A). However, there was no difference in TGF-β 
mRNA levels between genotypes at any time point (Figure 5.19A).  
 
α-SMA is a marker of myofibroblast cells, and it has been found to be highly 
expressed after bleomycin treatment (Zhang, Rekhter et al. 1994). In both genotypes, 
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α-SMA mRNA levels were increased in lung following bleomycin and were highest 
around 7-14d, decreasing to normal levels at 28d (Figure 5.19B). Although there was 
a trend for α-SMA to be higher in 11β-HSD1-deficient mice at 14d, it did not reach 
statistical significance (Figure 5.19B).  
 
Collagen levels are increased following bleomycin treatment (Meisler, Chiu et al. 
1999). Animal model studies show the myofibroblast to be the primary source of 
type I collagen gene expression in active fibrotic sites (Phan 2002). Because fibrosis 
appeared worse in 11β-HSD1-deficient mice, collagen type1 α2 mRNA levels were 
measured to see whether it was expressed differently between WT and 
11β-HSD1-deficient mice after bleomycin instillation. The increase in collagen type1 
α2 in both genotypes was evident from d2 (Figure 5.19C). Similar to α-SMA, 14d 
after bleomycin installation 11β-HSD1-deficient mice tended to have a higher level 
of collagen type1 α2 mRNA compared with WT mice (Figure 5.19C) but this effect 
did not reach significance.  
 
Arginase, which hydrolyzes arginine to urea and ornithine, is a precursor for the 
synthesis of polyamines and proline, the latter being abundant in collagen (Endo, 
Oyadomari et al. 2003). Levels of mRNA encoding Arginase I (Arg I) were measured 
in bleomycin-induced fibrosis. Arg1 was highly expressed 2d after bleomycin 
instillation, increased to 14d in both genotypes, then decreased to basal levels at 28d 
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(Figure 5.19D). However, at any time point, there was no difference in Arg I mRNA 
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Figure 5.19 Bleomycin treatment induced α-SMA, TGF-β, collagen typeI α2 and 
Arg I gene expression to a similar extent in both WT and 11β-HSD1-deficient 
mice 
Total RNA extracted from lungs of either WT or 11β-HSD1-deficient mice at 
different time points following bleomycin installation was analysed for TGF-β1 (A), 
α-SMA (B), collagen type1 α2 (C) and Arg I (D) mRNA by real-time PCR. Levels 
are expressed relative to the level of TBP mRNA and are in arbitrary units (AU). 
Two-way ANOVA showed an effect of time (p<0.0001) but no effect of genotype or 
interaction upon TGF-β1, α-SMA, collagen type1 α2 or Arg 1 expression between 
wild type (WT; black bars) and 11β-HSD1-deficient (KO; white bars) mice. Data are 









5.3.9.4 HIF-1α mRNA levels were upregulated after bleomycin  
Lung inflammation is likely to impair function and lead to localized hypoxia. 
Bleomycin treatment increases hypoxia-inducible factor-1 α (HIF-1α) expression in 
lungs (Lu, Azad et al. 2009). Consistent with this, HIF-1α mRNA levels were 
increased 2-fold 2d after bleomycin, remaining elevated at 7d and 14d and returing to 
basal by 28d (Figure 5.20). However, there was no difference in HIF-1α mRNA 















































Figure 5.20 Bleomycin treatment induced similar levels of HIF-1α gene 
expression in both genotypes 
Total RNA extracted from lungs of either WT or 11β-HSD1-deficient mice at 
different time points following bleomycin installation was analysed for HIF-α by 
real-time PCR. Levels are expressed relative to the level of TBP mRNA and are in 
arbitrary units (AU). Two-way ANOVA showed an effect of time (p<0.0001) but no 
effect of genotype or interaction upon HIF-1α expression between wild type (WT; 
black bars) and 11β-HSD1-deficient (KO; white bars) mice. Data are mean ± SEM 






5.3.9.5 No difference between WT and 11β-HSD1-deficient mice in levels of 
C/EBP-β and C/EBP-δ following bleomycin 
C/EBP-β plays a significant role in the development of pulmonary fibrosis (Hu, 
Ullenbruch et al. 2007); C/EBP-β–/– mice are resistant to bleomycin-induced fibrosis 
(Hu, Ullenbruch et al. 2007). C/EBP-β is a key regulator of myofibroblast 
differentiation in isolated lung fibroblasts, and stimulates the expression of α-SMA 
during myofibroblast differentiation by binding to a C/EBP-β binding element 
identified in the α-SMA promoter (Hu, Wu et al. 2004). Moreover, 
C/EBP-β regulates 11β-HSD1 expression (Williams, Lyons et al. 2000; Gout, Tirard 
et al. 2006; Arai, Masuzaki et al. 2007; Payne, Au et al. 2007; Sai, Esteves et al. 
2008). Whilst measurement of C/EBP-β mRNA by real-time PCR showed a 
significant increase in lungs of mice 2d following treatment with bleomycin, with 
levels remaining elevated at 14d, levels did not differ between WT and 
11β-HSD1-deficient mice at any time point (Figure 5.21A). 
 
C/EBP-δ is also a member of the C/EBP transcription factor family which is highly 
expressed in lung (Williams, Cantwell et al. 1991) and which has been found to 
repress 11β-HSD1 expression in transfected HepG2 hepatoma cells (Esteves et al, 
manuscript submitted). At d0, WT and 11β-HSD1-deficient mice showed similar 
levels of C/EBP-δ mRNA (Figure 5.21B). By 2d after bleomycin instillation, 
C/EBP-δ mRNA levels were increased in lungs of both genotypes with expression 



























































Figure 5.21 Bleomycin treatment induced similar level C/EBP-β and C/EBP-δ 
gene expression in both genotypes 
Total RNA extracted from lungs of either WT or 11β-HSD1-deficient mice at 
different time points following bleomycin installation was analysed for C/EBP-β (A) 
and C/EBP-δ (B) mRNA by real-time PCR. Levels are expressed relative to the level 
of TBP mRNA and are in arbitrary units (AU). Two-way ANOVA showed an effect 
of time (p<0.0001) but no effect of genotype or interaction upon C/EBP-β or 
C/EBP-δ expression between wild type (WT; black bars) and 11β-HSD1-deficient 






5.3.10 Regulation of pulmonary 11β-HSD1 expression during bleomycin 
induced lung inflammation 
11β-HSD1 is increased in some tissues during inflammation, but not all (Chapman, 
Coutinho et al. 2009) (and detailed in Chapter 1.6.3). To see whether 11β-HSD1 
expression was affected by bleomycin-induced lung inflammation and fibrosis and 
whether the promoter of 11β-HSD1 was changed during the progress of fibrosis (as 
fibroblasts mainly use the P1 promoter), 11β-HSD1 mRNA levels were measured by 
real-time PCR in C57BL/6J (WT) mice, following bleomycin treatment. 
 
5.3.10.1 Promoter usage of 11β-HSD1 after bleomycin treatment  
Total 11β-HSD1 mRNA levels in lung were not significantly changed by bleomycin 
treatment (Figure 5.22A) (P=0.15; ANOVA). However, levels of 11β-HSD1 
transcripts initiated at the P1 promoter were significantly changed following 
bleomycin (P<0.01; ANOVA), although they showed a very similar pattern to total 
11β-HSD1 mRNA. Thus, levels of P1-initiated mRNA increased between d2 and d14, 
falling back to basal levels by 28d (Figure 5.22B). P2 promoter-initiated transcripts 









A, Total 11β-HSD1 mRNA 
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Figure 5.22 Transcripts initiated at P1 promoter and P2 promoter of Hsd11b1 
are differentially regulated following bleomycin treatment of mice 
Total RNA was extracted from lungs of WT mice, killed at different time points after 
bleomycin treatment. Levels of total 11β-HSD1 mRNA (A) and 11β-HSD1 mRNA 
initiated at the P1 (B) or P2 promoter (C) were measured by real-time PCR. Levels 
are expressed relative to the level of TBP mRNA and are in arbitrary units (AU). 
Data are mean ± SEM with n = 5-8. Data were analysed by ANOVA followed by 




5.3.10.2 IHC staining suggests 11β-HSD1 is upregulated in WT lung 7d and 14d 
after bleomycin installation 
Paraffin-embedded lung sections from WT mouse lung collected 7d or 14d after 
bleomycin installation were stained with sheep anti-11β-HSD1 antibody at 1:1000 
dilution. Compared to untreated mice, 11β-HSD1 immunoreactivity was increased in 
the alveolar walls with strong staining of interstitial fibroblasts 7d and 14d following 
intratracheal instillation of bleomycin (Figure 5.23B and C). At 7d, strong staining 
was also seen in mononuclear cells, a population which was reduced at 14d 




















Figure 5.23 11β-HSD1 immunoreactivity is increased in mouse lungs following 
bleomycin installation. 
Immunohistochemistry was carried out on C57BL/6J (WT) mouse lung with purified 
sheep anti-11β-HSD1 antibody at 1:1000 dilution and biotinylated rabbit-anti-sheep 
2nd Ab at 1:400 dilution. (A), untreated lung; (B), 7d after bleomycin treatment; (C), 
14d after bleomycin treatment; (D), negative control (WT lung with 2nd Ab alone). 
All images captured at magnification, X400. Arrows indicate alveolar macrophages 







5.3.10.3 In situ hybridization showed no effect of bleomycin treatement on 
11β-HSD1 mRNA levels in WT lung 
Because IHC suggested that 11β-HSD1 was upregulated after bleomycin treatment, 
in situ mRNA hybridization was carried out on sections of WT mouse lung harvested 
7d or 14d after bleomycin installation, using an “antisense” [35S]-cRNA probe 
complementary to mouse 11β-HSD1 mRNA, as described in Chapter 2.2.11. Mouse 
kidney highly expresses 11β-HSD1 (Rajan, Chapman et al. 1995) and was used as a 
positive control (Figure 5.24E). A “sense” strand cRNA probe (the same as the 
mRNA) was used as a negative control.  
 
Autoradiography showed hybridization of antisense, but not sense, probe in lung 
(Figure 5.24A). This suggests specific hybridization. The hybridization signal was 
quantified as described in Chapter 2.2.11. Figure 5.24F shows that 11β-HSD1 mRNA 
levels were not changed 7d or 14d after bleomycin treatment, compared with 













Figure 5.24 Semi-quantitative analysis of 11β-HSD1 mRNA shows no change 
following bleomycin treatment. 
Representative autoradiographs showing in situ hybridization of an anti-sense 
[35S]-labelled 11β-HSD1 cRNA probe to paraffin-embedded WT lung from (A), 
untreated mice or mice killed (B), 7d or (C), 14d after bleomycin treatment; (D), 
representative autoradiograph of paraffin embedded untreated WT lung hybridized to 
a sense [35S]-labelled 11β-HSD1 cRNA probe (negative control); (E), representative 
autoradiograph of paraffin embedded untreated WT kidney hybridized to an 
anti-sense [35S]-labelled 11β-HSD1 cRNA probe (positive control); (F), 
Semiquantitative analysis of 11β-HSD1 mRNA levels by optical densitometry 
measurements in whole lung. One-way ANOVA revealed no difference between the 3 
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5.3.10.4 11β-HSD1 activity assay showed no increase in 11β-HSD1 activity 
following bleomycin installation 
Immunohistochemistry suggested protein levels of 11β-HSD1 may be upregulated, 
despite no significant increase in total 11β-HSD1 mRNA levels. However, given the 
problems with the 11β-HSD1 antibody described in Chapter 3.2.1.2, 11β-HSD1 
activity assays were carried out to confirm the increase in 11β-HSD1 after bleomycin 
installation.  
 
Lungs from control mice, or mice culled 7d or 14d after bleomycin treatment were 
homogenized and assayed for 11β-hydroxysteroid dehydrogenase activity as 
described in Chapter 2.2.23.2. A selective inhibitor of 11β-HSD1 which does not 
inhibit 11β-HSD2 (gift from Dr Scott Webster) was used to demonstrate that activity 
detected in lung homogenate was due to 11β-HSD1. 11β-HSD activity in lung 
homogenates was similar between untreated mice and following 7d bleomycin 
treatment and was ~0.8pmol dehydrocorticosterone/mg protein /min (Figure 5.25).  
 
Although there was a trend to decreased 11β-HSD activity at 14d, compared to 
control untreated mice, this did not achieve significance (Figure 5.26). Addition of 
50μM selective 11β-HSD1 inhibitor (CC002054) almost abolished 11β-HSD 
dehydrogenase activity (Figure 5.26) confirming that activity was due to 11β-HSD1 






































Figure 5.25 11β-HSD1 dehydrogenase activity did not differ in lung 
homogenates from control untreated mice or mice killed 7d after bleomycin 
treatment  
11β-HSD activity was measured by conversion of [3H]-B to [3H]-A in a 10min assay 
with 0.5mg/ml lung homogenate. Steroids were extracted by ethyl acetate and 
quantified by HPLC as described in Chapter 2.2.24. 11β-HSD activity is expressed as 
pmol of corticosterone (B) converted into 11-dehydrocorticosterone (A)/min/mg 













Figure 5.26 11β-HSD activity in mouse lung is largely attributable to 11β-HSD1 
and did not differ between control untreated mice and mice killed 14d after 
bleomycin installation in lung 
11β-HSD activity was measured by conversion of [3H]-B to [3H]-A in a 10min assay 
with 0.5mg/ml lung homogenate. 50μM 11β-HSD1 inhibitor (CC002054) or DMSO 
(vehicle) was added to the homogenate before the reaction. Steroids were extracted 
with ethyl acetate and quantified by HPLC as described in Chapter 2.2.24. 11β-HSD 
activity is expressed as pmol of corticosterone (B) converted into 
11-dehydrocorticosterone (A)/min/mg protein. Values are mean ± SEM of 6-8 lungs.  
A Student’s t-test showed no activity difference between control untreated mice and 









































5.3.10.5 Immunoblotting shows decreased 11β-HSD1 protein in mouse lung 
following bleomycin treatment 
To further test whether 11β-HSD1 protein levels were unchanged after bleomycin 
treatment, western blot of whole lung homogenate was performed, as described in 
Chapter 2.2.24. Immunoblotting with 11β-HSD1 antibody detected a protein of the 
predicted ~34kDa (Figure 5.27). Quantification of immunoblots showed a reduction 
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Figure 5.27 Western blotting shows decreased 11β-HSD1 levels following 
bleomycin installation in lung 
Western blot analysis was used to detect 11β-HSD1 protein expression in WT lung 
tissue following bleomycin treatment, using sheep-anti-mouse 11β-HSD1 antibody 
(primary antibody used at 1:1000 dilution, Alexa 680 conjugated anti-sheep antibody 
used at 1:10000 dilution). 15μg of protein was loaded per well. (A) representative 
image of western blot of protein extracts from lung of mice killed 0d, 7d or 14d after 
bleomycin. (B) Quantitation of western blots showed decreased 11β-HSD1 levels in 














5.4 Discussion  
The comparative assessment of bleomycin-induced lung inflammation and fibrosis 
described in this Chapter is consistent with a role for 11β-HSD1 in controlling 
inflammation. These results suggest that, compared to WT mice, lungs of 
11β-HSD1-deficient mice show an exaggerated inflammatory response and fibrosis 
following bleomycin instillation. Higher levels of iNOS and HO-1 mRNA in 
11β-HSD1-deficient mice parallel with greater macrophage infiltration, especially at 
14d after bleomycin treatment, which is consistent with the histological 
inflammatory score finding. The recruitment of more inflammatory cells in 
11β-HSD1-deficient mice is indicative of a greater inflammatory response. The 
collagen assay suggested a bigger gain in collagen in 11β-HSD1-deficient mice than 
in WT mice during the 28d following bleomycin treatment (although absulote levels 
in 11β-HSD1-deficient mice were similar to WT at 28d), which is consistent with the 
Picrosirius staining of lung sections. 
 
Blood inflammatory cell analysis indicated fewer circulating monocytes in 
11β-HSD1-deficient mice compared to WT mice, 7d and 14d after bleomycin 
treatment. At the same time, histological analysis showed 11β-HSD1-deficient mice 
had more inflammatory cells in lung. This suggests that after bleomycin treatment, 
more circulating monocytes infiltrated into the lung in 11β-HSD1-deficient mice 
than in WT mice. After bleomycin treatment, lung starts to express chemokines, such 
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as CXCL12 and CCL18 to recruit inflammatory cells (Phillips, Burdick et al. 2004; 
Pochetuhen, Luzina et al. 2007). Overexpression of those chemokines worsens the 
severity of lung inflammation (Pochetuhen, Luzina et al. 2007). There may be a 
difference between WT and 11β-HSD1-deficient mice in chemokine expression. In a 
model of myocardial infarction (MI), more macrophages infiltrated into the infarct 
zone in 11β-HSD1-deficient mice than in WT mice, 7d post MI (McSweeney, 
Hadoke et al. 2010). At the same time, monocyte chemoattractant protein-1 (MCP-1) 
mRNA was higher in 11β-HSD1-deficient mice than in WT mice (McSweeney, 
Hadoke et al. 2010). Similarly, inhibition of 11β-HSD1 in a mouse model of 
atherosclerosis (Apoe-/- mice) reduced atherosclerosis and also decreased plasma 
MCP-1 levels (Hermanowski-Vosatka, Balkovec et al. 2005). Thus, the increased 
inflammation in 11β-HSD1-deficient mice may be due to increased chemokine 
secretion, including MCP-1. It will be important, in the future, to measure MCP-1 
and other chemokines following bleomycin treatment.  
 
Inflammatory gene expression levels are consistent with the histological results. 
HO-1 has a role in the regulation of inflammatory processes (reviewed in (Morse and 
Choi 2002). Binding sites for NF-κB and AP-1 have been found in the promoter 
region of HO-1 (Lavrovsky, Schwartzman et al. 1994), and AP-1 regulates HO-1 
gene expression (Hartsfield, Alam et al. 1999). HO-1 has previously been shown to 
be strongly induced 14d after the instillation of bleomycin (Kaminski, Allard et al. 
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2000), which is consistent with my result. There may be a threshold effect for 
cytoprotection by HO-1. Suttner and coworkers observed that although moderate 
overexpression of HO-1 in lung fibroblasts conferred protection against oxidative 
injury, higher levels of HO-1 may be detrimental (Suttner, Sridhar et al. 1999). In 
different models of lung disease, the expression of HO-1 in lung has been localized 
to alveolar macrophages, bronchoalveolar epithelium, and interstitial and 
inflammatory cells (Lee, Alam et al. 1996; Nagatomo, Morimoto et al. 2007). Also 
HO-1 has been observed in various cultured cells including epithelial cells, 
fibroblasts, macrophages, and smooth muscle cells (Lee, Alam et al. 1996).  
 
After bleomycin treatment, both 11β-HSD1-deficient mice and WT mice showed 
increased numbers of alveolar macrophages in BALF compared to untreated mice, 
but there was no difference between genotypes. The histological result suggests there 
were more macrophages in 11β-HSD1-deficient mice than in WT mice in lung 
suggesting more interstitial macrophages, and this needs to be confirmed. The greater 
expression of HO-1 mRNA in 11β-HSD1-deficient mice could be due to the 
interstitial macrophages and alveolar macrophages in fibrosis lesions. This needs 
IHC to stain HO-1 in mice lung and find out where is the difference in HO-1 
expression between WT and 11β-HSD1-deficient mice 14d after bleomycin 
treatment. Atzori and colleagues used an HO-1 inhibitor to examine its effects on the 
development of pulmonary fibrosis in the bleomycin model and they found mice 
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treated with HO-1 inhibitor showed significantly less fibrosis (Atzori, Chua et al. 
2004). TGF-β1 is a ligand for the integrin αυβ6 (Munger, Huang et al. 1999). 
Integrin β6-/- mice develop inflammation but not fibrosis after bleomycin treatment, 
microarray data showed that HO-1 gene was dramatically induced by bleomycin in 
WT mice but was induced to a lesser degree in β6-/- mice (Kaminski, Allard et al. 
2000). The greater expression of HO-1 at 14d in 11β-HSD1-deficient mice may 
account, in fact, for the more severe fibrosis observed at 28d.  
   
Blocking induction of iNOS by taurine and niacin in the bleomycin model caused a 
significant reduction in lung hydroxyproline content compared with control mice 
(Gurujeyalakshmi, Wang et al. 2000). Diallylsulfide, an antioxidant and 
anti-inflammatory agent inhibited the increase in iNOS expression and reduced 
collagen deposition after bleomycin treatment in rats (Kalayarasan, Sriram et al. 
2008). In my experiment, 11β-HSD1-deficient mice showed higher levels of iNOS 
expression at 14d which is consistent with the greater fibrosis development in the 
11β-HSD1-deficient mouse lung. Expression of iNOS is mainly in activated 
macrophages (Nussler, Billiar et al. 1994), suggesting that there may be more M1 
(classically activated) macrophages in 11β-HSD1-deficient mice than in WT mice 
14d following bleomycin. Moreover, this is consistent with the histology and 
inflammation score, which showed more inflammatory cell infiltration in 
11β-HSD1-deficient mice than in WT mice, although this needs IHC to identify 
 
 226
M1-polarized macrophages to confirm this finding, such as colocalization of iNOS 
and F4/80. 
 
The activity of GCs is mediated via GR expression, which is significantly decreased 
in various inflammatory processes (Kamiyama, Matsuda et al. 2008). In most tissues, 
GC down-regulate GR (Kalinyak, Dorin et al. 1987). After bleomycin, GR 
expression was decreased in both genotypes, possibly as a mechanism to protect 
tissue from over exposure to GC. Interestingly, at all time points, including in naïve 
mice, 11β-HSD1-deficient mice showed lower GR expression than WT.  
 
Less GR expression in 11β-HSD1-deficient mice could be related to differences in 
early lung development. GR is essential for lung development (Cole, Blendy et al. 
1995; Nemati, Atmodjo et al. 2008). GR knockout mice die within a few hours after 
birth because of respiratory failure and lung structural immaturity (Cole, Blendy et al. 
1995; Nemati, Atmodjo et al. 2008). The differentiation of type I epithelial cells is 
decreased by about 50% and the mRNA levels of SP-A and SP-C are also reduced by 
approximately 50% in GR knockout mice at day 18.5 of pregnancy (Cole, Solomon 
et al. 2004). Although no gross differences was seen in histology in naïve mice (data 
not shown), there may be subtle differences in cell types present in 
11β-HSD1-deficient mice lung, reflected in decreased collagen content and GR 
mRNA expression. Alternatively, decrease in GR may be a compensatory mechanism 
 
 227
for altered intracellular GC levels in 11β-HSD1-deficient mice, although this has not 
been reported in other tissues except for the hypothalamus (Carter, Paterson et al. 
2009). Hundertmark and colleagues found 11β-HSD1-deficient mice exhibited 
delayed fetal lung development, with lower surfactant protein-A levels and 
significant depletion of lung surfactant (Hundertmark, Dill et al. 2002). Chemical 
inhibition of fetal 11β-HSD1 activity also reduced the gestation-dependent 
accumulation of SP-A and decreased lamellar body content in alveolar type II cells in 
lung (Hundertmark, Dill et al. 2002). My results showed lung collagen content was 
significantly lower in untreated 11β-HSD1-deficient mice, compared with WT mice. 
Which of the collagens accounted for this difference was not determined, but it is 
unlikely to be collagen type1 α2 expression, which was similar between naïve mice 
by real-time PCR measurement. In human fetal lung, GCs increase lung cell 
proliferation, differentiation of type 2 alveolar epithelial cells and thinning of 
alveolar walls (reviewed in (Garbrecht, Klein et al. 2006)). Thus there may be 
differences in the types of lung cells present between fetal 11β-HSD1-deficient mice 
and WT mice, reflected in decreased collagen content and GR mRNA expression. 
This needs further investigation in the future. Also, finding out which collagen is 
different between 11β-HSD1-deficient mice and WT mice may provide a clue to the 
mechanism.  
 
No significant difference in plasma corticosterone levels was detected between WT 
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and 11β-HSD1-deficient mice. Although there was variability between mice in each 
group and naïve mice showed stress level of corticosterone, the corticosterone levels 
were similar between WT and 11β-HSD1-deficient mice, so we cannot conclude 
whether bleomycin differentially activates the HPA axis in 11β-HSD1-deficient mice.  
However, there was a significant interaction of genotype and time, and it appears 
likely that after bleomycin, corticosterone levels return to basal more rapidly in WT 
mice than in 11β-HSD1-deficient mice. This would be consistent with worse (or 
prolonged) inflammation in 11β-HSD1-deficient mice and is similar to findings in an 
model of experimental arthritis (Coutinho 2009), where corticosterone remained 
elevated in 11β-HSD1-deficient mice 21d after treatment and at the same time, WT 
shows reduced corticosterone level. On the same genetic background as used here 
(C57BL/6J), 11β-HSD1-deficient mice showed similar circadian rhythms of plasma 
corticosterone to WT, and although they showed a greater plasma corticosterone 
response to stress, both genotypes returned to the same basal level at the same time 
(Carter, Paterson et al. 2009). 11β-HSD1-deficient mice show adrenal hypertrophy to 
compensate for lack of hepatic 11β-HSD1-medicated GC regeneration (Kotelevtsev, 
Holmes et al. 1997). However, although naïve 11β-HSD1-deficient mice showed 
heavier adrenal glands than WT mice before and until 14d after bleomycin treatment, 
they did not differ at 28d. The reason for this is not clear, but might be due to a 




The collagen difference in naïve mice could be due to the lower GR expression and 
presumed lower intracellular GC levels in 11β-HSD1-deficient mice. It is well 
established that GCs exert an anti-anabolic effect on collagen metabolism. 
Dexamethasone treatment of primary fetal chick lung and chick skin fibroblasts 
resulted in a marked decrease in the steady state levels of procollagen mRNAs 
(Sterling, Harris et al. 1983). Dexamethasone treatment of chick skin fibroblasts can 
decrease TGF-β levels, leading to less TGF-β-activated collagen synthesis (Cutroneo 
2002). Therefore, the developmental difference in collagen between WT and 
11β-HSD1-deficient mice may be due to a combination of reduced GR levels and 
reduced intracellular GC in 11β-HSD1-deficient mice leading to less collagen 
synthesis. It would be interesting to measure GR expression in fetal lung of WT and 
11β-HSD1-deficient mice to check whether 11β-HSD1-deficient mice express less 
GR during development, before the massive increase in 11β-HSD1 expression in 
lung, just prior to birth (Speirs, Seckl et al. 2004). 
 
In 11β-HSD1-deficient mice, biochemical and morphological characteristics of 
pulmonary fibrosis were observed 14d after bleomycin administration. Picrosirius 
red staining indicated more collagen deposition in 11β-HSD1-deficient mice. 
However, the quantification of Picrosirius red staining was not possible due to 
inter-animal variability in the disease process. The distribution of fibrosis in the lung 
was patchy, probably due to unequal distribution of bleomycin with the instillation 
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method. Some parts of lung showing normal structure could be found at all time 
points, with other some parts of lung showing dense fibrosis. In future, careful 
matching of specimens may allow a better quantification. Sircol assay confirmed an 
increase in total collagen content in both genotypes after bleomycin treatment. The 
difference in lung collagen content between naïve 11β-HSD1-deficient mice and WT 
mice disappeared after 28d bleomycin treatment suggesting that 11β-HSD1-deficient 
mice produce more collagen than WT mice.  
 
Increased fibrosis-related gene expression levels (TGF-β and collagen) are consistent 
with the histological findings in both genotypes. However, the gene expression 
analysis did not show a difference in fibrosis between genotypes. Previous work has 
shown that after bleomycin treatment, all of the extracellular matrix components 
including collagen type1 α2 were induced progressively throughout the 14d period 
(Kaminski, Allard et al. 2000). My results show that mRNA encoding collagen type1 
α2 increased markedly around 14d after bleomycin instillation, but did not differ 
between genotypes, so the difference between genotypes could be due to other 
collagen proteins, such as collagen type3 or collagen type1 α1 (Shahzeidi, Mulier et 
al. 1993; Liu, Dhanasekaran et al. 2004). Also collagen degradation may differ. The 
turnover of extracellular matrix is partially regulated by proteases such as 
metalloproteinases (MMPs) and their inhibitors (TIMPs) (Manoury, Nenan et al. 
2007). Activity of MMP-2 and MMP-9 peak at 7d after bleomycin installation, but 
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TIMP-1 and TIMP-2 levels peak at 14d after bleomycin (Oggionni, Morbini et al. 
2006), so an altered balance of MMP and TIMP may alter susceptibility to 
bleomycin-induced pulmonary fibrosis. 
 
Arginase I plays an important role in supplying proline, a key precursor in collagen 
synthesis and in the process of lung fibrosis (Endo, Oyadomari et al. 2003). In the 
current studies, arginase I mRNA levels increased 2d after bleomycin, peaked around 
7-14d, then returned to basal levels, similar to a previous report (Endo, Oyadomari et 
al. 2003). Endo and colleagues showed arginase I mRNA was undetectable at d0, was 
induced 5d after bleomycin treatment reaching a maximum at 7d, then decreased to 
undetectable levels by 14d (Endo, Oyadomari et al. 2003). They also found arginase I 
expression was mainly within a subpopulation of macrophages, by 
immunohistochemical analysis. Activated macrophages can be broadly divided into 2 
subpopulations, M1 (classically activated) macrophages and M2 (alternatively 
activated) macrophages (Gordon 2003). Unlike classically activated M1 
macrophages that secrete pro-inflammatory mediators and display phagocytic 
behaviour, alternatively activated macrophages secrete anti-inflammatory cytokines 
such as TGF-β and can be identified by their expression of arginase I and by 
secretion of the chitinase-like molecule YM1 (Raes, Van den Bergh et al. 2005). In 
the experiments reported here, arginase I mRNA levels were not different between 
genotypes; however, there may be a difference in protein levels. Following 
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myocardial infarction,  11β-HSD1-deficient mice showed more accumulation of 
alternatively activated macrophages, identified by YM1, than WT mice (McSweeney, 
Hadoke et al. 2010). 
 
C/EBP-β has a potential role in vivo in the pathogenesis of pulmonary fibrosis. Mice 
that lack C/EBP-β are resistant to bleomycin induced lung fibrosis (Hu, Ullenbruch 
et al. 2007) and there is a two-fold increase in C/EBP-β expression in lung of WT 
mice 7d after bleomycin treatment (Hu, Ullenbruch et al. 2007). My result shows a 
similar increase in C/EBP-β mRNA levels after bleomycin treatment, but levels did 
not differ between genotypes. However, there may be a difference at the protein level. 
There are two forms of C/EBP-β, liver activating protein (LAP) and liver inhibitory 
protein (LIP) which may be products of alternative translation (Descombes and 
Schibler 1991). The LAP protein is a transcriptional activator while LIP acts as a 
dominant negative inhibitor of LAP even when present at substoichiometric levels 
(i.e., LAP:LIP ratio of 5:1) (Descombes and Schibler 1991). Levels of LAP/LIP can 
regulate 11β-HSD1 expression in adipocytes and LAP/LIP ratio is altered in adipose 
tissue of high fat fed mice without changes in mRNA level (Esteves et al, manuscript 
submitted). So the ratio of LAP/LIP therefore determines the degree of gene 
activation. 
  
C/EBP-δ was induced in response to bleomycin (Liu, Dhanasekaran et al. 2004). 
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Recent data suggest C/EBP-δ may be a negative regulator of 11β-HSD1 expression 
(Esteves et al, manuscript submitted). My results show that C/EBP-δ is up-regulated 
after bleomycin. However, there was no difference between genotypes. C/EBP-δ is 
expressed in lung epithelial cells and regulates surfactant protein A (SP-A) (Lag, 
Skarpen et al. 2000; Matlapudi, Wang et al. 2002). Due to low expression of 
11β-HSD1 in epithelial cells, C/EBP-δ may not play an important role in regulating 
11β-HSD1 expression in the bleomycin model. 
 
The fibroblast to myofibroblast differentiation experiments described in Chapter 4 
suggest TGF-β regulates 11β-HSD1 expression in vitro. In vivo, TGF-β may 
decrease 11β-HSD1 expression to lower intracellular GC levels, which would 
otherwise restrict collagen deposition and fibrosis development. However, the in vivo 
regulation of 11β-HSD1 may be different from in vitro. After bleomycin treatment, 
TGF-β1 mRNA levels were up-regulated up to 2-fold after bleomycin treatment 
peaking around 7-14d, but total 11β-HSD1 mRNA was not changed. Moreover, the 
P1 promoter usage was increased, suggesting increased fibroblast proliferation, but 
not a promoter switch. Therefore TGF-β may not directly affect 11β-HSD1 
expression in the bleomycin model. Zhang and Daynes found increased 
TGF-β1 protein levels in 11β-HSD1-deficient mice, despite no difference in the 
encoding mRNA levels (Zhang and Daynes 2007). Accordingly, it is possible that 
TGF-β1 protein levels may be different between genotypes after bleomycin treatment 
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and this needs to be examined by western blot or by bioassay in the future. Also, 
11β-HSD1 expression is regulated by other transcription factors such as C/EBP-β 
and  C/EBP-δ and increased expression of TGF-β in vivo  may not be enough to 
reduce 11β-HSD1 expression. 
 
In other inflammation models, 11β-HSD1 is reported to be upregulated by the 
inflammatory condition or by inflammatory cytokines (Chapman, Coutinho et al. 
2009). After bleomycin treatment, real-time PCR showed that total 11β-HSD1 
mRNA levels did not significantly change, although there was a trend to increase 
between d2 and d14, then fall back to basal levels by 28d. Contrary to expectation, 
the level of P2 promoter usage was decreased, making less contribution to overall 
11β-HSD1 mRNA expression with most 11β-HSD1 transcribed from the P1 
promoter, which significantly increased after bleomycin. Perhaps because of the 
opposite (albeit small) effect of bleomycin treatment on P2-initiated mRNA between 
d2 and d14, the effect on total 11β-HSD1 mRNA levels did not achieve significance. 
These data do not support a promoter switch in vivo.  
 
The protein results showed no difference in 11β-HSD1 expression after bleomycin. 
Activity assay, the most quantitative assay, measured no difference in the activity of 
11β-HSD1 between d0, d7 and d14 and a trend toward a decrease on d14. 
Semi-quantitative measurement by western blotting showed a decrease in the protein 
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levels of 11β-HSD1. In contrast, IHC showed a marked increase in 11β-HSD1 7d 
and 14d after bleomycin treatment. However, IHC is more subject to artefact from 
cross-reactivity. Whilst controls appeared supportive, IHC results were not confirmed 
by western blotting using the same antibody or by activity assay. IHC of 11β-HSD1 
in kidney shows similar distribution to previously published ISH result (detailed in 
appendix 1). Therefore the antibody may have cross-reacted with a protein more 
highly expressed in WT after bleomycin treatment. 
 
The dissociation between 11β-HSD1 mRNA and protein levels has been described 
before (De Sousa Peixoto, Turban et al. 2008). The discrepancy in mRNA and 
protein (activity) may be due to use of different internal standards (TBP mRNA, 
β-tubulin protein) which may have been differentially affected by bleomycin. The 
effect of bleomycin on 11β-HSD1 mRNA is subtle and the effect on activity did not 
achieve significance. Overall, bleomycin may not affect the expression of 11β-HSD1 
and further work is needed to confirm this result. 
 
TNF-α and IL-1 are potent inducers of 11β-HSD1 in various cell culture systems 
including fibroblasts (Escher, Galli et al. 1997; Handoko, Yang et al. 2000; Cai, 
Wong et al. 2001; Tomlinson, Moore et al. 2001; Yong, Harlow et al. 2002; Sun and 
Myatt 2003; Hardy, Rabbitt et al. 2008). As TGF-β decreased 11β-HSD1 mainly by 
repressing the P1 promoter, TNF-α and IL-1 may induce 11β-HSD1 expression by 
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the P1 promoter as well. After bleomycin treatment, TNF-α was upregulated, but 
11β-HSD1 was not changed significantly, so TNF-α may not upregulate 11β-HSD1 
in lung fibroblasts in vivo. Other evidence supports my findings, TNF-α or IL-1 had 
no effect on 11β-HSD1 expression in vivo (Dover, Hadoke et al. 2007). Most people 
look at 11β-HSD1 in fibroblasts in culture. Perhaps in other fibroblasts, like lung, 
there is a P1 to P2 promoter switch. The fibroblasts examined by Hardy et al were 
skin, bone marrow and synovial (Hardy, Filer et al. 2006). It is important to examine 
which promoter is used in different types of fibroblast and whether there is a switch, 
as this will have implications for the regulation of 11β-HSD1 by TNF-α and IL-1. 
 
In summary, 11β-HSD1-deficient mice exhibit an exaggerated response in the 
bleomycin model of lung inflammation and fibrosis. This chapter corroborates 
previous findings in carrageenan-induced pleurisy experiments (Coutinho, Mohini 
Gray et al. 2006), suggesting that 11β-HSD1-deficient mice exhibit an altered course 
of inflammation and fibrosis. Importantly, the work described here demonstrated that 
the worse inflammatory response seen in 11β-HSD1-deficient mice is not limited to 
carrageenan-induced pleurisy. These findings strongly support a role for 11β-HSD1 
as an endogenous modulator of inflammation. The findings in the bleomycin model 
are novel but remain preliminary. However, they provide a basis for further 
investigation. Future experiments using this model should focus on identifying 
exactly which inflammatory cells were more abundant in 11β-HSD1-deficient lung 
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and whether those cells contribute to the more severe fibrosis in 11β-HSD1-deficient 
mice or whether the difference in fibrosis may be due to differences in the fibroblast 




























Pharmacologically, GC exert powerful immunosuppressive and anti-inflammatory 
effects. Physiological GC are also important modulators of inflammation and their 
levels are regulated “locally” by the 11β-HSDs. The aim of this thesis was to 
investigate whether amplification of intracellular GC levels by 11β-HSD1 represents 
an important endogenous mechanism to limit lung inflammation and fibrosis. Recent 
evidence (reviewed in (Chapman, Coutinho et al. 2009)), including work described 
in this thesis, suggests that 11β-HSD1 forms part of an endogenous 
anti-inflammatory mechanism engaged during an inflammatory response that may 
programme subsequent repair and resolution. The contribution of 11β-HSD1 during 
an inflammatory response was examined using 11β-HSD1-deficient mice and wild 
type control mice. Firstly, the expression of 11β-HSD1 was confirmed in lung as well 
as isolated alveolar macrophages, lung epithelial cells and lung fibroblasts. Lung 
fibroblasts especially, highly express 11β-HSD1 and show exclusively 11β-HSD 
reductase activity. Further, bleomycin-induced lung inflammation and fibrosis 
revealed prolonged inflammation and worse fibrosis in 11β-HSD1-deficient mice 
compared to WT mice. These data support the original findings, which suggested an 
anti-inflammatory function for 11β-HSD1 in models of peritonitis, pleurisy and 
self-resolving experimental arthritis (Coutinho, Mohini Gray et al. 2006; Gilmour, 
Coutinho et al. 2006; Coutinho 2009) and importantly, emphasize a role for 
11β-HSD1 in restraining inflammation. Furthermore, in contrast to the other organs 
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which express 11β-HSD1 from the P2 promoter, lung expresses 11β-HSD1 from the 
P1 promoter. Freshly isolated lung fibroblasts express 11β-HSD1 from the P1 
promoter but switch to the P2 promoter after culture. TGF-β decreased 11β-HSD1 
expression in fibroblasts; an effect which was not only reversed by SB431542, a 
TGF-β  receptor antagonist, but SB431542 increased 11β-HSD1 expression above 
levels in untreated cells. Also, TGF-β reduced levels of mRNA initiating at the P2 
promoter whilst initiation from the P1 promoter was completely repressed. Treatment 
with TGF-β receptor antagonist markedly increased levels of P1-initiated 11β-HSD1 
mRNA above levels in untreated cells. This finding provides a mechanistic insight 
into how 11β-HSD1 may be regulated during inflammatory conditions and also how 
other cytokines may regulate 11β-HSD1, such as IL-1 and TNF-α. The studies 
presented in this thesis suggest more fibrosis development in the bleomycin lung 
inflammation model, in 11β-HSD1-deficient mice. This may be due to 
11β-HSD1-deficiency in fibroblasts, which may lead to changes in chemokine 
expression or collagen synthesis. Further in vitro investigation of 
11β-HSD1-deficient fibroblasts is needed.  
 
6.2 Discussion 
The locus of the anti-inflammatory effect of 11β-HSD1 remains a central question. 
11β-HSD1 has been identified in immune cells (reviewed in (Chapman, Gilmour et 
al. 2006)). It is also expressed in lung epithelial cells (Brereton, van Driel et al. 2001) 
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and, as shown in the current work, in lung fibroblasts. Although lung fibroblasts are 
critical in lung inflammation, highly express 11β-HSD1 and show different 
transcriptional regulation of the 11β-HSD1 gene to other cells, it remains unclear 
whether it is the 11β-HSD1-deficiency in fibroblasts, in other lung cell populations 
or in the resident immune or recruited inflammatory cells that is responsible for the 
worsened inflammatory response and fibrosis in 11β-HSD1-deficient mice after 
bleomycin treatment or a combination of more than one of these factors. It will be 
important to clearly identify which of these cells are involved in the mechanism 
responsible for the anti-inflammatory effects of 11β-HSD1. 
 
During the course of my PhD research, 11β-HSD1-deficient mice were found to be 
“leaky”. My work confirmed these mice have 11β-HSD activity in lung. Moreover, 
recent work in the laboratory identified a “sub-line” of 11β-HSD1-deficient mice 
which showed 11β-HSD activity in liver and brain (J, Noble, personal 
communication), in contrast to the original line (Kotelevtsev, Holmes et al. 1997). 
This may have been due to a secondary mutation in the transgene cassette which 
allowed more P2 promoter activity. Nevertheless, the 11β-HSD1-deficient mice had 
lower levels of 11β-HSD1 in lung than WT mice and allowed the investigation of the 
effects of 11β-HSD1 deficiency to be investigated. With hindsight, a lung 
inflammation model may not have been the best choice given the level of 11β-HSD 
activity in 11β-HSD1-deficient mouse lung. However, this might model effects of 
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inhibitors of 11β-HSD1, which rarely give 100% enzyme inhibition. A new line of 
mice with a germline disruption of Hsd11b1 (created from a new line of “floxed” 
mice) and which lack 11β-HSD1 activity in all tissues is now available in the lab and 
it will be important to use these new mice to repeat the bleomycin experiments to 
investigate the anti-inflammatory mechanisms of 11β-HSD1. 
 
“Floxed” 11β-HSD1 mice are now available in the lab and a LysMcre 
myeloid-specific knockout of 11β-HSD1 has recently been generated, so these mice 
could be used to test whether 11β-HSD1-deficiency in myeloid cells causes more 
severe inflammation. A fibroblast specific-Cre mice has been reported, in which the 
fibroblast specific protein promoter drives Cre expression (Bhowmick, Chytil et al. 
2004), which could be used to examine the effect of 11β-HSD1-deficiency in 
fibroblasts. Also bone marrow transplantation can investigate the contribution of the 
host (non-immune or resident immune cells) in worsening inflammation.  
 
Additionally, in parallel to the investigations suggested above, it will be important to 
establish the mechanisms responsible for the greater number of inflammatory cells in 
lung in 11β-HSD1-deficient mice after bleomycin. Two possible mechanisms 
responsible for the greater recruitment of inflammatory cells are; first, greater 
cytokine and chemokine regulation of the inflammatory response involving the 
resident immune cell and/or incoming inflammatory cells, and second, the 
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immuno-regulatory function of resident fibroblasts and differentiated myofibroblasts. 
Future experiments using this model should focus on identifying exactly which 
inflammatory cells were more abundant in 11β-HSD1-deficient lung and whether 
those cells contribute to the more severe fibrosis in 11β-HSD1-deficient mice or 
whether the difference in fibrosis may be due to 11β-HSD1 function in the fibroblast 
and myofibroblast cells.  
 
In preliminary experiments in which flow cytometry was used to analyse 
collagenase-digested lung following bleomycin treatment both genotypes showed a 
similar percentage of apoptosis and necrotic cells. A “cocktail” of antibodies to Ly6C, 
CD11c, CD11b and MHC-II was used to identify monocytes, macrophages and DC 
in lung. However, the results were unclear and could not identify distinct cell 
populations (data not shown). Future experiments should focus on refining this 
technique to identify and phenotype the inflammatory cells in lung following 
bleomycin treatment, particularly the M1 and M2 macrophages. Classically activated 
M1 macrophages secrete pro-inflammatory mediators and display phagocytic 
behaviour; alternatively activated M2 macrophages secrete anti-inflammatory 
cytokines such as TGF-β and act to repair the damaged tissue by stimulating collagen 
deposition (Raes, Van den Bergh et al. 2005). Therefore an altered balance between 
M1 and M2 macrophages would affect the inflammatory and fibrosis condition. Such 
an altered balance has recently been suggested following myocardial infarction in 
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11β-HSD1-deficient mice where more M2 macrophages accumulated in the infarct 
zone of 11β-HSD1-deficient mice compared to WT (McSweeney, Hadoke et al. 
2010). 
 
The inflammation and fibrosis resulting from bleomycin treatment may reflect 
different mechanisms. TGF-β1 is a ligand for the integrin αυβ6 (Munger, Huang et 
al. 1999). Integrin β6−/− mice are protected against bleomycin-induced pulmonary 
fibrosis but show a greater inflammatory response (Munger, Huang et al. 1999), 
which suggests the protection from bleomycin-induced pulmonary fibrosis is not due 
to inhibition of the inflammatory response to bleomycin. To separate the processes of 
inflammation and fibrosis, it may also be possible to use silicon to induce fibrosis in 
lung without inducing strong inflammation.  
 
The focus of Chapter 4 was to further investigate 11β-HSD1 expression in fibroblasts 
from WT mice, since 11β-HSD1 had not been characterized in mouse lung 
fibroblasts before. Lung fibroblasts appear to be the main cell type in lung expressing 
11β-HSD1. TGF-β reduced 11β-HSD1 expression in primary cultures of lung 
fibroblasts; however, the mechanism of regulation is not clear. Real-time PCR 
showed no difference in mRNA encoding C/EBP-β, which has been shown to 
regulate 11β-HSD1 (Chapman, Coutinho et al. 2009), so it is important to measure 
C/EBP-β protein levels including the LAP/LIP ratio and also to measure 
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C/EBP-δ levels. During the differentiation of fibroblasts to myofibroblasts induced 
by TGF-β, dex treatment augmented TGF-β-induced α-SMA expression (Gu, Zhu et 
al. 2004). Based on this GC effect, it is possible that GC-regeneration by 11β-HSD1 
would increase fibroblast to myofibroblast differentiation. It will be important to test 
whether 11β-HSD1-deficient fibroblasts are more resistant to TGF-β induced 
differentiation. 
 
It is important to phenotype lung fibroblasts from 11β-HSD1-deficient mice. After 
GRdim mice (see Chapter 1.4) were wounded, they showed markedly enlarged 
granulation tissue with a high fibroblast density (Grose, Werner et al. 2002). This 
was attributed to increased migration and proliferation of GRdim fibroblasts together 
with increased expression of soluble factors, such as TGF-β and IL-1β. Lung 
fibroblasts from 11β-HSD1-deficient mice may show similar increased migratory 
and proliferative capacity to GRdim mice, as this phenotype reflects the function of 
endogenous glucocorticoids. It is possible that 11β-HSD1-deficient fibroblasts show 
a higher level of expression and secretion of cytokines and/or chemokines to recruit 
inflammatory cells which might lead to the more severe inflammation in 
11β-HSD1-deficient mice. These possibilities could be tested in fibroblasts isolated 
using flow cytometry or MACS bead separation by CD90+ to analyze mRNA or 




These findings raise intriguing questions about the importance of local modulation of 
GC by 11β-HSD1 in lung, particular in fibroblasts, and provide a basis for further 
investigation (Figure 6.1). Besides lung, kidney is the other main tissue expressing 
11β-HSD1 from the P1 promoter (V. Kelly et al, unpublished). Like lung, kidney is 
also susceptible to fibrosis. Understanding the role and regulation of 11β-HSD1 in 
lung fibrosis may shed light into research on kidney fibrosis. The efficacy of high 
dose, long-term, GC-based therapeutic regimes are compromised by side effects, it 
may therefore be desirable to target the beneficial effects of GC to fibroblasts in 
certain conditions where activated fibroblasts contribute to disease.  
 
In conclusion, the experiments described in this thesis support an anti-inflammatory 
and anti-fibrotic role for 11β-HSD1 during bleomycin-induced lung inflammation 
and fibrosis and begin to address the underlying mechanisms for the altered 
inflammatory phenotype of 11β-HSD1-deficient mice. These studies have provided a 
basis for future experiments to tease apart the role and regulation of 11β-HSD1 in 
inflammation. Thus, further investigations are warranted and better understanding of 
the immune-regulated role of 11β-HSD1 in inflammation may lead to improved and 













Figure 6.1 Models of the inter-relationship between TGF-β, 11β-HSD1 P1 and P2 
promoter, GC and fibrosis. 
Bleomycin treatment induces strong fibrosis in part by increasing TGF-β action 
which stimulates collagen synthesis. GC inhibit collagen production. TGF-β strongly 
reduced the P1 promoter of 11β-HSD1 and reduced the P2 promoter of 11β-HSD1 to 
a lesser extent. Less 11β-HSD1 will result in lower intracellular GC levels, which is 
predicted to lead to more collagen production and severe fibrosis. As 11β-HSD1 
-deficient mice only have 30% of 11β-HSD activity compared to WT mice. It 
generates much less intracellular GC, which lead to more severe fibrosis, compared 
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Appendix I: Comparison of in situ hybridization and IHC using sheep 
anti-11β-HSD1 antibody on kidney section 
The specificity of the purified sheep anti-11β-HSD1 antibody was determined by 
staining kidney section. In kidney 11β-HSD1 is expressed in all renal tubular 
epithelia but is not detected in medullary interstitial cells (Yau, Van Haarst et al. 1991) 
(Figure 1.1A and B). Paraffin-embedded kidney sections from C57BL/6 control (WT) 
mice were stained with purified sheep anti-11β-HSD1 antibody at 1:1000 dilution. 
Positive staining was seen in proximal and distal tubular epithelia and glomeruli did 























Figure 1.1 Immunohistochemical staining of 11β-HSD1 in mouse kidney shows 
expression in renal tubular epithelial cells. 
(A and B) previously published in situ hybridization result showing 11β-HSD1 
expression in (A), juxtamedullary cortex/outer medulla; (B), renal tubular epithelial 
cells of proximal (P) and distal (D) convoluted tubules. Interstitial cells and 
glomerular (G) epithelium are negative (Yau, Van Haarst et al. 1991). (C) 
Representative image of Immunohistochemistry carried out on kidney sections from 
WT mice with purified sheep anti-11β-HSD1 antibody at 1:1000 dilution and 
biotinylated rabbit-anti-sheep 2nd Ab at 1:400 dilution. Image was captured at 
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